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ABSTRACT 
It has been hypothesized that the polypropionates isolated from Siphonaria zelandica, 
siphonarin B, caloundrin B, baconipyrone A, and baconipyrone C, originate by non-enzymatic 
processes on a common ‘acyclic’ biosynthetic precursor. In previous work in the Ward group, 
the putative common precursor was synthesized and transformed into siphonarin B, 
baconipyrone A, and baconipyrone C. However, caloundrin B was not detected in these 
experiments and its origin remained as a missing piece of the puzzle. Thereafter, it was 
hypothesized that caloundrin B could be an unstable biosynthetic product from which the 
formation of the other polypropionates could be readily explained. To test that hypothesis, a new 
strategy to synthesize caloundrin B was proposed. 
 
This thesis describes and analyzes the manner in which the first synthesis of ent-
caloundrin B was achieved. The two key steps towards the target molecule involved the 
synthesis of the trioxaadamantane motif and the assembly of the complete skeleton of ent-
caloundrin B via a novel aldol coupling between the trioxaadamantane-containing ketone and the 
γ-pyrone-containing aldehyde, that proceeds with kinetic resolution.  
 
viii 
 
The studies toward the synthesis of caloundrin B allowed the development of new 
methodologies and the application of a recently disclosed protocol to design aldol reactions that 
proceed with kinetic resolution. During the course of those studies, a non-linear effect was 
identified and characterized. 
After completion of the synthesis, ent-caloundrin B was isomerized to ent-siphonarin B 
under thermodynamic conditions, thus confirming the relative and absolute configuration of ent-
caloundrin B. This transformation leads to the conclusion that caloundrin B is much less stable 
than siphonarin B; as a consequence, caloundrin B cannot be an artifact of isolation as previously 
proposed, but instead, it could be the biosynthetic product from which siphonarin B, 
baconipyrone A, and baconipyrone C are formed. 
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CHAPTER 1 
1 INTRODUCTION 
1.1 Polypropionates from Siphonaria zelandica 
Marine polypropionates have been poorly studied and very little is known about their 
biological activity or role in the chemical ecology of the producing organisms.1, 2 The main 
difficulties are that only very small amounts of material are available by extraction of marine 
organisms (e.g., mollusks) and, in many cases, the isolated compounds are thought not to be 
genuine biosynthetic products but rather artifacts of isolation.  
Marine pulmonates of the genus Siphonaria, also known as false limpets, are intertidal air-
breathing mollusks that are a rich source of polypropionates.3 For example, the decapropionates  
siphonarins A (1) and B (2), baconipyrones A (4), B (5), C (6) and D (7) and caloundrin B (3), 
have been isolated from Siphonaria zelandica (Figure 1.1).4 
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Figure 1.1 Siphonariid polypropionates isolated from Siphonaria zelandica. 
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1.1.1 Structure and isolation 
In 1984, Faulkner et al. reported the isolation of siphonarin A (1) and siphonarin B (2) 
from Siphonaria zelandica collected in the intertidal zone along the coast of New South Wales, 
Australia, with a yield of ca. 0.05 mg of each siphonarin/animal.5 The structure and relative 
configuration of siphonarin A (1) was determined by spectroscopic and X-ray analysis. The 
homologue siphonarin B (2) has an ethyl rather than a methyl group at C-19 and was assigned 
the same relative configuration as in 1 by analogy. In 1994, Garson et al. determined the absolute 
configuration of 1 by X-ray analysis of its p-bromophenylboronate derivative.6 
Contemporaneously, Paterson et al. were able to assign the absolute configuration of siphonarins 
1 and 2 by enantioselective synthesis of the γ-pyrone acid 9, a degradation product isolated with 
dihydrosiphonarin B (8) (Figure 1.2).7 Subsequently, the total syntheses of siphonarin B (2) by 
Paterson et al.8 and Beye and Ward,9 confirmed the absolute configuration of 1 and 2.  
O
O
O
OH
OH
HO
O
O
OH O
O
O
HO
O
dihydrosiphonarin B (8)
O O
O
O
O
9
TIPSO
10 11  
Figure 1.2 Assignment of the absolute configurations of 1 and 2 by synthesis of 9. 
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The isolation of the baconipyrones 4-7 from specimens of Siphonaria baconi* collected at 
the intertidal zone near Melbourne, Australia (Figure 1.1) was reported in 1989 by Faulkner et 
al.10 The amounts isolated for each compound were: 4, 0.05 mg/animal; 5, 0.046 mg/animal; 6, 
0.016 mg/animal; 7, 0.046 mg/animal; and 1, 0.008 mg/animal. The structure and relative 
configuration of baconipyrone B (5) was determined by X-ray analysis and showed that the 
configurations at C-4, C-6, C-10, C-11, C-12, and C-14 were identical to those of siphonarin A 
(1) (Figure 1.1). In contrast to 1, 2, and 3, the baconipyrones do not contain a contiguous carbon 
skeleton of polypropionate units. Due to the stereochemical similarities between the siphonarins 
and baconipyrones, Faulkner et al.10 suggested that baconipyrones A (4) and B (5) are generated 
from siphonarins A (1) and B (2), respectively, via a retro-Claisen reaction (Scheme 1.1). 
Scheme 1.1 Rationale for the transformation of siphonarins to baconipyrones. 
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* Siphonaria baconi is considered synonymous with Siphonaria zelandica 
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Thus, Faulkner et al.10 hypothesized that ring opening of siphonarins 1 or 2 followed by a 
retro-Claisen reaction would produce enolate 12 (Scheme 1.1). Subsequent protonation of 12 
would produce baconipyrones C (6) or D (7), while a stereoselective intramolecular aldol 
reaction on 12 would afford baconipyrones A (4) or B (5). Additionally, 4 or 5 might produce 6 
or 7, respectively, via a retro-aldol reaction. Based on the proposed mechanistic rationale, the 
authors suggested that the relative configuration at the stereogenic centres in baconipyrones C 
(6) and D (7) are identical to those in baconipyrones A (4) and B (5). 
After a careful extraction from S. baconi, Garson et al. did not observe the presence of 
any baconipyrones (4-7). This observation suggested that the baconipyrones could be artifacts 
formed during metabolites extraction and isolation.11  
In 2000, Paterson et al. achieved the total synthesis of baconipyrone C (6) demonstrating 
that its absolute configuration corresponded with the independently reported siphonarins 1 and 
2.12 The synthesis of 6 also corroborate previous studies where the absolute configuration of 
siphonarins 1 and 2 and baconipyrones 4-7 was confirmed through the synthesis of the γ-pyrone 
acid 9 (Figure 1.2).7 Baconipyrone C (6) has also been synthesized by Gillingham and Hoveyda13 
and Yadav and coworkers;14 more recently, Beye and Ward synthesized 4 and 6 from its putative 
acyclic precursor.9 
In 1994, Garson and coworkers reported the isolation of caloundrin B (3) (1.6 mg) 
together with siphonarins A (1) and B (2) from 160 specimens of S. zelandica collected from 
rock platforms at Caloundra, Australia.15 The structure of caloundrin B (3) was deduced by 
spectroscopic methods providing strong evidence for the presence of a γ-pyrone and the 
trioxaadamantane motif with the indicated relative configuration.   The C-12 to C-21 fragment 
seemed to match with the same fragment present in baconipyrone C (6) (Figure 1.1). However, 
  5 
the relative configuration along the chain (C-10 to C-14) and the overall absolute configuration 
of caloundrin B (3) were assigned based on the presumed relationship with the co-metabolite 
siphonarin B (2). These isomers were hypothesized to originate from a common intermediate 
(Scheme 1.2). 
Apparently, the trioxaadamantane moiety in caloundrin B (3) was not stable and the 
isolated sample decomposed during the studies. Attempts to re-isolate 3 or isomerize siphonarin 
B (2) under acidic conditions to produce 3 were unsuccessful.15 To date, there have been no 
further reports of isolation of caloundrin B (3) nor has its total synthesis been disclosed. 
Therefore, the proposed relative and absolute configuration of 3 as well as the presumed link 
between 3, siphonarin B (2) and baconipyrones A (4) and C (6) through a common acyclic 
precursor remain as hypotheses. 
Scheme 1.2 Proposed cyclization pathways for the two epimers at C-8 of 13. 
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1.1.2 Biosynthesis 
In 1990, Manker, Garson, and Faulkner studied the biosynthesis of the siphonariids 
denticulatin A (21) and denticulatin B (10 epi-21) isolated from Siphonaria denticulata (Figure 
1.3).16 The studies revealed that these metabolites arose from condensation of propionate-derived 
units similar to the biosynthesis of macrolide17 and polyether antibiotics.18 Some years later, 
Garson et al. studied the biosynthesis of siphonarins A (1) and B (2).6 Similar to the previous 
observations on denticulatin A (21), incorporation of 14C in 1 and 2 was observed after injection 
of [1-14C] propionate to the foot tissue of Siphonaria zelandica. Therefore, they suggested that 1 
is formed from one acetate and nine propionate units, whereas 2 would come from ten propionate 
units. In order to determine the direction of the chain assembly in 1, they studied the biosynthetic 
origin of C-19. After degradation of 14C-labeled 1 via ozonolysis and derivatization with p-
Br(C6H4)COCH2Br, they obtained unlabeled p-bromophenacyl acetate coming from C-19. This 
result is consistent with a chain assembly from C-19 to C-1, as described in pathway A (Scheme 
1.3).6 
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Scheme 1.3 Biosynthetic studies on siphonarin A (1). 
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In addition to the biosynthetic studies, Garson et al. compared the relative configurations 
of the uncyclized tautomers of siphonarins 1 and 2, muamvatin (19), and denticulatin A (21).19 
This comparison revealed a common tetrapropionate unit among these polypropionates. 
Interestingly, this tetrapropionate unit also matched with the PAPA model proposed by Cane-
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Clemer-Westley† for the biosynthesis of polyether antibiotics (Figure 1.3).18 Therefore, it was 
suggested that siphonariid polypropionates might share a common genetic origin with polyether 
antibiotics. There were also similarities between the siphonarins and the Celmer macrolide 
model.17, 20 
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Figure 1.3 Stereochemical comparison of siphonariid polypropionates 
                                                
† PAPA model (Propionate-Acetate-Propionate-Acetate units) is one of the empirical models used as a guide to 
assign the structure and stereochemistry of polyethers.  
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1.1.3 Hypothesis on the origin of siphonariid polypropionates 
Based on the structural, stereochemical, and biosynthetic studies developed on the 
siphonariid polypropionates 1 and 2, it was hypothesized that siphonarin B (2), caloundrin B (3), 
and baconipyrones A (4) and C (6) originated via non-enzymatic processes from a common 
'acyclic' biosynthetic precursor (23).11, 15, 20 Considering that C-8 in 23 is stereochemically labile 
via keto-enol tautomerism, one epimer would produce siphonarin B (2) and the other would 
generate caloundrin B (3). In addition, the baconipyrones 4 and 6 could be artifacts of isolation 
coming from rearrangements on 2.11  
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Figure 1.4 Hypothesis about the biosynthetic origin of siphonariid polypropionates  
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1.2 Total syntheses of siphonarin B 
1.2.1 Paterson’s synthesis 
The approach for the synthesis of siphonarin B by Paterson et al. involved coupling of the 
two main fragments 26 and 33 via an aldol reaction producing a protected acyclic precursor 34, 
which required the introduction of an ethyl group and functional group manipulations to generate 
siphonarin B (Scheme 1.4).8 The preparation of the keto fragment 26 started with the synthesis of 
ketone 24 (≥97% ee) from the (R)-Roche ester in 59% yield over 3 steps.21 A boron mediated 
aldol reaction of 24 with propionaldehyde followed by an in situ syn reduction provided diol 25 
in 86% yield and > 95:5 dr.22 Diol 25 was bis-DEIPS protected, hydrolyzed at the least hindered 
position, and then oxidized to produce the DEIPS protected ketone 26 in 49% yield over 3 steps. 
The pyrone containing aldehyde fragment 33 was prepared from the (S)-Roche aldehyde 49% 
yield over 8 steps.7, 12 A Sn(II) mediated aldol reaction of 33 with the TIPS protected ketone 28 
gave 31 in 59% yield. Functional group manipulations on 31 (i.e., Evans-Tishchenko reduction,23 
PMB protection, TIPS and acetyl removal) produced diol 32.7, 12 Aldehyde 33 was obtained after 
bis-TMS protection of diol 32, followed by selective deprotection of the primary alcohol, and 
oxidation.  
Aldol coupling of 33 with 26 via its Sn(II) enolate produced a mixture of three aldol 
diastereomers in 92% yield. Removal of the TMS protecting group and Swern oxidation 
produced 34 and 8-epi-34, which after DEIPS deprotection, furnished hemiacetal 35. 
Interestingly, when hemiacetal 35 was exposed to mildly acidic (i.e., SiO2) or basic conditions, it 
underwent a retro-Claisen reaction producing a fragment similar to baconipyrone C (6). This 
observation strongly supported the hypothesis that the baconipyrones are rearranged products 
from siphonarins10 or artifacts from isolation as Ireland and Garson had proposed.11, 20 
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Scheme 1.4 Paterson’s synthesis of siphonarin B (2). 
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Careful removal of the Bn group on 35, followed by oxidation and introduction of a vinyl 
group employing the Kishi-Nozaki conditions (CrCl2, 5% NiCl2, DMF)24, 25 provided compound 
36, which was then oxidized and hydrogenated to afford siphonarin B (2) in low yield. 
Interestingly, caloundrin B (3) was not observed as a product in the final cyclization process. 
Siphonarin B (2) was synthesized in 25 linear steps from the Roche aldehyde 29 in 0.8% overall 
yield.  
1.2.2 Ward’s synthesis 
1.2.2.1 Synthesis of siphonarin B from the putative acyclic linear precursor 
Ward et al. developed a strategy for the preparation of 48, the putative acyclic precursor 
of the siphonariid polypropionates 1-5.9 In contrast with Paterson’s synthesis,8 this approach 
involved the construction of the complete carbon skeleton prior to cyclization. Because the 
formation of γ-pyrones from cyclization of β-triketides requires special conditions,26-28 it was 
considered unlikely that pyrone formation could occur during the isolation process. Therefore, 
the γ-pyrone motif was installed in the acyclic precursor. The synthesis of 48 allowed studying 
its cyclization under different conditions thereby directly testing the previous hypotheses about 
the origin of 2, 3, 4, and 6.  
The synthesis of 48 commenced with the readily available starting materials 38 and 44 
prepared via the thiopyran route to polypropionates extensively studied in the Ward group 
(Scheme 1.5).29 The γ-pyrone was constructed by a sequence where 38 was protected and 
desulfurized followed by aldol reaction of the resulting ketone 39 with aldehyde 40. The aldol 
adduct was oxidized to produce the desired γ-pyrone 41; however, the reaction conditions also 
induced hydrolysis of the acetal and elimination of the pivaloate. To reinstall the required 
stereogenic centre at C-5” in 41, diastereoselective Luche reduction and O-benzyl protection of 
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the formed alcohol was followed by oxymercuration30, 31 producing diol 42. Taking advantage of 
the resistance of the secondary alcohol in 42 to react with triethylsilyl triflate (TESOTf), the 
primary alcohol was selectively TES-protected, followed by MOM protection of the secondary 
alcohol. Subsequent removal of the silyl group and oxidation of the resulting alcohol produced 
the aldehyde 43 which then was coupled with the enantioenriched ketone 44 (>98% ee) via its 
Ti(IV) enolate to give adduct 45 in 79% yield and >20:1 dr. Simple functional group 
manipulations on 45 produced the desired acyclic precursor 48, which existed as a complex 
mixture of keto-enol and ring-chain tautomers with the three hemiacetal forms 49, 50, and 51 or 
52 predominating. The synthesis of 48 was achieved in 18 linear steps with an overall yield of 
3.1%. 
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Scheme 1.5 Ward’s synthesis of acyclic precursor 48. 
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With the acyclic precursor 48 in hand, its isomerisation was studied under different 
conditions (Scheme 1.6). This was the first time that the thermodynamic equilibrium of 
siphonariid polypropionates could be studied starting from 48. As noted above, 48 was a 
complex mixture of tautomers with three hemiacetal forms 49, 50, and 51 or 52 predominating. 
This mixture was essentially unchanged after 28 days in CDCl3. However, treatment of 48 with 
imidazole in CDCl3 for 24 h produced 2 in 70% isolated yield. Reaction of 48 with DBU in C6D6 
solution for 1 h produced a mixture of baconipyrone C (6) (50%) and its C-14 epimer (30%). 
Treatment of 48 with neutral alumina in refluxing ethanol produced a 10:3:7:3 mixture of 53 
(40% isolated), 4 (10% isolated), 6, and 2, respectively.  The major product 53, a structural 
isomer of baconipyrone C (6) arising from retro-Claisen fragmentation of hemiacetal 50 or 52, 
had not been previous reported. Finally, treatment of 2 with neutral alumina in refluxing ethanol 
produced a 2.3:3:1:1 mixture of 2, 6, 4, and 48, respectively, but not 53. It is noteworthy that 
both 4 and 6 were stable to these reaction conditions. Surprisingly, caloundrin B (3) was never 
detected in the isomerization experiments and its presence remained as a missing piece of the 
puzzle about the origin of all of those polypropionates.9 
Preparation of compound 54, where the OH group at C-11 was protected thereby limiting the 
options for cyclization, allowed the assessment of another isomerisation experiment. After 
exposure of compound 54 to neutral alumina in refluxing ethanol and then debenzylation, 
baconipyrones 4 and 6 were produced in 18% and 70% yields, respectively. 
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Scheme 1.6 Isomerization of acyclic precursor 48.  
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1.2.2.2 Revised hypothesis on the origin of siphonariid polypropionates 
Very important conclusions emerged from the Ward and Beye syntheses of siphonarin B 
(2), baconipyrone A (4) and C (6) from the presumed acyclic precursor 48.9 With the information 
provided by Ward9 and Garson11 it was conclusive that the baconipyrones were likely artifacts 
from isolation coming from the hemiacetal forms of 48 or by ring-opening of siphonarin B (2). 
These observations supported the previously proposed hypothesis but also established new 
questions about the origin of those compounds. In this context, it was proposed that if 
baconipyrones 4 and 6 came from the acyclic precursor 48; then, the hemiacetal forms 49 and 
50,‡ compound 53 and 14-epi-6 should be observed during the isolation process. Because none of 
these compounds had been isolated from Siphonaria zelandica, it was most likely that the 
baconipyrones 4 and 6 originate from 2. Additionally, 2 could be the biosynthetic product. 
However, this hypothesis would not explain the origin of 3. 
Therefore, it was hypothesized that 3 could be less stable than 2 or that access to 3 involved a 
high energy barrier. Indeed, 3 could be the biosynthetic product from which the formation of 2, 
4, and 6 could be explained. However, this revised hypothesis could only be tested if the 
synthesis of 3 could be achieved (Figure 1.5). 
                                                
‡ The hemiacetal forms 49 and 50 coming from the acyclic precursor 48 were stable to storage in CDCl3 for 28 d and 
exposure to SiO2. 
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 Figure 1.5 Revised hypothesis on the origin of siphonariid polypropionates 
1.3 Syntheses of trioxaadamantane ring systems 
1.3.1 Hoffmann’s synthesis of the trioxaadamantane ring system of muamvatin 
Isolated in 1986 from Siphonaria normalis, muamvatin (19; Figure 1.3) was the first 
natural product identified containing a trioxaadamantane ring system.32 In 1994, initial studies to 
form the racemic trioxaadamantane model 58 were reported by Hoffmann et al.33 The synthesis 
started with methacrolein to produce aldehyde 55 after 7 steps. Aldol reaction of 55 with the (Z)-
enol borinate from 3-pentanone afforded 56 as a single diastereomer in 85% yield. Finally, 
Swern oxidation on 56 gave the protected 3-hydroxy-1,5,7-trione 57, that after exposure to 
HFpyridine and H2O in THF furnished the trioxaadamantane 58 in 49% yield after 2 steps. 
 
 
 
 
  19 
Scheme 1.7 Model studies to form the trioxaadamantane moiety of muamvatin (19). 
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In order to establish the absolute and relative configuration of muamvatin (19) at C-10, 
Hoffmann studied the synthesis of aldehydes 65 and 69 (Scheme 1.8).34, 35 One of the aldehydes 
was previously obtained from degradation of muamvatin (19) by Ireland.32   
Hoffmann’s approach started from methacrolein and 59 to produce aldehyde 60 in 7 
steps. Thereafter, aldol reactions of 60 with the (Z)-enol borinates of 61 or ent-61 produced the 
aldol adducts 62 and 66, respectively. After Swern oxidation and prolonged exposure to 
HFpyridine and H2O in THF, 62 and 66 were converted to 64 (60%) and 68 (45%), 
respectively. The aldehydes 65 and 69 were obtained from 64 and 68, respectively, by O-
debenzylation and subsequent oxidation. Aldehyde 65, which possesses the (S)-configuration at 
C-10, has the same relative configuration as the trioxaadamantane fragment present in 
muamvatin (19). 
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Scheme 1.8 Formation of the trioxaadamantane moiety of muamvatin (19). 
 
1.3.2 Paterson’s synthesis of muamvatin 
In 1993, Paterson achieved the first total synthesis of muamvatin (19), confirming the 
relative and absolute configuration of the compound.36 The synthesis of the trioxaadamantane 
moiety ent-64 involved a Sn(II) mediated aldol reaction between ketone 24 and propionaldehyde, 
followed by a selective anti reduction of the aldol adduct 70, silyl protection, debenzylation, and 
oxidation to produce aldehyde 71. Aldol reaction of 71 with the boron enolate of 24 produced 72, 
which after silyl deprotection cyclised to the hemiacetal 73 as a single isomer in 72% yield. 
Further oxidation of 73 produced the hemiacetal 74, a tautomer of the trioxaadamantane ring 
system. However, exposure of 74 to acidic conditions, only produced dehydration. In contrast, 
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exposure of 74 to silica gel for 18 h produced the desired trioxaadamantane ring system ent-64 in 
92% yield.  
Scheme 1.9 Paterson’s synthesis of muamvatin (19). 
 
Hydrogenolysis of the benzyl ether in ent-64 followed by oxidation of the resulting 
alcohol generated aldehyde ent-65 which was in agreement with the trioxaadamantane aldehyde 
isolated from degradation of muamvatin 19.32 Therefore, the relative configuration at C-10 was 
established.  Further manipulations to introduce the diene fragment and establish the 
configuration at C-11, produced muamvatin (19) in 14 steps. Paterson proposed that due to the 
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straightforward formation of the trioxaadamantane ent-64 under SiO2 conditions, muamvatin (19) 
could be an artifact of isolation. 
1.3.3 Perkins’ approach to Dolabriferol 
It is interesting that in one of the approaches towards the synthesis of dolabriferol (83), 
Perkins observed the formation of the trioxaadamantane ring system 79 (Scheme 1.10).37 When 
compound 78 (Scheme 1.10) was subjected to tris(dimethylamino)sulphonium 
difluorotrimethylsilicate (TAS-F) to remove the silyl groups,38 followed by addition of DBU, 
surprisingly compound 79 was produced in 78%. Similarly, treatment of 78 with HFpyridine 
and pyridine in THF efficiently provided the trioxaadamantane 79 in 88% yield. These last 
conditions used to form 79 were very similar to those used by Hoffmann in his model studies for 
the preparation of trioxaadamantanes 64 and 68 (Scheme 1.8). To date, this is the only example 
of the formation of a trioxaadamantane bearing a side chain larger than three carbons from a 3-
hydroxy-1,5,7-trione or hemiacetal precursor. 
Exposure of 79 to DBU for a longer reaction time produced 80 from a ring opening and 
retro-Claisen reaction sequence.  Finally, the ester was transformed to the enone 81 on prolonged 
exposure to DBU. On the other hand, spiroketal 82 was obtained when 80 was treated with 
aqueous HF, a process that presumably involved a Claisen reaction. This is the only example 
where a retro-Claisen fragmentation (e.g., 79 to 80) has been shown to be reversible. 
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Scheme 1.10 Formation of a trioxaadamantane moiety during Perkin’s approach towards 
the synthesis of dolabriferol (83). 
 
   
1.3.4 Ward’s synthesis of the trioxaadamantane ring systems of muamvatin and 
caloundrin B 
In 2009, Ward et al. performed model studies to form the trioxaadamantane ring systems 
present in muamvatin (19) and caloundrin B (3).39 Their strategy, utilized thiopyran fragments to 
form sulphur-bridged trioxaadamantanes 87 and 93, that subsequently could be desulfurized and 
finally isomerized to the more stable trioxaadamantane species 89 and 58, respectively.39 
Interestingly, the isomerizations of trioxaadamantanes, 88 and 94, were very different. Whereas 
isomerization of 94 in the presence of imidazole cleanly formed the more stable 
trioxaadamantane 58 in excellent yield, isomerization of 88 produced the trioxaadamantane 89 
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along with the hemiacetal form 90 and the ester 91; the latter produced from a retro-Claisen 
reaction of the hemiacetal forms (i.e. 90). This methodology, allowed the selective preparation of 
compounds 89, 90, and 91, truncated forms of caloundrin B (3), siphonarin B (2), and 
baconipyrone C (6), by using the appropriate isomerization conditions. This was the first 
example where the formation of the trioxaadamantane moiety from caloundrin B (2) was 
demonstrated. 
 Scheme 1.11 Synthesis of model trioxaadamantanes (58 and 89) from muamvatin (19) 
and caloundrin B (2). 
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1.4 Conclusions 
To date, the achievements in the synthesis of 2, 4, and 6 and their putative acyclic precursor 
48 have confirmed their relative and absolute configurations and afforded the study of their inter-
relationships. Yet the synthesis of 3 remains a challenge to be solved. Achievement of the 
synthesis of 3 would allow confirmation of the proposed structure and would allow testing of the 
revised hypothesis about the origin of the siphonariid polypropionates. 
Since caloundrin B (3) was not observed during the biomimetic synthesis of 2, 4, and 6 
from the corresponding acyclic precursor (48), the synthesis of 3 should be approached using a 
different strategy. As an alternative, a convergent synthesis of 3 is proposed, where the γ-pyrone 
fragment would be coupled with a preformed trioxaadamantane fragment. Several different 
procedures to form the trioxaadamantane fragment of muamvatin (19) have been reported by 
Hoffman,33-35 Paterson,36 Perkins,37 and Ward.39 However, the only report for the formation of 
the trioxaadamantane ring system of caloundrin B was disclosed by Ward et al. in 2009.39 With 
this precedent in hand, research was directed towards the synthesis of caloundrin B. 
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CHAPTER 2 
2 RESULTS AND DISCUSSION 
2.1 Research objectives 
One of the key objectives in this research project was to explore the relationship between 
the siphonariid polypropionates caloundrin B (3) and its structural isomers siphonarin B (2), 
baconipyrone A (4) and C (6), all isolated from extracts of Siphonaria zelandica. To enable this 
study, it was essential to have access to caloundrin B (3). However, there are no reports on the 
synthesis of caloundrin B (3) and the single report on the isolation of 3 (1.6 mg from 160 
animals) revealed that it was unstable. Therefore, a carefully designed synthetic route would be 
required to obtain 3 by total synthesis (Figure 2.1). 
Caloundrin B (3) was not observed in various attempts at isomerizations of the putative 
common acyclic precursor (48)9 or siphonarin B (2).9, 15 Therefore, a convergent synthesis of 3 
was proposed involving aldol coupling of the trioxaadamantane-containing ketone 95 with the γ-
pyrone-containing aldehyde (±)-30. The proposed use of the racemic fragment (±)-30 for this 
strategy would require studies of methodology on the design of aldol reactions that proceed with 
kinetic resolution (vide infra). On the other hand, the stereoselective synthesis of the 
trioxaadamantane fragment using the thiopyran route to polypropionates29, 40 was envisaged. 
However, the development of a methodology to form a trioxaadamantane possessing an 
appropriate functional ‘handle’ would be required. 
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 Figure 2.1 Major objectives of the research 
2.2 Retrosynthetic analysis of caloundrin B 
The failure to produce caloundrin B (3) by attempted isomerization of either 2 or 48 
seemed to predicate a synthetic plan based on elaboration of a preformed trioxaadamantane 
fragment.9 The presence of the β-hydroxyketone in 3 suggested a convergent approach based on 
aldol coupling of two fragments of similar size. The perhaps more obvious disconnection of the 
C-11, C-12 bond was rejected because of anticipated difficulties in forming an enolate in the 
presence of a pyrone and in achieving the required 10,11-anti-11,12-anti-12,14-anti 
stereoselectivity. Instead, disconnection of the C-12, C-13 bond was envisaged to produce the 
two key fragments, 95 and (±)-30 (Scheme 2.1). Both enantiomers of the aldehyde 30 are 
known7, 12, 41 and the unknown (±)-30 should be available from the γ-pyrone 96,42 easily prepared 
  28 
by oligomerization of propionic acid as described by Mullock and Suschitzky.43 The more 
challenging fragment 95 could be prepared by strategically cleaving the bond between C-8 and 
C-9 in its open tautomeric form 97, which would generate the synthon 98 and fragment 99. The 
later fragment (99) is easily accessible in enantioenriched form employing the methodology 
developed in the Ward group for the synthesis of tetrapropionate units.29, 40, 44 Finally, the 
enantiopure fragment 98 could be generated by several different methods; for example, from a 
thiopyran fragment (i.e. 100), by hydroboration of an olefin and then insertion of an ethyl group, 
or employing the Roche ester (ent-27) followed by functionalization and chain extension. 
Scheme 2.1 Synthetic strategies for the synthesis of caloundrin B (3). 
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2.3 Formation of the trioxaadamantane ring system of caloundrin B 
To date, the only study on the formation of the trioxaadamantane ring system present in 
caloundrin B (3) was reported by Ward et al.39 In that work, the pentacyclic sulphur-bridged 
trioxaadamantane 106 (R = Et) was produced directly during FeCl3 mediated deprotection of the 
TES ether and ethylene acetal present in 104 (R = Et). The latter was easily prepared by an 
aldol/oxidation sequence on readily available tetrapropionate precursor 102. Desulfurization of 
106 (R = Et) produced the isolable 107 (R = Et) as a thermodynamically unstable protected form 
of a 3-hydroxy-1,5,7-trione. Ring-chain tautomerism of 107 (R = Et) was studied under various 
reaction conditions and under thermodynamic control, the isomeric trioxaadamantane 108 (R = 
Et) was virtually the exclusive product. The transformation of 107 to 108 required isomerization 
at C-8 and this was shown to occur via keto-enol tautomerism of the open form 112 (R = Et). It 
should be noted that because 108 (R = Et) was produced under thermodynamic control, it could 
be anticipated that the synthesis of any of the tautomers [e.g., 107 (R = Et), 112 (R = Et), 113 (R 
= Et)] would also lead to 108 (R = Et) under thermodynamic control. 
In the present research, two different approaches were proposed to study the formation of 
trioxaadamantane fragments with different substituents at C-9 that might be suitable for 
elaboration into the desired 95. The first route (route A in Scheme 2.2) was analogous to the 
approach previously developed by Ward et al. to form 108 (R = Et) as a model trioxaadamantane 
ring system for caloundrin B.39 Alternatively, in route B it was proposed to start with the 
desulfurized aldol adduct 109. Aldol reaction of 109 with a suitable aldehyde would give 110. In 
contrast to 103, an oxidation/deprotection sequence on 110 would be unproductive as 3-hydroxy-
1,5,7-triones are known to be unstable to the acidic conditions necessary to remove an ethylene 
acetal.8, 33, 36 Acid mediated deprotection of 110 should be feasible but would require a 
chemoselective oxidation of the resulting diol 111 to obtain a tautomer of the desired 108. 
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Scheme 2.2 Strategies proposed to form trioxaadamantane systems 108. 
 
The goal of this study was to identify suitable precursors for the formation of a 
trioxaadamantane bearing a substituent at C-9 that would allow further manipulation to ketone 
95. The 'R groups' illustrated in Scheme 2.2 were selected for several reasons. The 
trioxaadamantane needs to be formed under thermodynamic control and it was anticipated that 
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the steric and electronic properties of the C-9 substituent would influence the equilibrium. 
Examination of the isopropyl substituent (from iPrCHO) would confirm whether use of a 
substituent more hindered than ethyl would still favour trioxaadamantane formation. Successful 
formation of trioxaadamantane 114 with a 2-propenyl substituent (from acrolein) would allow 
functionalization, for example via hydroboration to give 115 (Scheme 2.3). Alternatively, 
producing a trioxaadamantane system such as 117 would require minimal functional group 
manipulations to produce the desired ketone 95. Finally, the use of Roche ester-derived aldehyde 
29 could provide the minimally functionalized trioxaadamantane system 116. The protected 
hydoxypropyl substituent in aldehyde 29 is similar in size to the isopropyl group and the 
configuration at C-10 in the resulting trioxaadamantane 116 would be fixed. Subsequently, that 
substituent could be elongated by addition of an ethyl group to produce the desired 95. 
With the above objectives in mind, studies on the formation of the proposed 
trioxaadamantane ring systems were pursued and are described in this section. 
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Scheme 2.3 Proposed approaches for the generation of trioxaadamantane systems that 
would allow further manipulation. 
 
2.3.1 Sulfur-bridged trioxaadamantanes from 5-alkanoyl-3-[hydroxy(4-oxotetrahydro-
2H-thiopyran-3-yl)methyl]dihydro-2H-thiopyran-4(3H)-one precursors 
2.3.1.1 The isopropyl analogue (from the 5-(2-methylpropanoyl) precursor) 
Previously in the Ward group, it was demonstrated that the formation of a 
trioxaadamantane system bearing an ethyl substituent was possible using route A in Scheme 2.2. 
Thus, the first question in this project was if the size and complexity of the substituent were 
increased, would the trioxaadamantane still be thermodynamically favoured? In order to gain 
some insight on the impact of the size of the C-9 substituent, formation of the isopropyl analogue 
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following route A (Scheme 2.2) was attempted. The aldol reaction of the boron enolate of 
racemic 102§ with isobutyraldehyde produced 118 as a single diastereomer in 82% yield 
(Scheme 2.4). Based on previous studies in the Ward group,45, 46 aldol reactions of the TES 
protected boron enolate of (±)-102 are known to produce aldol adducts with a 3,5-trans-5,1''-anti 
relative configuration. The aldol product 118 was subjected to oxidation with IBX in DMSO for 
10 h; subsequently, the crude product from oxidation was treated with FeCl36H2O in refluxing 
acetone for 12 h affording 63% of the desired trioxadithiopentacycle 119. Raney-Ni 
desulfurization of 119 afforded trioxaadamantane 120 in 61% yield. Exposure of 120 to 
imidazole at 40 °C for 8 days gave the thermodynamically more stable isomer 121 in 40% 
isolated yield.  
Scheme 2.4 Formation of trioxaadamantane system bearing an isopropyl substituent 
following route A. 
 
The mechanism for the isomerization of 120 to 121 involved a ring opening of the 
trioxaadamantane 120 to initially produce hemiacetal 123 that would be in equilibrium with the 
open form 122 and the other three hemiacetal forms 124, 125, and 126 (Scheme 2.5). The more 
                                                
§ Preparation of the TES deprotected (±)-102 was optimized to produce 10 g of product in 81% yield.39 
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stable trioxaadamantane 121 would result from cyclization of 125. In addition to this 
isomerization process, other side reactions could occur, which in principle are responsible of the 
reduced yield of 121. For instance, a retro-Claisen reaction can occur from any of the formed 
hemiacetal forms 123-126. Sequentially, the retro-Claisen product 128 can undergo elimination 
to produce the enone 129. Additionally, the hemiacetal forms are susceptible to dehydration 
furnishing dihydropyrone 127. 
Scheme 2.5 Isomerization of trioxaadamantane 120 to 121 under basic conditions. 
 
 In order to gain more insight about the equilibration process, a sample of 
trioxaadamantane 120, was exposure to imidazole in CDCl3 at 40 °C and its isomerization was 
followed by 1H-NMR (Table 2.1). After 8 days, the reaction was worked up and fractionated. 
During this process, the formation of trioxaadamantane 121 and hemiacetal 124 were observed 
along with 127, 128, and 129. Plotting the relative amounts of 120, 121, and 124 as a function of 
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time (Chart 2.1) revealed that the isomerization reached equilibrium after 96 h with a 6:1 ratio of 
trioxaadamantanes 121:120. At longer reaction times the amount of 121 was reduced because 
there were inceasing amounts of other products formed by irreversible reactions (i.e. retro-
Claisen, dehydration, elimination).  
Table 2.1 Isomerization of trioxaadamantane 120 in CDCl3. 
 components present (% by 1H NMR) 
Time 
(h) 120 
 
128 129 124 127 121 
0 100 0 0 0 0 0 
17 58 4 0 16 0 21 
41 27 12 0 10 7 44 
70 14 15 3 7 5 57 
96 10 17 4 6 5 58 
142 8 19 7 5 7 53 
169 8 21 10 3 7 51 
209 8 21 12 4 9 45 
a 9 20 12 6 8 46 
b 6.5 17 5 8 7 40 
a Crude product obtained after 210 h. b Isolated products from crude.  
Chart 2.1 Isomerization of trioxaadamantane 120 in CDCl3. 
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2.3.1.2 The 3-benzyloxy-2-methylpropyl analogue (from the Roche ester) 
With the successful synthesis of 121, the next step was to investigate the formation of a 
trioxaadamantane bearing a (1-benzyloxy)-isopropyl substituent at C-9 using the sequence of 
reactions described in route A (Scheme 2.2). The boron mediated aldol reaction of enantiopure 
102 with the Roche ester-derived aldehyde 29 produced a single diastereomer in 82% yield. 
Oxidation of the alcohol with IBX in DMSO for 5.5 h followed by deprotection of the TES and 
acetal groups by treatment with FeCl36H2O for 12 h produced the desired 
trioxadithiopentacycle 131 in 58% yield over 2 steps. Raney-Ni desulfurization of 131 provided 
a mixture of trioxaadamantane 133 and its debenzylated form 132 in low yield. Surprisingly, 
isomerization of 133 in the presence of imidazole at 40 °C gave only hemiacetal 134 by 1H-
NMR without evidence for the presence of the expected 116. 
Scheme 2.6 Approach to trioxaadamantane 116 from 102 and Roche ester-derived 
aldehyde 29. 
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Because of the problems encountered in the formation of the trioxadithiopentacycle 131 
and its subsequent desulfurization with Raney-Ni, the possibility for preparation of a 
trioxaadamantane such as 116 employing route B (Scheme 2.2) was considered. 
2.3.2 Trioxaadamantanes from 2-substituted 7-hydroxy-4,6,8-trimethylundecane-3,5,9-
trione precursors 
2.3.2.1 7-hydroxy-2,4,6,8-tetramethylundecane-3,5,9-trione precursor 
To study route B in Scheme 2.2, the precursor 135 was prepared by desulfurization of 
aldol 118 in 92% yield. Subsequently, the protecting groups (i.e., TES and ethylene acetal) were 
hydrolyzed by treatment with FeCl36H2O in acetone at room temperature for 1 h to afford 136 
in 72% yield. Reaction of 136 with TESOTf was attempted to determine which of the two 
alcohols was more reactive. At moderate conversion the C-9 protected 137 was produced 
selectively in 50% yield along with unreacted starting material suggesting that selective 
oxidation of the C-9 alcohol in diol 136 could be achieved. 
Scheme 2.7 Formation of trioxaadamantane system 121 following route B. 
 
As anticipated, diol 136 was oxidized with DMP observing predominantly a selective 
oxidation at C-9 to produce the 5-hydroxy-3,7,9-trione as a mixture of three hemiacetal forms 
(i.e., 124 and 124a) along with minor amounts of other tautomers (i.e. enol and keto forms). 
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Submission of this mixture of tautomers to imidazole at 40 °C in CDCl3, afforded the expected 
trioxaadamantane 121. Monitoring the isomerization by 1H-NMR indicated that the maximum 
amount of 121 (ca. 70%) was present after ca. 2 days; Table 2.2).  After a reaction time of 125 h, 
121 was isolated in 35% yield.  
Table 2.2 Isomerization to trioxaadamantane 121 in CDCl3 . 
components present (% by 1H-NMR) 
Time (h) 122 128 129 124 127 121 
21 0 16 0 9 7 68 
53 0 18 0 4 7 71 
71 0 18 3 4 8 67 
116 0 20 5 4 8 63 
a 7 16 4 5 7 61 (35)b 
a Crude product after 125 h. b Isolated product from crude. 
2.3.2.2 2-Methylidene precursor 
Raney-Ni desulfurization of the tetrapropionate unit (−)-102 afforded the enantioenriched 
ketone (+)-109 in 85% yield (Scheme 2.8). A boron mediated aldol reaction of (+)-109 with 
methacrolein produced 138 as a single diastereomer in 55% yield. Deprotection of the TES and 
ethylene acetal groups was achieved with FeCl3·6H2O to give diol 139 in 52% yield. Although 
attempted selective oxidation of 139 with MnO2 did not produce the desired product, treatment 
with DMP was successful. The resulting product 140, a mixture of tautomers, was directly 
submitted to imidazole in CDCl3 at room temperature for 19 h to give the retro-Claisen product 
141 in 24% yield as the only isolable material without evidence of the presence of the desired 
trioxaadamantane 114. In view that those results were not promising for the formation of the 2-
propenyl substituted trioxaadamantane system, it was decided to investigate other suitable 
substituents at C-9. 
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Scheme 2.8 Approach to a trioxaadamantane system bearing a 2-propenyl substituent. 
 
2.3.2.3 2-Benzyloxymethyl precursors (from the Roche ester) 
Following route B in Scheme 2.2, aldol reaction of the Roche ester-derived aldehyde 29 
with the enantioenriched ketone (+)-109 via its Ti ‘ate’ or Li enolate produced keto alcohol 142 
as a mixture of 3 or 4 diastereomers. In a three step procedure, hydrolysis of the TES and 
ethylene acetal protecting groups in 142 followed by chemoselective DMP oxidation of the 
resulting diol and then exposure to imidazole produced mainly hemiacetal 134 along with traces 
of the desired trioxaadamantane 116 (Scheme 2.9). 
Scheme 2.9 Approach to trioxaadamantane 116 from Roche ester-derived aldehyde 29. 
 
  40 
Several experiments were performed with hemiacetal 134 with the objective of inducing 
its isomerization to the trioxaadamantane 116 (Scheme 2.10). Exposure of hemiacetal 134 to 
imidazole at 40 °C for 33 h, provided recovered hemiacetal 134 in ca. 75% with traces of the 
desired trioxaadamantane 116 together with other species (e.g., retro-Claisen and elimination 
products). It was hypothesized that hemiacetal form 134 could be stabilized by H-bonding, 
thereby disfavouring the trioxaadamantane form 116. Therefore, it was proposed that the use of a 
polar solvent for the isomerization step (i.e. THF or MeOH), might disrupt the putative 
intramolecular H-bond in hemiacetal 134, and facilitate the formation of the desired 
trioxaadamantane 116. When the hemiacetal 134 was submitted to imidazole in refluxing THF or 
MeOH for 1 h, the starting hemiacetal form 134 remained as the major compound in the mixture. 
Motivated by Paterson’s report on the synthesis of muamvatin,36 where their respective 
hemiacetal (76 in Scheme 1.9) produced the desired trioxaadamantane ring system on exposure 
to silica, a sample of hemiacetal 134 was adsorbed on a SiO2 PTLC plate and extracted after 18 
h. The resulting mixture consisted of hemiacetal 134 (ca, 40%), desired trioxaadamantane system 
116 (ca. 15%) and other species (e.g. retro-Claisen and/or elimination products; ca. 45%) by 1H 
NMR. However, these results were not very promising because the hemiacetal 134 was always 
the predominant component after attempted isomerization and, at best, only a small amount of 
the desired trioxaadamantane 116 was formed along with significant amounts of side products. 
Concluding that this method would not provide synthetically useful amounts of 
trioxaadamantane 116, a final approach involved the use of a TIPS protecting group to disfavour 
the putative stabilizing intramolecular H-bond in 134.  The TIPS protected trioxaadamantane 143 
was prepared by desulfurization of 131 (in Scheme 2.6) followed by treatment with TIPS-OTf.   
Trioxaadamantane 143 was stable to imidazole in CDCl3 at room temperature for 10 h; however, 
  41 
after 5 days at 40 °C 143 was completely consumed and hemiacetal 144 was the only isolated 
product. 
Scheme 2.10 Attempts for folding hemiacetal 134 or 144 to the trioxaadamantane system 
116 or 145. 
 
The unfavourable results in these experiments deserved a careful conformational analysis 
in order to find an explanation for the observed outcomes. At this time, it was hypothesized that 
the configuration at C-10 could be playing an important role in the formation of the 
trioxaadamantane system. Simple molecular mechanics calculations, employing the software 
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Spartan,** on the trioxaadamantanes 148 and 10-epi-148 suggested that the latter was ca. 0.5 
Kcal/mol more stable (Figure 2.2). Similar calculations on the most stable hemiacetal tautomers 
146 and 10-epi-146 suggested that 146 was considerably more stable (4.4 Kcal/mol) primarily 
due to a favourable H-bond between the hemiacetal OH and methyl oxygen. The above 
calculations suggested that the unfavourable equilibrium observed in the attempted formation of 
148 might be reversed in the 10-epi diastereomer. To test that hypothesis, the preparation of 10-
epi-116 following route B in Scheme 2.2 was attempted. 
 
 Figure 2.2 Ground state energies for the equilibrium conformer of 146, 10-epi-146, 148, 
and 10-epi-148.  
                                                
** All calculations were performed using the software Spartan ’08 V 1.1.2 for Mac from Wavefunction, Inc. The 
calculations were performed by finding the equilibrium conformer using Molecular Mechanics / MMFF (Merck 
Molecular Force Field) model and the ground state energies were taken. 
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The preparation of 10-epi-116 would require ketone 109 and ent-29; however, ent-10-epi-
116 could be prepared from ent-109 and 29. Experimentally, the second option was used because 
aldehyde 29 was on hand and both enantiomers of 109 were available.††  
 
 Figure 2.3 Starting materials to prepare trioxaadamantanes 116, ent-116, 10-epi-116, and 
ent-10-epi-116. 
Following the same route as illustrated in Scheme 2.9, aldol reaction of 29 with the Ti 
‘ate’ or Li enolates of ent-109 gave a mixture of aldol adducts 149 (79-81%). Gratifyingly, after 
TES and acetal deprotection, DMP oxidation and isomerization with imidazole, 149 was 
converted to the desired trioxaadamantane ent-10-epi-116 in 42% overall yield. 
                                                
†† The preparation of the Roche ester-derived aldehyde 29 required 3 steps starting from the commercially available 
Roche ester.46  
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Scheme 2.11 Synthesis of the trioxaadamantane ent-10-epi-116. 
 
In view of these experimental results and the molecular mechanics calculations, it seemed 
clear that H-bonding was playing an important role for the stabilization of certain hemiacetal 
forms, thus favouring the equilibrium towards the hemiacetal 134 in the first attempt (Scheme 
2.9) and towards the trioxaadamantane ent-10-epi-116 in the second attempt (Scheme 2.11). 
Comparing hemiacetals 134 and 10-epi-134 (Figure 2.4) where both have all the large groups in 
equatorial orientations in a chair conformation, H-bonding between the anomeric OH and OBn 
group in 134 can occur without any syn pentane interactions in the molecule. In contrast, the 
same H-bonding in 10-epi-134 results in a syn pentane interaction between the methyl groups as 
illustrated in Figure 2.4.  
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Figure 2.4 Formation of 134 and 10-epi-116 after isomerization with imidazole. 
2.3.2.4 2-(4-benzyloxytetrahydro-2H-thiopyran-3-yl) precursor 
In view of the successful preparation of trioxaadamantane ent-10-epi-116, the formation 
of a trioxaadamantane with a 2-(4-benzyloxytetrahydro-2H-thiopyran-3-yl) substituent could be 
another possibility towards the synthesis of caloundrin B (3) because this would have all the 
necessary carbons in place to generate 10-epi-95 (Scheme 2.3). The main question was if the 
trioxaadamantane could be formed with this relatively more hindered substituent. The 
preparation of the required aldehyde 159 began with a baker's yeast reduction of 154 to yield the 
enantioenriched syn-β-hydroxy ester 155 in 75% and 93% ee (Scheme 2.12).47 Subsequently, 
reduction of the ester 155 with NaBH4 produced diol 156 that was protected as its benzylidene 
acetal 157.  Regioselective reduction of the acetal in 157 with DIBAL-H afforded the primary 
alcohol 158 that was treated with IBX to produce the desired enantioenriched aldehyde 159. 
  46 
Because 159 was prone to isomerization and decomposition (elimination) it was used 
immediately in the aldol reaction with 109. 
Scheme 2.12 Preparation of enantioenriched aldehyde 159. 
 
Reaction of 159 with 109 via its (Z)-lithium enolate gave 160 as a mixture of at least 
three aldol adducts in 77% yield. This mixture of aldol adducts 160 was submitted to the 
standard three step procedure of FeCl36H2O mediated deprotection of the TES and ethylene 
acetal groups, chemoselective oxidation of the resulting diol with DMP, and finally submission 
to imidazole; however, the hemiacetal product 161 was the only product isolated (31% yield over 
3 steps) without detection of the desired trioxaadamantane 162.  
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Scheme 2.13 Approach to trioxaadamantane 162. 
 
At this point, it seemed that the nature of C-9 had a profound effect on the facility to fold 
a trioxaadamantane ring system under thermodynamic control. It was concluded that the best 
option was to continue towards the synthesis of caloundrin B (3) via the trioxaadamantane 
system ent-10-epi-116, because from all previous attempts, this was the only system that would 
afford the preparation of synthetically useful amounts of the trioxaadamantane.  
 
2.3.3 Installing the correct configuration at C-10 for caloundrin B 
Despite several attempts to prepare a trioxaadamantane fragment suitable for application 
towards the synthesis of caloundrin B, only ent-10-epi-116 could be obtained in a reasonable 
yield. Therefore, it was decided to use ent-10-epi-116 towards the synthesis of ent-caloundrin B 
(ent-3). However, to pursue this objective, the configuration at C-10 in ent-10-epi-116 had to be 
corrected (Figure 2.5).   
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Figure 2.5 Structures of caloundrin B (3) and ent-3.  
In order to prevent unfolding of the acid- and base-sensitive trioxaadamantane ring 
system in ent-10-epi-116, the alcohol was protected as its TMS ether by treatment with TMSOTf 
to furnish ent-10-epi-163 in 87% yield. Then debenzylation using Pd/C, H2 48 of ent-10-epi-163 
produced alcohol ent-10-epi-164 in 86% yield. At this point, efforts were directed towards 
elimination of the alcohol group in ent-10-epi-164 with the expectation that the desired relative 
configuration could be installed by hydroboration of the resulting alkene; however, all attempts 
under different conditions (i.e. selenation,49, 50 mesylation) failed (Scheme 2.14).  
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Scheme 2.14 Attempts to invert the configuration at C-10 of ent-10-epi-164 or ent-10-
epi-167. 
 
Oxidation of ent-10-epi-164 with IBX in DMSO51 successfully afforded aldehyde ent-10-
epi-167 in quantitative yield. It was attempted to form the enol ether ent-10-epi-167 with hopes 
of producing the desired aldehyde ent-167 by hydrolysis under kinetic control. Again, all 
attempts exploring this approach failed.  
Finally, the isomerization of ent-10-epi-167 under basic conditions was investigated. 
When a solution of ent-10-epi-167 in CDCl3 was exposed to imidazole at 40 °C for 1 day,52 a 
separable 4:1 equilibrium mixture of ent-10-epi-167 and ent-167 was produced. Similarly, 
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exposure of a solution of ent-10-epi-167 in DMSO to L-proline53 at room temperature for 10 
days produced the same ratio of the two aldehydes. Despite the unfavourable equilibrium, 
submission of ent-10-epi-167 to six isomerization cycles allowed aldehyde ent-167 to be 
obtained in 49% yield along with recovered ent-10-epi-167 in 28% yield. 
An alternative method for epimerizing C-10 was attempted with ketone ent-10-epi-95. 
This ketone was prepared from aldehyde ent-10-epi-167 by reaction with EtMgBr to afford 
essentially a single diastereomer of ent-10-epi-169 in 88% yield that was oxidized with IBX in 
DMSO51 to produce ketone ent-10-epi-95 in 99% yield. Unfortunately, ent-10-epi-95 proved to 
be quite stable and no isomerization was observed in the presence of imidazole in CDCl3. 
Nevertheless, the preparation of ent-10-epi-95 was useful in the study of aldol reactions with 
kinetic resolution (see Section 2.4.4). 
Reaction of aldehyde ent-167 with EtMgBr produced ent-170 as a 4:1 mixture of the two 
possible diastereomers in 99% yield. Without separation, ent-170 was oxidized with IBX in 
DMSO51 to produce the desired ketone ent-95 in 87% yield (Scheme 2.15). The preparation of 
ent-95 opened the possibility to continue with the study of the next key step towards the 
synthesis of ent-3. 
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Scheme 2.15 Preparation of ketones ent-10-epi-95 and ent-95. 
 
2.4 Application of aldol coupling with kinetic resolution to the synthesis of caloundrin B 
2.4.1 The thiopyran route to polypropionates: design of aldol reactions that proceed with 
kinetic resolution.  
The development of new strategies and their application in the synthesis of 
polypropionates is one of the main topics of research in the Ward group. A very solid 
methodology based on the aldol reaction of thiopyran units has been developed and applied to 
the synthesis of diverse marine polypropionates.29 My contribution to this area involved the 
study of aldol reactions that proceed with kinetic resolution.46  
In all aldol reactions between two chiral fragments, three stereocontrol elements 
contribute to the stereochemical outcome of the resulting aldol products. These are: i) aldehyde 
diastereoface selectivity, ii) enolate diastereoface selectivity, and iii) relative topicity of the aldol 
reaction. Therefore, if the three stereocontrol elements are highly selective,‡‡ it would be possible 
                                                
‡‡ In Heathcock’s studies for acyclic stereoselection in aldol reactions he postulated that: “In reactions involving two 
chiral racemic compounds, the magnitude of mutual kinetic resolution depends upon the diastereoselectivity shown 
by the two reactants in their reactions with achiral reaction partners”. Thus, application of the multiplicativity rule 
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to predict which would be the stereochemical outcome of the major product by application of the 
multiplicativity rule.54-56 
From previous studies in the Ward group, it was established that the enolate diastereoface 
selectivity of tetrapropionate aldol adducts 171 (Scheme 2.16) could be manipulated by the 
absence (i.e. 3,5-syn selectivity) or presence (i.e. 3,5-trans selectivity) of a protecting group on 
the C-1' OH group.45 In addition, the diastereoface selectivity of the aldehyde 173 was shown to 
be highly Felkin selective; i.e., leading to products with a 1”,6”-syn relative configuration.45 In 
this research, the development of conditions to switch the relative topicity (5,1”-anti or 5,1”-syn) 
of the aldol reactions between (±)-171 and (±)-173 were studied. Thereafter, the optimized 
conditions for the aldol reactions were performed with enantiopure ketone 171 in order to 
achieve kinetic resolution.§§  
High 5,1”-anti selectivity (i.e. 174, s = 15-20) was achieved in reactions between (±)-173 
and the enol dicyclohexylborinates of the four diastereomeric aldol adducts (±)-171, whereas 
high 5,1”-syn selectivity (i.e. 175, s = 10-20) was achieved in the same reactions by using the 
Ti(IV) 'ate' enolates of (±)-171 formed by reaction of the LDA-generated Li enolates with 
Ti(OiPr)4 (Scheme 2.16). The same aldol reactions using enantiopure ketones 171 with (±)-173 
proceeded with kinetic resolution allowing access to enantiopure aldol adducts 174 and 175, 
which are useful for further application in synthesis. In addition, this strategy for achieving 
kinetic resolution was thought to be applicable to aldol reactions with suitable substrates and to 
other related processes. 
 
                                                                                                                                                       
to calculate the kinetic resolution selectivities (s = kfast/kslow) in aldol couplings of chiral reactants gives: s = 
(ERA+E+R+A)/(ER+EA+RA+1), where E = enolate diastereoface selectivity; A = aldehyde diastereoface 
selectivity; R = relative topicity of the coupling. 
 
§§ This work was developed in collaboration with Mohammad M. Zahedi. 
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Scheme 2.16 Rational design of aldol reactions with kinetic resolution. 
 
2.4.2 Non-linear effects in the enantiotopic group selectivity of aldol reactions of chiral 
reactants  
To identify conditions for kinetic resolution, reactions of racemic reactants 171 and 173 
were screened under numerous conditions. When both reactants are racemic these reactions 
occur with mutual kinetic enantioselection (MKE) and appropriate analysis of the distribution of 
diastereomers formed allows determination of the ratio of rate constants in the related KR when 
one of the reactants is enantiopure and the other is racemic (i.e. s = kfast/kslow).57  
After optimization of the reaction between (±)-176 and (±)-173 with TiCl2(OiPr)2 to 
produce 5,1”-syn selectivity,58 the same conditions were applied using enantioenriched enolate 
177 (i.e. >94% ee) and racemic (±)-173 in order to perform KR and produce enantioenrich aldol 
adduct 178.  Surprisingly, the selectivity of this reaction did not follow the expected behaviour 
(i.e. SR/SS = kSR/kSS).  
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Performing a series of aldol reactions of racemic (±)-173 with ketone 176 of varying 
enantiomeric purities (Table 2.3, entries 1-7) demonstrated that the diastereoselectivity of the 
reaction decreased as the ee of 176 increased. In addition, similar results were observed when 
ketone aldol adduct (3,1’-syn, 6’,1’-anti 171, R = Ac) was used.*** Non-linear relationships 
between the enantiopurity of a reagent and the enantioselectivity of its reactions have been 
observed previously and are usually attributed to reaction mechanisms involved dimeric or 
oligomeric species.59-62 However, there appears to be no previous reports of a non-linear 
relationship between the enantiopurity of a reactant and its enantiomer selectivity in a kinetic 
resolution. 
It is known that Ti(IV) species can exist as dimers in solution.63 Therefore, if dimeric Ti 
species are formed during the reaction and both reactants are racemic, then the presence of 
homochiral or heterochiral Ti(IV) 'dimers' can be present in solution. In contrast, if both 
reactants are enantiopure, only homochiral 'dimers' are possible. As a consequence, it was 
hypothesized that different reactivities and concentrations of diastereomeric Ti(IV)  'dimers' were 
the cause of the observed change in the selectivities of the reactions with racemic vs. enantiopure 
177. That is, the formation of the putative homochiral Ti(IV) 'dimers' would become increasingly 
favored as the enolate used was increasingly enantioenriched. If the reaction of the putative 
homochiral Ti 'dimer' was less selective than that of the heterochiral 'dimer' and if the formation 
of the heterochiral 'dimer' was thermodynamically favored, then the results observed in Table 
2.3, entries 1-7, could be rationalized.  
 
 
 
                                                
*** Reactions performed by Mohammad M. Zahedi. 
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Table 2.3 Aldol reactions of (±)-173 with TiCl(OiPr)2 enolate 177.  
 
Entry Enolate a (±)-173 (equiv)  
  ee of 176 
(%) 
Conversion d 
(%) 178/179 
d 
1 (±)-177  2 0 81 15 : 1 
2 (-)-177 2 20 73 13 : 1 
3 (-)-177  2 39 70 10 : 1 
4 (-)-177  2 60 77 6 : 1 
5 (-)-177  2 78 72 4.5 : 1 
6 (-)-177  2 98 81 4 : 1 
7 (-)-177  3 98 81 4 : 1 
8 (±)-177b 2 0 84 16 : 1 
9 (±)-177c 2 0 55 19 : 1 
10 (-)-177b 2 98 82 4 : 1 
11 (-)-177c 2 98 56 9 : 1 
12 (±)-177  0.5 0 quant 17 : 1 
13 (±)-177b (+) 0.5   0 quant 4 : 1 
a Reactions at -78 ºC in CH2Cl2, TiCl2(OiPr)2 (4.0 equiv), iPr2NEt (4.0 equiv), enolization time 4 h, reaction time 3 h, 
reaction concentration 0.06 M. b Reaction concentration 0.1 M. c Reaction concentration 0.02 M. d Conversions and 
178/179 ratios were determined by 1H-NMR from the crude sample. 
 
Interestingly, when the reaction was performed at lower concentrations, the selectivity 
slightly improved (Table 2.3, entries 1 and 9). Because lower concentrations should reduce 
proportion of Ti(IV) 'dimers', this observation implied that the reaction of monomeric species 
was more selective than that of 'dimers.' Consistent with that observation, when the reactions of 
enantioenriched enolate were conducted at lower concentration, the selectivity increased 
markedly (Table 2.3, entries 6 and 11). 
Surprisingly, performing the aldol reaction between racemic enolate 177 and a deficiency 
of enantioenriched aldehyde 173 also showed poor selectivity (Table 2.3, entries 12 and 13). The 
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observed result indicates that the enantiopurity of the aldehyde was also contributing to the non-
linear behavior. Thus, it seems that a more complex system perhaps involving coordination of 
aldehyde 173 to a dimeric species of the Ti(IV) enolate of 177 was involved. 
In conclusion, the nonlinear effect in the selectivity was characterized using two different 
substrates. Apparently, both ketone 176 and aldehyde 173 contributed to the selectivity in the 
reaction, and as a consequence, the relative facility of the like vs. unlike combination of reactant 
enantiomers (i.e., kSR/kSS) is dependent on the ee of both reactants, this observation appears to be 
unprecedented. 
2.4.3 Study of the selectivity in the aldol reactions between 3-pentanone and racemic 2-(6-
ethyl-3,5-dimethyl-4-oxo-4H-pyran-2-yl)propanal 
The racemic aldehyde bearing the γ-pyrone fragment (30) was successfully elaborated 
from propionic acid using the conditions of Mullock and Suschitzky to generate the γ-pyrone 
96.43 Subsequently, an aldol-type reaction of paraformaldehyde with the anion generated by 
treatment of 96 with NaHMDS afforded alcohol 180,42 that was oxidized with IBX to produce 
the desired racemic aldehyde 30 in quantitative yield.††† 
Scheme 2.17 Preparation of aldehyde (±)-30. 
 
To establish the diastereoface selectivity of aldehyde 30, various aldol reactions were 
performed with 3-pentanone (Table 2.4). Reaction of the LiHMDS-generated Li enolate of 3-
pentanone64 with (±)-30, produced a mixture of 181 (39%), 182 (9%), and 183 (10%); i.e., 83% 
                                                
††† The procedure for preparation of aldehyde (±)-30 was studied and developed by Leon Lai, unpublished results. 
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of products resulted from Felkin addition to 30. Similar reaction of the Sn(II) enolate of 3-
pentanone (prepared by reaction with Sn(OTf)2/Et3N,65 known to produce Z enolates) with (±)-
30 gave the Felkin adduct 181 as the sole product. Reaction of the (E)-boron enolate of 3-
pentanone (c-Hex)2BCl/Et3N)66 gave a 20:1 mixture of the Felkin adducts 182 and 181, 
respectively. In contrast, reaction of the (E)-lithium enolate of 3-pentanone (LiNtBu(SiMe3))67 
gave a 1.8:1 mixture of the same adducts. Despite the poorly selective relative topicity observed 
in the reaction, addition to the aldehyde (±)-30 was highly Felkin selective. Finally, exchange of 
the LiNtBu(SiMe3)-produced Li enolate of 3-pentanone with (c-Hex)2BCl, in order to produce a 
boron enolate,68-70 followed by reaction with (±)-30 produced a 5.9:1 mixture of 182 and 181, 
respectively. In contrast to the aldol reaction of the unadulterated Li enolate, addition of (c-
Hex)2BCl resulted in marked improvement in stereoselectivity favoring the 4,5-anti product 182, 
but was less selective than the reaction of the traditionally prepared boron enolate. Again, high 
Felkin selectivity was observed for addition to (±)-30. 
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Table 2.4 Aldol reactions between pentanone and racemic 2-(6-ethyl-3,5-dimethyl-4-
oxo-4H-pyran-2-yl) propanal. 
 
Entry Enolate Aldol productsf 
1a LiHMDS  181 (39%), 182 (9%), 183 (10%) 
2b Sn(OTf)2  181 (67%) 
3c (c-Hex)2BCl 182:181 (20:1), 95% conversion 
4d LiNtBu(SiMe3) 182:181 (1.8:1), 90% conversion 
5e 
i) LiNtBu(SiMe3), ii) 
(c-Hex)2BCl 182:181(5.9:1), 91% conversion 
a 3-pentanone (0.480 mmol, 2 equiv), (±)-30 (0.240 mmol, 1 equiv), LiHMDS (0.504 mmol, 2.1 equiv), at -78 °C in 
THF for 30 min. Isolated yield after FCC. b 3-pentanone (0.692 mmol, 3 equiv), (±)-30 (0.230 mmol, 1 equiv), 
Sn(OTf)2 (0.899 mmol, 3.9 equiv), Et3N (1.037 mmol, 4.5 equiv) at -78 °C in CH2Cl2. Enolate formation 30 min and 
aldol reaction for 2 h. Isolated yield after FCC. c 3-pentanone (0.120 mmol, 1 equiv), (±)-30 (0.120 mmol, 1 equiv), 
(c-Hex)2BCl (0.132 mmol, 1.1 equiv), Et3N (0.144 mmol, 1.2 equiv), enolate formation at 0 °C for 1 h and aldol 
reaction at -50 °C for 3 h in ethyl ether. Conversion calculated from 1H-NMR of the crude. d 3-pentanone (0.120 
mmol, 1 equiv), (±)-30 (0.120 mmol, 1 equiv), LiNtBu(SiMe3) (0.132 mmol, 1.1 equiv) at -78 °C in THF. Enolate 
formation 30 min and aldol reaction 5 min. Conversion calculated from 1H-NMR of the crude. e Same amounts as in 
entry 4. Li enolate formation 15 min and then (c-Hex)2BCl (0.120 mmol, 1 equiv) for 15 min. f The set of aldol 
adducts 181, 182, 183, and 184 were previously synthesized and characterized by Leon Lai. 
 
 From the above studies, it was observed that the aldol reactions of 3-pentanone with 
aldehyde (±)-30 were highly Felkin selective under a variety of experimental conditions. 
Therefore, the study of enolate diastereoface selectivity for ent-95 and ent-10-epi-95 under 
different experimental conditions in order to produce the precursor to ent-caloundrin B (ent-3) 
were investigated. 
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2.4.4 Study of the stereoselectivity of aldol reactions between the enantiopure 
trioxaadamantane ketone fragment and the racemic pyrone aldehyde fragment 
Having in mind that aldehyde (±)-30 is highly Felkin selective, aldol reactions of (±)-30 
with ketones ent-95 and ent-10-epi-95 can produce up to four adducts with Felkin selectivity 
(Scheme 2.18). 
Scheme 2.18 Possible products from the aldol reaction of ent-10-epi-95 and (±)-30, 
assuming that Felkin aldehyde diastereoface selectivity is favored. 
 
As was observed in the aldol reaction of (±)-30 with 3-pentanone, the aldol reaction of 
the LiHMDS-generated Li enolate of ent-10-epi-95 with (±)-30 exhibited poor stereoselectivity 
producing a mixture of four diastereomers in a 1.3:1.3:0.8:1 ratio as determined by 1H-NMR of 
the crude reaction mixture. In contrast, addition of (±)-30 to the putative (Z)-boron enolate 
prepared from reaction of ent-10-epi-95 with 9-BBN-OTf and Et3N66, 71 gave a 7:1 mixture of 
two aldol adducts. The major adduct, 185, was isolated in 74% yield. Reduction of 185 with 
NaBH(OAc)372 afforded 78% yield of crystalline diol 189. X-ray analysis of diol 189 established 
the indicated relative configuration of the molecule.  
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Figure 2.6 ORTEP representation for 189. 
The structure of 189 shows that the initial aldol reaction of ent-10-epi-95 with (±)-30 
proceeded predominantly with 12,13-syn relative topicity, Felkin aldehyde diastereoface 
selectivity (13,14-syn), and 10,12-syn enolate diastereoface selectivity. The relative topicity of 
the reaction agreed with the reports in the literature for the diastereoselectivity observed from 
(Z)-enolates in acyclic systems.66 However, the Felkin aldehyde diastereoface selectivity 
observed was opposite to the generally expected results in aldol reactions of chiral Z-enolates 
and chiral 2-Me aldehydes (i.e. 10,12-anti-12,13-syn-13,14-anti).73 A possible explanation could 
be that the pyrone group in aldehyde (±)-30 resembles that of a phenyl group, where the addition 
to the aldehyde occurs predominantly at the Felkin face. 
 In addition, the 13C chemical shifts from C-12 to C-16 of aldol adduct 185 were very 
close to those of the model aldol adduct 181 (Table 2.5 and Chart 2.2). 
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Scheme 2.19 Derivatization of 185 to determine the relative configuration. 
 
Table 2.5  Comparison of 13C-NMR chemical shifts of aldol adducts 181, 182, 183, 184, 
and 185. 
183 
δC (ppm) 
181 
δC (ppm) 
182 
δC (ppm) 
184 
δC (ppm) 
185 
δC(ppm) Assignment 
 
 
12,13-syn 
13,14-anti  
12,13-syn  
13,14-syn  
12,13-anti 
 13,14-syn 
12,13-anti  
13,14-anti  
 
C-11 216.3 216.3 218 217.3 215.4 
C-12 46.8 47.6 47.0 47.0 48.6 
C-13 72.5 72.4 77.0 77.6 71.9 
C-14 38.2 38.8 40.5 40.0 38.4 
H3CC-12 9.3 10.0 15.9 15.9 10.1 
H3CC-14 14.7 15.7 15.2 15.5 16 
C-15 164.1 163.9 164.5 164 164.4 
C-16 119.7 119.0 118.7 119.5 119.1 
H3CC-16 9.8 9.9 9.7 10.1 9.8 
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Chart 2.2 Comparison of 13C-NMR chemical shifts of 185 with those of the model aldol 
adducts (181, 182, 183, and 184). 
 
In addition, when the 1H-NMR chemical shifts of 185 and those of the model adducts 
181, 182, 183, and 184 were compared, the characteristic signal for HC-13 indicated that the 
product had a 12,13-syn selectivity and that for H3CC-14 indicated that the product had a 13,14-
syn selectivity (Table 2.6). This is, the relative topicity of the aldol reaction was 12,13-syn and 
the diastereoface selectivity for addition to the aldehyde was Felkin (13,14-syn) (Table 2.6).   
Table 2.6 Comparison of 1H-NMR chemical shifts of aldol adducts 181, 182, 183, 184 and 185. 
183 
δH (ppm) 
 181 
δH (ppm) 
182 
δH (ppm) 
184 
δH (ppm) 
185 
δH (ppm) Assignment  
 
12,13-syn 
13,14-anti  
12,13-syn 
13,14-syn 
12,13-anti 
13,14-syn 
12,13-anti 
13,14-anti  
 
HC-12 2.71 2.37-2.28 2.54-2.42 2.78 2.92 
HC-13 4.20 4.18 3.68 3.74 4.32 
HC-14 3.08 3.00 3.04 3.12 3.07 
H3C-12 1.22 1.08 1.22 1.29 1.14 
H3C-14 1.13 1.33 1.32 1.23 1.34 
H3C-16 1.95 1.96 1.84 1.97 1.98 
H3C-18 1.92 1.92 1.91 1.94 1.92 
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Aldol reaction of (±)-30 with the putative (E)-boron enolate prepared from ent-10-epi-95 
and (c-Hex)2BCl/Et3N66 produced a 4:1 a mixture of adducts in 83% yield. Following the trends 
from previous results with the (Z)-enolate and knowing that the aldehyde (±)-30 has a strong bias 
for aldol addition with Felkin selectivity, it was presumed that both products resulted from 
Felkin addition (13,14-syn). Because the products were derived from a (E)-boron enolate, 
presumably both products had a 12,13-anti relative configuration. Therefore, it was hypothesized 
that the enolate diastereoface selectivity led to a major product with 10,12-syn relative 
configuration and a minor compound with 10,12-anti relative configuration. Although the 
relative configurations for the aldol adducts were not confirmed, comparison of their 1H-NMR 
signals for HC-13 and H3CC-14 (Table 2.7) and 13C-NMR chemical shifts with those for the 
model adducts 181, 182, 183, and 184 suggested that the major product was 188 and the minor 
product was 186 (Chart 2.3 and 2.4). 
Table 2.7 Comparison of 1H-NMR chemical shifts of aldol aducts 181, 182, 183, 184, 186 and 
188. 
183 
δH (ppm) 
 181 
δH (ppm) 
182 
δH (ppm) 
184 
δH (ppm) 
186 
δH (ppm) 
188 
δH (ppm) Assignment  
 
12,13-syn 
13,14-anti  
12,13-syn 
13,14-syn 
12,13-anti 
13,14-syn 
12,13-anti 
13,14-anti    
HC-12 2.71 2.37-2.28  2.54-2.42  2.78 3.04 3.12 
HC-13 4.20 4.18 3.68 3.74 3.82 3.83 
HC-14 3.08 3.00 3.04 3.12 3.38 2.91 
H3C-C12 1.22 1.08 1.22 1.29 1.28 1.13 
H3C-C14 1.13 1.33 1.32 1.23 1.31 1.30 
H3C-16 1.95 1.96 1.84 1.97 1.88 2.02 or 1.87 
H3C-18 1.92 1.92 1.91 1.94 1.93 2.02 or 1.87 
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Chart 2.3 Comparison of 13C-NMR chemical shifts of 188  (major compound) with those 
of the model aldol adducts (181,182,183, and 184). 
 
Chart 2.4 Comparison of 13C-NMR chemical shifts of 186 (minor compound) with those 
of the model aldol adducts (181, 182, 183, and 184). 
 
In summary, it was confirmed that the aldehyde (±)-30 had a strong preference towards 
Felkin selectivity in aldol reactions under the experimental conditions examined. In addition, the 
enolate diastereoface selectivity for both (E) and (Z) boron enolates of ent-10-epi-95 led 
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preferentially to 10,12-syn aldol adducts and reactions with (±)-30 proceeded with kinetic 
resolution with moderate selectivity. 
In order to synthesize ent-3, it was necessary to prepare aldol adduct 191. Compound 191 
would arise from an aldol reaction between ent-95 and (S)-30. From the studies above, it was 
anticipated that aldol reactions of an (E)-boron enolate of ent-95 would produce adducts with 
10,12-syn-12,13-anti relative configuration and that reaction with the Felkin-selective (±)-30 
would proceed via kinetic resolution with preferential reaction of (S)-30 to give 191. However, 
attempted reaction of ent-95 with (c-Hex)2BCl/Et3N followed by addition of (±)-30 gave a 
mixture of mainly anti aldol adducts, apparently corresponding to 191 and 193 (Scheme 2.20), in 
very low yield. The low conversion was attributed to ineffective formation of the boron enolate; 
thus, alternative conditions to produce the (E)-enolate of ent-95 were investigated. 
Scheme 2.20 Aldol reaction of enantiopure ent-95 and (±)-30 assuming that Felkin 
aldehyde diastereoface selectivity is favored. 
 
There are few reports on the stereoselective formation of (E) Li-enolates.67, 74, 75 As 
previously attempted with 3-pentanone, the reaction of ent-95 with LiNtBuSiMe3, known to 
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produce (E)-Li enolates from ethyl ketones,67 followed by addition of (±)-30 produced a mixture 
of 4 different aldol adducts. After fractionation, the two major aldol products were obtained that 
were tentatively assigned as 12,13-syn aldol adducts 190 and 192 by comparison of their 1H and 
13C chemical shifts with those of the model compounds 181, 182, 183, and 184 (Table 2.8, Chart 
2.5 and 2.6). 
Table 2.8 Comparison of 1H-NMR chemical shifts of aldol aducts 181, 182, 183, 184, 
190 and 192. 
183 
δH (ppm) 
 181 
δH (ppm) 
182 
δH (ppm) 
184 
δH (ppm) 
190 
δH 
192 
δH Assignment  
 
12,13-syn 
13,14-anti  
12,13-syn 
13,14-syn 
12,13-anti 
13,14-syn 
12,13-anti 
13,14-anti    
HC-12 2.71 2.37-2.28  2.54-2.42  2.78 2.78 2.73 
HC-13 4.20 4.18 3.68 3.74 4.08 4.05 
HC-14 3.08 3.00 3.04 3.12 3.04 3.03 
H3CC-12 1.22 1.08 1.22 1.29 1.09 1.07 
H3CC-14 1.13 1.33 1.32 1.23 1.35 1.34 
H3C-16 1.95 1.96 1.84 1.97 1.99 1.98 
H3C-18 1.92 1.92 1.91 1.94 1.95 1.95 
 
Chart 2.5 Comparison of 13C-NMR chemical shifts of 190 (minor compound) with those 
of the model aldol adducts (181, 182, 183, and 184). 
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Chart 2.6 Comparison of 13C-NMR chemical shifts of 192 (major compound) with those 
of the model aldol adducts (181, 182, 183, and 184). 
 
Because formation of the (E)-boron enolate of ent-95 was not efficient using (c-Hex)2BCl 
/Et3N, it was decided to attempt 'transmetallation' of (E) Li enolate with (c-Hex)2BCl. The 
conditions used were inspired by the early reports by Hoffmann et al. on the formation of boron 
enolates by transmetallation of the corresponding Li enolates.68, 69 
Reaction of ent-95 with LiNtBu(SiMe3) followed by addition of (c-Hex)2BCl and, after  
75 min, addition of (±)-30 produced one major aldol adduct isolated in 60% yield along with 
18% of a 2:1 mixture of other aldol adducts (Scheme 2.21). The stereoselectivity of this reaction 
was very different from that observed in the reaction of the LiNtBu(SiMe3)-generated enolate 
without addition of (c-Hex)2BCl. The major product was tentatively assigned as 191 with 12,13-
anti-13,14-syn relative configuration by comparison of its 1H and 13C chemical shifts with those 
of the model compounds 181, 182, 183, and 184 (Table 2.9 and Chart 2.7). A 10,12-syn relative 
configuration for 191 was presumed based in literature reports on the diastereoface selectivity of 
(E)-enolates of chiral ethyl ketones in aldol reactions.76-79 Based on its assigned structure, aldol 
191 was subjected to the transformations described in Section 2.5 towards the synthesis of ent-3. 
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Scheme 2.21 Aldol reactions of ent-95 and (±)-30 under different conditions. 
 
Table 2.9 Comparison of 1H-NMR chemical shifts of aldol aducts 181, 182, 183, 184, 
and 191. 
183 
δH (ppm) 
 181 
δH (ppm) 
182 
δH (ppm) 
184 
δH (ppm) 
191 
δH Assignment  
 
12,13-syn 
13,14-anti  
12,13-syn  
13,14-syn 
12,13-anti  
13,14-syn 
12,13-anti 
13,14-anti   
HC-12 2.71 2.37-2.28  2.54-2.42  2.78 2.93 
HC-13 4.20 4.18 3.68 3.74 3.89 
HC-14 3.08 3.00 3.04 3.12 3.11 
H3C-C12 1.22 1.08 1.22 1.29 1.12 
H3C-C14 1.13 1.33 1.32 1.23 1.29 
H3C-16 1.95 1.96 1.84 1.97 1.92 or 1.93 
H3C-18 1.92 1.92 1.91 1.94 1.92 or 1.93 
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Chart 2.7 Comparison of 13C-NMR chemical shifts of 191 (major compound) with those 
of the model aldol adducts (181, 182, 183, and 184). 
 
In summary, aldol reactions of ent-10-epi-95 and ent-95 with (±)-30 produced various 
aldol adducts under different conditions and proceeded with kinetic resolution with moderate to 
good enantioselectivity. It was possible to establish that additions to (±)-30 were highly Felkin 
selective under all conditions used. The relative topicity of the aldol reaction could be modulated 
by varying the enolate geometry to produce either 12,13-syn or 12,13-anti products and the 
enolate diastereoface selectivity preferentially gave 10,12-syn products in most cases. 
 
2.5 Synthesis of ent-caloundrin B (ent-3) 
With aldol adduct 191 in hand, the completion of the synthesis of ent-3 was envisaged. A 
1,3-syn selective reduction of 191 was achieved by treatment with Et2BOMe and NaBH4 to 
afford the desired syn-diol 194 in 84% yield (Scheme 2.22).80 When compound 194 was 
submitted to TESOTf in the presence of 2,6-lutidine, it was observed that reaction of the OH 
group at C-11 was faster than that at C-13. Therefore, selective protection would be possible. 
However, because recycling would be complicated, the reaction was stopped at the first 
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appearance of the bis-silyl ether (<50% conversion) to give the desired 195 (31%) along with 
recovered 194 (61%). IBX oxidation of 195 produced ketone 196 in excellent yield. Finally, 
exposure of 196 to HF·pyridine cleanly produced ent-3 ([α]D +50; c 0.2, CHCl3), that gave 
spectroscopic data (MS, IR, 1H and 13C NMR) that matched perfectly with those reported15 for 
isolated 3 ([α]D −19; c 0.2, CHCl3) (Tables 2.10 and 2.11).  
Scheme 2.22 Completion of the synthesis of ent-3. 
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Table 2.10 Comparison of 1H-NMR spectra (CDCl3) of natural 3 and synthetic ent-3. 
 
Natural a  
caloundrin B (3)  Assignment 
Synthetic b 
 (ent-3) 
δH (ppm) 
(400 
MHz) multiplicity J (Hz)  
δH (ppm) 
(500 
MHz) multiplicity J (Hz) 
4.13 q 7 HC-14 4.14 q 7 
3.95 d 7.9 HOC-11 3.95 d 7.5 
3.81 br d 3.5 HC-5 3.83 br d 3.5 
3.67 ddd 
7.9, 5, 
4.7 HC-11 3.68 ddd 7.5, 5, 5 
3.01 dq 7, 5 HC-12 3.03 dq 7, 5 
2.6 br s  HOC-7 2.62 br s  
2.55 q 7.6 H2C-20 2.62-2.52 m  
2.22 q 6.7 HC-8 2.24 q 6.5 
2.09 dq 7, 3.5 HC-4 2.10 dq 7, 3.5 
2.04 dq 7.6, 4.7 HC-10 2.09-2.03 2H, m 
1.96 dq 7, <1 HC-6 overlap   
2.06 s  H3CC-16 2.07 s  
1.94 s  H3CC-18 1.95 s  
1.59 q 7.5 H2C-2 1.65-1.54 m  
1.36 d 6.7 H3CC-14 1.38 d 7 
1.15 t 7.6 H3CC-21 1.16 t 7.5 
1.08 d 7 H3CC-6 1.09 d 7 
1.01 d 7 H3CC-12 1.03 d 7 
0.98 d 6.7 H3CC-8 0.99 d 6.5 
0.95 d 7 H3CC-10 0.97 d 7 
0.91 t 7.5 H3C-1 0.93 t 7.5 
0.91 d 7 H3CC-4 0.93 d 7 
a Data and assignments from Garson et al.15 b In this work it was used δH CHCl3 = 7.26. 
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Table 2.11 Comparison of 13C-NMR spectra of natural 3 and synthetic ent-3. 
 
Natural a  
caloundrin B (3) δC (ppm) Assignment a 
Synthetic b,c 
 (ent-3) δC (ppm) 
213.1 C-13 213.4 
179.6 C-17 179.8 
164.8 C-19 165.0 
160.1 C-15 160.3 
120.2 C-16 120.4 
118.5 C-18 118.7 
102.9 C-9 103.1 
102.8 C-3 103.0 
97.2 C-7 97.4 
78.4 C-5 78.6 
77.4 C-11 77.7 
50.4 C-14 50.7 
46.2 C-12 46.5 
41.7 C-10 42.0 
36.7 C-8 36.9 
36.6 C-4 36.8 
35.6 C-6 35.8 
29.7 C-2 29.7 
24.7 C-20 24.9 
16.1 H3CC-12 16.3 
13.4 H3CC-14 13.6 
13.4 H3CC-6 13.6 
12.3 H3CC-4 12.6 
11.3 H3C-21 11.5 
11.2 H3CC-10 11.4 
10.1 H3CC-16 10.4 
9.5 H3CC-18 9.8 
7.5 H3CC-8 7.7 
6.3 H3C-1 6.5 
a Data and assignments from Garson et al. (inverse detection at 500 MHz).15 
b
 
13C-NMR at 125 MHz. c Chemical shifts of ent-3 are consistently 0.2-0.3 ppm higher than natural 3 presumably 
due to a different standard. In this work it was used δC CDCl3 = 77.23. 
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In conclusion, the first synthesis of ent-3 was achieved in 16 linear steps starting from ent-
102. The key steps in the synthesis involved the formation of the thermodynamically stable 
trioxaadamantane system ent-10-epi-116 and its transformation to ent-167 by isomerization of 
ent-10-epi-167. Finally, the rationally designed aldol reaction between the putative (E)-enolate of 
ent-95, formed by transmetallation of the Li enolate with (c-Hex)2BCl, with (±)-30 proceeded 
with kinetic resolution and constituted the first synthetic application of this unusual 
transformation.  
 
2.6 Isomerization of ent-caloundrin to ent-siphonarin B 
To investigate the thermodynamic stability and possible isomerization of caloundrin B, 
ent-3 was treated with imidazole in CDCl3 at room temperature and the reaction was monitored 
by 1H-NMR (Figure 2.7). The rapid (reversible?) formation of an unidentified species along with 
the slow accumulation of ent-2 was observed. After 24 hours, the 1H-NMR of the crude (after 
work up) showed that ent-siphonarin B (ent-2) was the predominant component (ca. 50%). 
Fractionation of the mixture by PTLC afforded ent-siphonarin B (ent-2) (50%), a mixture of 
hemiacetal forms (22%), along with traces of ent-3 and the unidentified new species observed 
above. Spectroscopic data (1H and 13C-NMR) for ent-2 ([α]D –50; c 0.1, CHCl3) were fully 
consistent with those reported5 for siphonarin B ([α]D +13.2; c 0.01361, CHCl3) (see Tables 2.12 
and 2.13). 
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Figure 2.7 1H-NMR of the isomerization of ent-3 in a solution of imidazole in CDCl3 at 
room temperature for 1 day.  
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 Table 2.12 Comparison of 1H-NMR spectra of natural 2 and synthetic ent-2. 
 
Natural a  
siphonarin B (2)  Assignment 
Synthetic b 
 (ent-2) 
 δH 
(ppm)  multiplicity J (Hz)  
δH (ppm) 
(600 MHz) multiplicity J (Hz) 
5.14 s - HO 5.12 s  
3.88 br d 10.5 HC-5 3.91 dd 10.5,1.5 
3.81 br s - HC-11 3.81 br s - 
3.28 q 7 HC-14 3.27 q 7 
3.11 br s - HO 3.09 br s - 
2.79 q 7 H2C-20 2.77 ap q 7.5 
2.66 q 6.5 HC-8 2.66 dq 7, 1.5 
2.61 br q 7 HC-4 2.61 br q 6.5 
2.48 dq 18.5, 7 HC-2 2.48 dq 18.5, 7 
2.28 dq 10.5, 6.5 HC-6 2.32-2.18 2H, m - 
2.25 dq 18.5,7 HC-2 - - - 
2.04 dq 7, 2.5 HC-12 2.05 dq 7, 2.5 
2.00 s - H3CC-18 1.97 s - 
1.98 s - H3CC-16 1.96 s - 
1.83 dq 7, 2 HC-10 1.86 dq 7, 2 
1.25 d 7 H3CC-12 1.25 d 7 
1.21 d 7 H3CC-10 1.21 d 7 
1.20 t 7 H3CC-20 1.21 t 7.5 
1.18 d 7 H3CC-14 1.18 d  7 
1.07 d 7 H3CC-4 1.07 d 7 
1.07 d 6.5 H3CC-8 1.07 d 6.5 
0.94 t 7 H3C-1 0.94 t 7 
0.76 d 6.5 H3CC-6 0.77 d 6.5 
a Data and assignments from Faulkner et al.5, 15 b In this work it was used δH CHCl3 = 7.26. 
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 Table 2.13 Comparison of 13C-NMR spectra of natural 2 and synthetic ent-2 (inverse 
detection at 600 MHz). 
 
Natural a siphonarin B (2)  
δC (ppm) Assignment b 
Synthetic c (ent-2) 
 δC (ppm) 
213.3 C-3 213.4 
206.4 C-7 206.5 
179.8 C-17 179.9 
165.5 C-19 165.6 
161.6 C-15 161.6 
121.6 C-16 121.7 
117.2 C-18 117.2 
105.1 C-9 105.2 
103.1 C-13 103.2 
74.6 C-5 74.6 
74.6 C-11 74.6 
50.0 C-8 50.0 
46.0 C-4 46.1 
45.3 C-6 45.4 
42.4 C-14 42.5 
38.7 C-12 38.8 
38.4 C-10 38.5 
35.6 C-2 35.7 
24.7 C-20 24.7 
13.0 H3CC-10 - 
12.6 H3CC-12 12.7 
11.9 H3CC-14 12 
11.4 H3CC-20 11.5 
10.9 H3CC-16 11.1 
9.4 H3CC-18 9.4 
9.3 H3CC-6 - 
8.6 H3CC-8 8.7 
8.2 H3CC-4 - 
7.4 H3C-1 7.6 
a Data from Faulkner et al.4 b Assignments from Garson et al.15 c There were four unresolved ‘missing’ signals at 8.2, 
9.3, 13.0, and 74.6. 
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Following the isomerization of ent-3 under the conditions used above for 5 days 10 h and 
then fractionation of the crude by PTLC produced ent-2 (33%), ent-baconipyrone C (ent-6) 
(19%), ent-14-epi-baconipyrone C (ent-14-epi-6) (16%), and hemiacetal forms from ent-48 (ca. 
20%). 
To follow the isomerization process more closely, to a solution of ent-3 in CH3CN was 
added imidazole and the reaction followed by HPLC (Figure 2.8). Using pure samples, retention 
times for ent-caloundrin B (ent-3), siphonarin B (2), and the mixture of hemiacetal forms from 
ent-48 were established. After 2 hours, ca. 1:1 mixture of ent-3 and an unknown compound was 
observed and this ratio remained essentially constant over several days. After 1 day, ca. 20% of 
the mixture was ent-siphonarin B (ent-2) growing to ca. 70% after 6 days. The mixture was 
essentially unchanged after 8 days, and consisted of ent-siphonarin B (ent-2), mixture of 
hemiacetal forms from ent-48, and other unidentified components with no more than traces of 
ent-3 remaining. 
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Figure 2.8 HPLC studies for the isomerization of ent-3 in a solution of imidazole in 
CH3CN at room temperature for 8 days. 
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Monitoring the isomerization of ent-3 in the presence of imidazole both by 1H-NMR and 
HPLC indicated that the process involved a rapid equilibrium between ent-3 and an unknown 
intermediate. To determine the identity of this intermediate, the reaction of ent-3 with imidazole 
in CDCl3 was stopped after 1 h affording a 1.3:1 ratio of ent-3 and the unknown intermediate (by 
1H-NMR). Analysis of the 13C-NMR spectrum of the mixture clearly indicated that the unknown 
contained a trioxaadamantane fragment in its structure (signals at δC 102.7, 102.8, and 97.6).  
Comparison of the 13C-NMR chemical shifts of ent-3 and the unknown revealed the same trends 
as a similar comparison of baconipyrone C (6) and 14-epi-baconipyrone C (14-epi-6) (Table 
2.14).9 Thus, it was concluded that the unknown intermediate was most likely ent-14-epi-3. 
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Table 2.14 Comparison of 13C-NMR spectra of ent-3, ent-14-epi-3, 6 and 14-epi-6. 
 
ent-3 
δC(ppm) 
ent-14-epi-3 
δC(ppm) 
Assignmenta 6b  
δC(ppm) 
14-epi-6b 
δC(ppm) 
6.5 6.5 C-1 
29.7 29.6 C-2 
103 102.7 C-3 
36.8 36.9 C-4 
78.6 78.2 C-5 
35.8 35.7 C-6 
97.4 97.6 C-7 
36.9 36.9 C-8 
103.1 102.8 C-9 
 
c 
42.0 42.4 C-10 41.3 42.4 
77.7d 76.2d C-11 77.8 76.6 
46.5d 45.1d C-12 48.8 47.8 
213.4 213.5 C-13 210.7 210.6 
50.7d 47.5d C-14 51.2 48.7 
160.3d 159.7d C-15 160.8 160.0 
120.4 120.4 C-16 120.6 120.4 
179.8 179.8 C-17 179.9 179.9 
118.7 118.6 C-18 118.5 118.3 
165.0 165.1 C-19 164.8 165.0 
24.9 24.9 C-20 24.9 25.0 
11.5 11.6 C-21 11.5 11.5 
12.6 12.5 H3CC-4 
13.6 13.4 H3CC-6 
7.7 7.6 H3CC-8 
 
c 
11.4 10.3 H3CC-10 15.3 15.1 
16.3 16.9 H3CC-12 14.4 14.9 
13.6 13.3 H3CC-14 13.4 13.5 
10.4 10.3 H3CC-16 10.1 10.0 
9.8 9.7 H3CC-18 9.7 9.7 
b Data and assignments for 6 according to Faulkner.10 b Taken from reference 9 c Fragments from C1-to C-9 are 
structurally different between ent-3 and 6, therefore those chemical shifts are not comparable. d Δ δC > 0.6 ppm.  
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Thus, the initial transformation after exposure of ent-3 to imidazole was the 
epimerization at C-14, and then ent-3 isomerized to ent-siphonarin B (ent-2). Therefore, during 
the isomerization process the ratio between ent-3 and ent-14-epi-3 remained constant, as 
observed by HPLC. However, once the equilibrium was reached, mainly ent-2 was formed in the 
mixture. In addition, longer reaction time in imidazole also produced ent-baconipyrone C (ent-6) 
and ent-14-epi-6 confirming that baconipyrones 4 and 6 correspond to artifacts from isolation. 
Scheme 2.23 Study of the isomerization of ent-3 into ent-2. 
 
The close correspondence of the spectroscopic data of synthetic ent-3 with those of 
isolated 3, clearly demonstrated their enantiomeric relationship. The relative configuration 
assigned to ent-3 is based on the relative configuration of the aldol adduct 191. Although the 
assignment of the 12,13-anti-13,14-syn relative configuration in 191 was based on spectroscopic 
  82 
evidence, the assignment of 10,12-syn was tentative and based on literature precedents (see 
section 2.4.4). The relatively 'clean' isomerization of ent-3 to ent-2 of known structure clearly 
confirms for the both the relative and absolute configuration proposed for caloundrin B (3) 
because both compounds share the same configuration at C-4, C-5, C-6, C-10, C-11, C-12, and 
C-14, differing only at C-8. Besides, it was proved that ent-3 is thermodynamically less stable 
than ent-2 and therefore, it cannot be an artifact from isolation. In addition, the hypothesis that 
proposed 3 as the biosynthetic product from which 2, 4, and 6 are formed is more viable. 
 
2.7 Conclusions 
In summary, the first synthesis of ent-3 was achieved in 16 linear steps from ent-102. In the 
presence of imidazole, ent-3 was cleanly isomerized to ent-siphonarin B ent-2 with no more than 
traces of ent-3 remaining. The isolation of ent-3 from this experiment clearly establishes that 
caloundrin B (3) and siphonarin B (2) share the same absolute configurations at all stereocentres 
(except C-8) and confirms the proposed relative and absolute configuration for 3. These results 
also firmly establish that caloundrin B (3) is thermodynamically much less stable than siphonarin 
B (2) confirming previous calculations and explaining the failure9 to obtain 3 by attempted 
isomerization of 48. Consequently, caloundrin B (3) cannot be an isolation artifact of siphonarin 
B (2) but presumably is formed in an enzyme-mediated or other templated process. Thus, 
caloundrin B (2) must now be considered as a plausible biosynthetic product from which the 
formation of siphonarin B (2), baconipyrone A (4), and baconipyrone C (6) can be readily 
explained (see section 1.2.2.2).  
The synthesis of ent-3 required the development of various methodologies that were 
crucial for understanding the requirements for formation of the desired trioxaadamantane ring 
system and for assembling the complete carbon skeleton of ent-3 with the correct relative 
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configuration. It was discovered that the C-10 configuration had a profound influence on the 
thermodynamic stability of the trioxaadamantane ring system. Because of avoidance of syn-
pentane interaction between the methyl groups at C-8 and C10, the C-10 configuration dictates 
the orientation between the side chain and the trioxaadamantane. This orientation facilitates a 
stabilizing H-bond in the trioxaadamantane or a hemiacetal tautomer that strongly influences the 
position of the equilibrium. Unfortunately, the 'wrong' C-10 configuration was required to allow 
formation of the trioxaadamantane under thermodynamic control. As a consequence, a correction 
of the C-10 configuration after formation of a stable trioxaadamantane was required. The rather 
lengthy isomerization sequence used was effective but a second generation synthesis will be 
much more efficient if a better solution to this problem can be designed.  
Applying the multiplicativity rule to rationally design aldol reactions that proceed with 
kinetic resolution was shown to be possible in a proof-of-concept study.46 During the 
development of this methodology, an unprecedented non-linear effect was discovered and 
characterized in which the enantioselectivity was shown to be dependent on the enantiopurity of 
both reactants. Building on the principles established, aldol reactions of achiral ketones with 
aldehyde (±)-30 were shown to be highly Felkin diastereoface selective suggesting that (±)-30 
would react with kinetic resolution with suitable enantiopure ketones. The synthesis of the 
epimeric ketones ent-95 and ent-10-epi-95 allowed preliminary studies that informed the 
prediction that the (E)-boron enolate of ent-95 would react with (±)-30 to produce an aldol 
adduct with the correct selectivity to permit synthesis of ent-3. During the studies, it was 
discovered that the desired (E)-enol borinate of ent-95 could be prepared by transmetallation of 
the LiNtBu(SiMe3)-generated (E)-Li enolate and its reaction with (±)-30 gave the desired adduct 
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191 (dr 3.3), as predicted. This method of forming boron enolates will be likely be useful in other 
difficult cases. 
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3 EXPERIMENTAL PROCEDURES 
3.1 General methods 
Anhydrous solvents were distilled under argon atmosphere as follows: Tetrahydrofuran 
(THF) from benzophenone sodium ketyl; CH2Cl2 from CaH2; MeOH from Mg(OMe)2; DMSO 
from CaH2 at reduced pressure (stored over 4Å molecular sieves). All experiments involving air- 
and/or moisture-sensitive compounds were conducted in an oven dried round-bottom flask 
capped with a rubber septum, and attached via a needle and connecting tubing to an argon 
manifold equipped with mercury bubbler (ca. 5 mm positive pressure of argon). Low 
temperature baths were: ice/water (0 °C), CO2(s)/CH3CN (–50 °C), and CO2(s)/acetone (–78 °C). 
Unless otherwise noted, reaction temperatures refer to that of the bath. Concentration refers to 
removal of volatiles at water aspirator pressure on a rotary evaporator. Preparative TLC (PTLC) 
was carried out on glass plates (20×20 cm) pre-coated (0.25 mm) with silica gel 60 F254. 
Materials were detected by visualization under an ultraviolet lamp (254 nm) and/or by treating a 
1 cm vertical strip removed from the plate with a solution of phosphomolybdic acid (5%) 
containing a trace of ceric sulfate in aqueous sulfuric acid (5% v/v) followed by charring on a hot 
plate. Flash column chromatography (FCC) was performed according to Still et al.1 with silica 
gel 60 (40-63 µm). All mixed solvent eluents are reported as v/v solutions. Unless otherwise 
noted, all reported compounds were homogeneous by thin layer chromatography (TLC) and by 
1H NMR. HPLC experiments were performed using a reverse-phase Zorbax SB-C18® column 
(3.6 um particle size silica, 3.0-100 mm) and a linear gradient of acetonitrile in water (25% to 
75%) was employed as the mobile phase (0 to 35 min).  
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3.2 Spectral data 
High resolution mass spectra (HRMS) and low resolution mass spectra (LRMS) were 
obtained on a double focusing high resolution spectrometer; only partial data are reported. EI 
ionization was accomplished at 70 eV and CI ionization at 50 eV with ammonia as the reagent 
gas; only partial data are reported. Alternatively, HRMS were obtained on an LC-MS/MS time-
of-flight high resolution spectrometer with electrospray ionization (ESI) from acetonitrile 
solution. IR spectra were recorded on a Fourier transform interferometer using a diffuse 
reflectance cell (DRIFT); only diagnostic and/or intense peaks are reported. Unless otherwise 
noted, NMR spectra were measured in CDCl3 solution at 500 MHz for 1H and 125 MHz for 13C. 
Signals due to the solvent (13C NMR) or residual protonated solvent (1H NMR) served as the 
internal standard: CDCl3 (7.26 δH, 77.23 δC). The 1H NMR chemical shifts and coupling 
constants were determined assuming first-order behavior. Multiplicity is indicated by one or 
more of the following: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad), ap 
(apparent); the list of couplings constants (J) corresponds to the order of the multiplicity 
assignment. Coupling constants (J) are reported to the nearest 0.5 Hz (i.e., ±0.25 Hz as consistent 
with the digital resolution ca. 0.2 Hz/pt). The 1H NMR assignments were made based on 
chemical shift and multiplicity and were confirmed by homonuclear decoupling and/or two-
dimensional correlation experiments (gCOSY, gHSQC, gHMBC). The 13C NMR assignments 
were made on the basis of chemical shift and multiplicity (as determined by 13C-DEPT or 
gHSQC) and were confirmed by two-dimensional 1H/13C correlation experiments (gHSQC 
and/or gHMBC). Specific rotations ([α]D) are the average of 5 determinations at ambient 
temperature using a 1 mL, 10 dm cell; the units are 10-1 deg cm2 g-1, the concentrations (c) are 
reported in g/100 mL, and the values are rounded to reflect the accuracy of the measured 
concentrations (the major source of error). 
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3.3 Materials 
The following compounds and reagents were prepared as described previously: 96;43 (S)-30;81, 82 
(-)-109 (>98% ee) and (+)-ent-109 (>98% ee);40, 46 W-2 Raney nickel;83, 84 IBX;85 DMP (from 
IBX).86 iPr2NH was freshly distilled under argon atmosphere from CaH2. 2,6-Lutidine was 
distilled from CaH2 and stored over 4Å molecular sieves. All other reagents were commercially 
available and unless otherwise noted, were used as received. 
 
3.4 Experimental procedures and characterization data 
(3S,5S)-rel-3-[(R)-(6S)-1,4-Dioxa-8-thiaspiro[4.5]dec-6-yl(triethylsilyloxy)methyl]-5-[(S)-1-
hydroxy-2-methylpropyl]tetrahydro-4H-thiopyran-4-one (118) 
S S
SiEt3
O OOO
HO
3
2
1''
3''
2''
6
5
1'
2' 3'
7'
10'
9'
6'
3''
   118 
A solution of (±)-102 (500 mg, 1.19 mmol) in CH2Cl2 (8 mL) was added via syringe to a 
stirred solution of (c-C6H11)2BCl (1 M in hexanes; 2.4 mL, 2.4 mmol) and Et3N (0.350 mL, 2.51 
mmol) in CH2Cl2 (14 mL) at 0 °C under Ar. After 30 min, the reaction mixture was cooled to –
78 °C and a solution of isobutyraldehyde (0.218 mL, 2.39 mmol) in CH2Cl2 (3.5 mL) was added 
via syringe over ca. 8 min. After 16 h, the reaction was quenched by sequential addition of 
phosphate buffer (pH=7; 10 mL), methanol (3 mL) and 30% aq H2O2 (6 mL) with vigorous 
stirring. The mixture was warmed to 0 °C and, after 10 min, was diluted with ice-water and 
saturated aqueous Na2SO3 and extracted with CH2Cl2. The combined organic layers were dried 
over Na2SO4 and concentrated to give the crude product whose 1H NMR spectrum suggest the 
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presence of a single adduct. Fractionation of the crude by FCC (10-20% ethyl acetate in hexanes) 
afforded recovered 102 (59 mg, 12%) and the title compound as a colorless oil (485 mg, 82%). 
IR νmax 3544 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 4.71 (1H, br s, HC-1'), 3.98-3.82 (4H, m, HC-2', HC-3'), 3.65 
(1H, ddd, J = 4, 4, 7.5 Hz, HC-1"), 3.20 (1H, dd, J = 11, 13 Hz, HC-2), 3.06 (1H, d, J = 4 Hz, 
HO), 2.96 (1H, dd, J = 5.5, 12.5 Hz, HC-6), 2.90-2.73 (5H, m, HC-3, HC-5, HC-2, H2C-7'), 
2.67-2.57 (3H, m, HC-6, H2C-9'), 2.13-2.06 (1H, m, HC-6'), 2.06-1.99 (1H, m, HC-10'), 1.83-
1.72 (1H, m, HC-2"), 1.63-1.54 (1H, m, HC-10'), 0.99 (3H, d, J = 7 Hz, HC-3"), 0.95 (9H, t, J = 
8 Hz, H3CCSi ×3), 0.90 (3H, d, J = 7 Hz, HC-3"), 0.64 (6H, ap q, J = 8 Hz, H2CSi ×3). 
13
C NMR (125 MHz, CDCl3) δ 211.9 (s, C-4), 109.0 (s, C-5'), 77.7 (d, C-1"), 69.3 (d, C-1'), 64.5 
(t, C-2' or C-3'), 63.8 (t, C-2' or C-3'), 60.6 (d, C-3), 51.3 (d, C-5), 47.8 (d, C-6'), 34.5 (t, C-10'), 
29.8 (d, C-2"), 29.4 (t, C-7'), 27.1 (t, C-6), 26.8 (t, C-9'), 26.1 (t, C-2), 20.3 (q, C-3"), 15.4 (q, C-
3"), 7.1 (q ×3, CH3CSi), 5.3 (t ×3, CH2Si). 
LRMS (CI, NH3), m/z (relative intensity): 491 ([M+1]+, 1), 419 (24), 389 (23), 303 (37), 287 
(70), 229 (100), 132 (36), 99 (53). 
HRMS m/z calcd for C23H42O5S2Si+H: 491.2321; found: 491.2302 (CI, NH3). 
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(4S,4aS,5aR,9aS,10R,10aS,12S)-rel-Octahydro-5a,4,10-(epoxymethenoxy)-4a-hydroxy-12-
(1-methylethyl)-1H,4aH,5aH-bisthiopyrano[4,3-b:3',4'-e]pyran (119) 
O
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  119 
IBX (1.04 g, 3.71 mmol) was added to a stirred solution of aldol adduct 118 (485 mg, 
0.989 mmol) in dry DMSO (70 mL) at room temperature under Ar. After 10 h, the mixture was 
diluted with ethyl acetate and washed sequentially with saturated aq NaHCO3, H2O and brine. 
The organic layer was dried over Na2SO4 and concentrated to give the crude product that was 
taken up in acetone (225 ml). FeCl3·6H2O (374 mg, 1.39 mmol) was added to the stirred solution 
and the resulting dark brown mixture was heated under reflux. After 12.5 h (the solution was 
yellow), the mixture was diluted with ethyl acetate and washed sequentially with saturated aq 
NaHCO3, H2O and brine. The organic layer was dried over Na2SO4, concentrated and 
fractionated by FCC (30% ethyl acetate in hexanes) to give the title compound as a yellow solid 
(219 mg, 63% over 2 steps). 
IR νmax 3397 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 4.28 (1H, d, J = 3 Hz, HC-1'), 3.55 (1H, dd, J = 3.5, 14 Hz, HC-
2), 3.40 (1H, dd, J = 3, 14 Hz, HC-6), 2.97 (1H, ddd, J = 3,13.5,13.5 Hz, HC-6'), 2.81 (1H, dd, J 
= 12.5, 13 Hz, HC-2'), 2.79 (1H, br s, HO), 2.56 (2H, br d, J = 14 Hz, HC-2, HC-6), 2.44 (1H, , J 
= 2.5, 3, 4, 13.5 Hz, HC-6'), 2.40 (1H, ddd, J = 3, 3, 12.5 Hz, HC-3'), 2.23 (1H, ddd, J = 3, 3, 13 
Hz, HC-2'), 2.12 (1H, br s, HC-3), 2.09 (1H, br s, HC-5), 2.04-1.98 (2H, m, HC-2", HC-5'), 1.87 
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(1H, ddd, J = 4, 13.5, 13.5 Hz, HC-5'), 1.04 (3H, d, J = 7 Hz, HC-3"), 0.90 (3H, d, J = 7 Hz, HC-
3"). 
13
C NMR (125 MHz, CDCl3) δ 102.9 (s, C-1"), 99.0 (s, C-4'), 95.1 (s, C-4), 76.8 (d, C-1'), 45.1 
(d, C-3'), 41.5 (d, C-5), 37.6 (t, C-5'), 35.6 (d, C-3), 32.8 (d, C-2''), 28.9 (t, C-2), 27.5 (t, C-2'), 
25.2 (t, C-6'), 24.4 (t, C-6), 15.9 (q, C-3"), 15.1 (q, C-3"). 
LRMS (EI), m/z (relative intensity): 330 ([M]+, 100), 242 (34), 209 (29), 154 (31), 153 (35), 126 
(52), 99 (37), 71 (61), 67 (70). 
HRMS m/z calcd for C15H22O4S2: 330.0960; found: 330.0968 (EI). 
(1R,3R,5R,7R,8S,9S,10S)-rel-3-Ethyl-8,9,10-trimethyl-5-(1-methyl)ethyl-2,4,6-
trioxatricyclo[3.3.1.13,7]decan-1-ol (120) 
O
O
O
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Raney nickel (W2; 2 mL settled volume) was transferred to a solution of 119 (50 mg, 
0.15 mmol) in absolute ethanol (1 mL) and the resulting suspension was heated under reflux with 
vigorous stirring in a (previously heated) oil bath at 80 °C. The reaction was monitored by TLC 
and after 30 min, additional Raney nickel (0.5 mL) was added. After 40 min, the suspension was 
allowed to settle and the supernatent was decanted. The solid was resuspended in ethanol and 
heated under reflux for 10 min. This washing procedure was repeated with ethanol, with 
methanol and acetone. The combined supernatents were filtered through Celite®, concentrated, 
and fractionated by FCC (20% ethyl acetate in hexane) to obtain the title compound as a white 
solid (25 mg, 61%). 
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IR νmax 3398 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 3.85 (1H, d, J = 3 Hz, HC-7), 2.57 (1H, s, HO), 2.13 (1H, dq, J = 
3, 7 Hz, HC-10), 2.07 (1H, br q, J = 7.5 Hz, HC-8), 1.98 (1H, dq, J = 1.5, 6.5 Hz, HC-9), 1.86 
(1H, qq, J = 6.5, 7 Hz, HC-2''), 1.63-1.49 (2H, m, H2C-1'), 1.18 (3H, d, J = 7.5 Hz, H3CC-8), 
1.06 (3H, d, J = 6.5 Hz, H3CC-9), 0.99 (3H, d, J = 6.5 Hz, H3C-2''), 0.92-0.86 (9H, m, H3C-2'', 
H3C-2', H3CC-10). 
13
C NMR (125 MHz, CDCl3) δ 102.9 (s, C-3), 102.7 (s, C-5), 98.9 (s, C-1), 79.1 (d, C-7), 43.8 
(d, C-9), 37.3 (d, C-10), 35.4 (d, C-8), 32.7 (d, C-1''), 29.7 (t, C-1'), 16.0 (q, C-2''), 15.2 (q, C-2''), 
14.6 (q, CH3C-8), 12.9 (q, CH3C-10), 10.4 (q, CH3C-9), 6.4 (q, C-2'). 
LRMS (CI, NH3), m/z (relative intensity): 271 ([M+1]+, 31), 253 (100), 249 (20), 183 (35), 165 
(21), 153 (17), 127 (20), 125 (22), 96 (22), 71 (29). 
HRMS m/z calcd for C15H26O4+H: 271.1909; found: 271.1902 (CI, NH3). 
(3S,5S)-3-[(R)-(6S)-1,4-Dioxa-8-thiaspiro[4.5]dec-6-yl(triethylsilyloxy)methyl]-5-[(S)-(2S)-1-
hydroxy-2-methyl-3-(phenylmethoxy)propyl]tetrahydro-4H-thiopyran-4-one (130) 
S S
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A solution of (-)-102 (300 mg, 0.716 mmol) in CH2Cl2 (4 mL) was added via syringe in 2 
min to a stirred solution of (c-C6H11)2BCl (1 M in hexanes; 1.4 mL, 1.4 mmol) and Et3N (0.210 
mL, 1.50 mmol) in CH2Cl2 (6 mL) at 0 °C under Ar. After 30 min, the reaction mixture was 
cooled to –78 °C and a solution of Roche aldehyde (S)-29 (241 mg, 1.35 mmol) in CH2Cl2 (4 
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mL) was added slowly via syringe (ca. 10 min). After 18 h, the reaction was quenched by 
sequential addition of phosphate buffer (pH 7; 7 mL) and MeOH (2 mL). The mixture was then 
transferred to an ice bath and 30% aq H2O2 (4.5 mL) was added with vigorous stirring. After 10 
min, the mixture was diluted with ice-water and saturated aq Na2SO3 and extracted with CH2Cl2. 
The combined organic layers were dried over Na2SO4, concentrated, and fractionated by FCC 
(2% ethyl acetate in dichloromethane) to obtain recovered 102 (51 mg, 17%) and the title 
compound as a colorless oil (350 mg, 82%). 
[α]D –58 (c 2.2, CHCl3) 
IR νmax 3517 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 7.37-7.25 (5H, m, Ph), 4.70 (1H, br s, HC-1'), 4.52 (1H, d, J = 12 
Hz, HCPh) 4.49 (1H, d, J = 12 Hz, HCPh), 3.90-3.70 (5H, m, HC-1", H2C-2', H2C-3'), 3.65 (1H, 
dd, J = 7, 9 Hz, HC-3"), 3.44 (1H, dd, H= 5, 9 Hz, HC-3'') 3.43 (1H, d, J = 4.5 Hz, HO), 3.17-
3.11 (2H, m, HC-2, HC-6), 3.05 (1H, ddd, J = 6, 6, 9 Hz, HC-5), 2.91-2.85 (1H, m, HC-3), 2.85-
2.77 (3H, m, HC-2, H2C-7'), 2.71 (1H, dd, J = 9.5, 12 Hz, HC-6), 2.64-2.61 (2H, m, H2C-9'), 
2.11-2.02 (3H, m, HC-2'', HC-6', HC-10'), 1.58 (1H, ap ddd, J = 6, 6, 14 Hz, HC-10'), 1.03 (3H, 
d, J = 7 Hz, H3CC-2"), 0.96 (9H, t, J = 8 Hz, H3CCSi ×3), 0.64 (6H, ap q, J = 8 Hz, H2CSi ×3). 
13
C NMR (125 MHz, CDCl3) δ 211.5 (s, C-4), 138.6 (s, Ph), 128.5 (d ×2, Ph), 127.7 (d, Ph), 
127.6 (d ×2, Ph), 109.1 (s, C-5'), 75.2 (d, C-1"), 73.5 (t, CH2Ph), 72.4 (t, C-3"), 69.2 (d, C-1'), 
64.5 (t, C-2'), 63.9 (t, C-3'), 60.4 (d, C-3), 51.9 (d, C-5), 47.8 (d, C-6'), 35.6 (d, C-2"), 34.6 (t, C-
10'), 29.5 (t, C-7'), 27.7 (t, C-6), 26.9 (t, C-9'), 26.3 (t, C-2), 15.8 (q, CH3C-2''), 7.2 (q ×3, 
CH3CSi), 5.3 (t, CH2Si). 
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LRMS (EI), m/z (relative intensity): 596 ([M]+, 2), 567 (10), 551 (20), 550 (35), 549 (100), 521 
(10), 506 (8). 
HRMS m/z calcd for C30H48O6SiS2+Na: 619.2553; found: 619.2540 (ESI). 
(4S,4aS,5aR,9aS,10R,10aS,12S)-Octahydro-5a,4,10-(epoxymethenoxy)-4a-hydroxy-12-[(S)-
1-methyl-2-(phenylmethoxy)ethyl]-1H,4aH,5aH-bisthiopyrano[4,3-b:3',4'-e]pyran (131) 
O
O
O
HO
S
S S
OH O O
3
2
1'' 2''
6
5
1'
2'
3'
6'
O
5'
2'
1'
2''
6
54
46'
5'
S
H
3''
3''
OBn
OBn
   131 
IBX (155 mg, 0.555 mmol) was added to a stirred solution of aldol adduct 130 (88 mg, 
0.15 mmol) in dry DMSO (10 mL) at room temperature under Ar. After 5.5 h, the mixture was 
diluted with ethyl acetate and washed sequentially with saturated aq NaHCO3, H2O and brine, 
dried over Na2SO4, and concentrated to give the crude dione (mainly enol form by 1H NMR). 
FeCl3·6H2O (56 mg, 0.21 mmol) was added to a stirred solution of the above crude in acetone 
(33.6 mL) and the resulting purple solution was heated under reflux. After 12 h (reaction mixture 
had turned yellow), the mixture was diluted with ethyl acetate and washed sequentially with 
saturated aq NaHCO3, H2O and brine, dried over Na2SO4, concentrated, and fractionated by FCC 
(25% ethyl acetate in hexanes). The fraction containing the desired product was refractionated by 
PTLC (30% ethyl acetate in hexanes x 3) to give the title compound (38 mg, 58%). 
[α]D +15 (c 0.7, CHCl3) 
IR νmax 3384 cm
-1
. 
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1H NMR (500 MHz, CDCl3) δ 7.34 (4H, d, J = 4.5 Hz, Ph), 7.31-7.24 (1H, m, Ph), 4.55 (1H, d, 
J = 12 Hz, HCPh), 4.46 (1H, d, J = 12 Hz, HCPh), 4.30 (1H, br d, J = 3 Hz, HC-1') 4.03 (1H, dd, 
J = 3, 9 Hz, HC-2"), 3.54 (1H, dd, J = 3.5, 14 Hz, HC-2), 3.42-3.35 (2H, m, HC-2'', HC-6), 2.95 
(1H, dt, J = 2.5, 13, 14 Hz, HC-6'), 2.80 (1H, dd, J = 12.5, 13 Hz, HC-2'), 2.57-2.53 (2H, m, HC-
2, HC-6), 2.43 (1H, dddd, J = 3, 3, 4, 14 Hz, HC-6'), 2.35 (1H, ddd, J = 3.5, 4, 12.5 Hz, HC-3'), 
2.27-2.17 (2H, m, HC-2', HC-2"), 2.14-2.09 (2H, m, HC-3, HC-5), 2.00 (1H, ddd, J = 2.5, 3, 14 
Hz, HC-5'), 1.81 (1H, dt, J = 4, 13, 14 Hz, HC-5'), 1.64 (1H, br s, HO), 1.06 (3H, d, J = 7 Hz, 
HC-3"). 
13
C NMR (500 MHz, CHCl3) δ 138.9 (s, Ph), 128.5 (d ×2, Ph), 127.8 (d ×2, Ph), 127.6 (d, Ph), 
102.9 (s, C-1"), 99.0 (s, C-4'), 95.0 (s, C-4), 76.9 (d, C-1'), 73.4 (t, CH2Ph), 70.8 (t, C-3"), 45.2 
(d, C-3'), 41.4 (d, C-5), 38.8 (d, C-2"), 37.5 (t, C-5'), 35.6 (d, C-3), 28.9 (t, C-2), 27.5 (t, C-2'), 
25.2 (t, C-6'), 24.4 (t, C-6), 11.6 (q, CH3C-1''). 
LRMS (EI), m/z (relative intensity): 436 ([M]+, 29), 259 (23), 241 (20), 153 (15), 91 (100), 67 
(25), 55 (16). 
HRMS m/z calcd for C22H28O5S2: 436.1378; found: 436.1390 (EI). 
(4R,5S,6R)-6-(2-Ethyl-1,3-dioxolan-2-yl)-5-triethylsilyloxy-4-methylheptan-3-one (ent-109).  
O
SiEt3
O
OO
17
52' 3
4' 5'
1''
2''    (−)-109 (ent-109)  
Raney nickel (W2; 20 mL settled volume) was transferred to a solution of (+)-102 (4.20 g, 10.0 
mmol) in absolute ethanol (30 mL) and the resulting suspension was heated under reflux with 
vigorous stirring in an oil bath previously heated to 80 °C. The reaction was monitored by TLC 
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and additional Raney nickel (5 mL settled volume) was added at ca. 40 min intervals. After a 5.5 
h (30 mL of additional Raney nickel added), the reaction mixture was allowed to settle and the 
supernatant was decanted. The solid was suspended in ethanol (50 mL) and heated under reflux 
for 10 min with vigorous stirring and then the mixture was allowed to settle and the supernatant 
was decanted. The washing procedure was repeated 4 times and then 5 times using methanol. 
The combined supernatants were filtered through Celite®, concentrated, and fractionated by 
FCC (10% ethyl acetate in hexane) to obtain the titled compound as a colorless oil (2.9 g, 80%). 
[α]D –68 (c 1.0, CHCl3) 
IR  νmax: 1714 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 4.26 (1H, dd, J = 1.5, 5 Hz, HC-5), 3.90-3.70 (4H, m, H2C-4', 
H2C-5'), 2.79 (1H, dq, J = 5.5, 7 Hz, HC-4), 2.59 (1H, dq, J = 18, 7 Hz, HC-2), 2.44 (1H, dq, J = 
18, 7 Hz, HC-2), 1.78 (1H, dq, J = 1.5, 7 Hz, HC-6), 1,68 (1H, dq, J = 14.5, 7.5 Hz, HC-1"), 1.60 
(1H, dq, J = 14.5, 7.5 Hz, HC-1"), 1.03 (3H, t, J = 7 Hz, H3C-1), 1.00 (3H, d, J = 7 Hz, H3CC-4), 
0.97 (9H, t, J = 8 Hz, H3CCSi ×3), 0.90 (3H, d, J = 7 Hz, H3C-7), 0.82 (3H, t, J = 7.5 Hz, H3C-
2''), 0.61 (6H, ap q, J = 8 Hz, H2CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 213.0 (s, C-3), 113.8 (s, C-2'), 70.9 (d, C-5), 65.2 (t, C-4' or C-
5'), 64.9 (t, C-4' or C-5'), 54.0 (d, C-4), 40.8 (d, C-6), 36.3 (t, C-2), 26.2 (t, C-1"), 10.9 (q, CH3C-
4), 10.5 (q, C-7), 7.7 (q, C-1), 7.2 (t ×3, CH2Si), 7.1 (q, C-2"), 5.4 (q ×3, CH3CSi) 
LRMS  (CI, NH3), m/z (relative intensity): 359 ([M]+, 10), 227 (36), 101 (100) 
HRMS  m/z calcd for C19H38O4Si+H: 359.2618; found: 359.2623 (CI, NH3). 
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(4S,5R,6S)-6-(2-Ethyl-1,3-dioxolan-2-yl)-5-triethylsilyloxy-4-methylheptan-3-one (109).  
O
SiEt3
O
OO
17
52' 3
4' 5'
1''
2''    (+)-109  
Raney nickel (W2; 20 mL settled volume) was transferred to a solution of (-)-102 (0.510 g, 1.22 
mmol) in absolute ethanol (43 mL) and the resulting suspension was heated under reflux with 
vigorous stirring in an oil bath previously heated to 80 °C. The reaction was monitored by TLC 
and after a 25 min, the reaction mixture was allowed to settle and the supernatant was decanted. 
The solid was suspended in ethanol (50 mL) and heated under reflux for 10 min with vigorous 
stirring and then the mixture was allowed to settle and the supernatant was decanted. The 
washing procedure was repeated 2 times and then 3 times using methanol and 3 times using 
acetone. The combined supernatants were filtered through Celite®, concentrated, and 
fractionated by FCC (10% ethyl acetate in hexane) to obtain the titled compound as a colorless 
oil (373 mg, 85%). [α]D +70 (c 1.0, CHCl3); NMR data for (+)-109 were consistent with those 
reported for (-)-109.  
(4S,5R,6S)-rel-6-(2-Ethyl-1,3-dioxolan-2-yl)-5-triethylsilyloxy-4-methylheptan-3-one (109).  
O
SiEt3
O
OO
17
52' 3
4' 5'
1''
2''     (±)-109  
Raney nickel (W2; 14 mL settled volume) was transferred to a solution of (±)-102 (522 mg, 
1.246 mmol) in absolute ethanol (44 mL) and the resulting suspension was heated under reflux 
with vigorous stirring in an oil bath previously heated to 80 °C. The reaction was monitored by 
TLC and after 20 min, additional Raney nickel (6 mL settled volume) was added. After 30 min, 
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the reaction mixture was allowed to settle and the supernatant was decanted. The solid was 
suspended in ethanol and heated under reflux for 10 min with vigorous stirring and then the 
mixture was allowed to settle and the supernatant was decanted. The washing procedure was 
repeated 2 times and then 3 times using methanol and 3 times using acetone. The combined 
supernatants were filtered through Celite®, concentrated, and fractionated by FCC (10% ethyl 
acetate in hexane) to obtain the titled compound as a colorless oil (360 mg, 80%). NMR data for 
(±)-109 were consistent with those reported for (-)-109.  
(2S,3R,4S,6S,7S)-rel-2-(2-Ethyl-1,3-dioxolan-2-yl)-3-triethylsilyloxy-7-hydroxy-4,6,8-
trimethylnonan-5-one (135) 
SiEt3
O OOO
HO
4
8
6
4' 5'
1
1''
2''
2
2'
   135 
Raney nickel (W2; 10 mL settled volume) was transferred to a solution of aldol adduct 
118 (293 mg, 0.597 mmol) in absolute ethanol (10 mL) and the resulting suspension was heated 
under reflux with vigorous stirring in an oil bath at 80 °C (previously heated). After 40 min, the 
mixture was allowed to settle and the supernatent decanted. The solid was suspended in ethanol 
heated under reflux for 10 min, and decanted. The washing procedure was repeated with 
methanol and acetone. The combined supernatents were filtered through Celite® and 
concentrated to give the title compound (237 mg, 92%) that was homogeneous by 1H NMR. 
IR νmax 3508 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 4.27 (1H, dd, J = 1.5, 5 Hz, HC-3), 3.90-3.80 (4H, m, H2C-4', 
H2C-5'), 3.44 (1H, ddd, J = 4, 6, 7 Hz, HC-7), 3.03 (1H, dq, J = 5, 7 Hz, HC-4), 2.89 (1H, dq, J = 
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7, 7 Hz, HC-6), 2.27 (1H, d, J = 6 Hz, HO), 1.90 (1H, dq, J = 1, 7 Hz, HC-2), 1.80-1.57 (3H, m, 
H2C-1'', HC-8), 1.07 (3H, d, J = 7 Hz, H3CC-6), 1.04 (3H, d, J = 7 Hz, H3CC-4), 1-0.95 (12H, m, 
H3C-9, H3CCSi ×3), 0.94 (3H, d, J = 7 Hz, H3C-1), 0.91 (3H, d, J = 6.5 Hz, H3C-9), 0.84 (3H, t, 
J = 7.5 Hz, H3C-2''), 0.64 (6H, ap q, J = 8 Hz, H2CSi ×3). 
13
C NMR (125 MHz, CDCl3) δ 217.4 (s, C-5), 114.0 (s, C-2'), 79.1 (d, C-7), 69.9 (d, C-3), 65.3 
(t, C-4'), 64.9 (t, C-5'), 55.3 (d, C-4), 48.7 (d, C-6), 40.9 (d, C-2), 30.3 (d, C-8), 26.5 (t, C-1''), 
20.2 (q, C-9), 15.4 (q, C-9), 13.5 (q, CH3C-6), 11.4 (q, CH3C-4), 10.7 (q, C-1), 7.3 (q, C-2''), 7.3 
(q ×3, CH3CSi), 5.5 (t ×3, CH2Si). 
LRMS (CI, NH3), m/z (relative intensity): 431 ([M+1]+, 10), 430 (6), 429 (20), 401 (52), 386 
(100). 
HRMS m/z calcd for C23H46O5Si+Na: 453.3006; found: 453.3024 (ESI). 
(4S,5S,6S,8S,9S)-rel-5,9-Dihydroxy-4,6,8,10-tetramethylundecane-3,7-dione (136) 
HO O HO
9
11
75
1
3
O
11    136 
FeCl3·6H2O (103 mg, 0.382 mmol) was added to a stirred solution of aldol 135 (235 mg, 
0.546 mmol) in acetone (124 mL) at room temperature. After 1 h, the mixture was diluted with 
ethyl acetate and washed sequentially with saturated aq NaHCO3, water and brine, dried over 
Na2SO4, concentrated, and fractionated by FCC (30% ethyl acetate in hexane) to provide the title 
compound (109 mg, 72%). 
IR νmax 3473 cm
-1
. 
  99 
1H NMR (500 MHz, CDCl3) δ 4.14 (1H, d, J = 8.5 Hz, HC-5), 3.55 (1H, d, J = 4.5 Hz, HC-9), 
3.48 (iH, br s, HO), 2.89-2.75 (3H, m, HO, HC-6, HC-8), 2.70-2.61 (1H, m, HC-4), 2.61-2.44 
(2H, m, HC-2), 1.84-1.72 (1H, m, HC-10), 1.15 (3H, d, J = 7 Hz, H3CC-4), 1.06 (3H, d, J = 7 
Hz, H3CC-8), 1.03 (3H, t, J = 7.5 Hz, H3C-1), 1.01 (3H, d, J = 7 Hz, H3CC-6), 0.98 (3H, d, J = 7 
Hz, H3C-11), 0.88 (3H, d, J = 7 Hz, H3C-11). 
13
C NMR (125 MHz, CDCl3) δ 218.8 (s, C-7), 216.0 (s, C-3), 77.7 (d, C-9), 73.0 (d, C-5), 50.2 
(d, C-8), 47.6 (d, C-6), 46.7 (d, C-4), 34.9 (t, C-2), 29.8 (d, C-10), 20.3 (q, C-11), 15.2 (q, C-11), 
13.8 (q, CH3C-4 or CH3C-8), 13.7 (q, CH3C-4 or CH3C-8), 9.7 (q, CH3C-6), 7.8 (q, C-1). 
LRMS (CI, NH3), m/z (relative intensity): 273 ([M+1]+, 52), 255 (100), 237 (74), 183 (70), 165 
(52), 86 (43), 57 (96). 
HRMS m/z calcd for C15H28O4+H: 273.2066; found: 273.2069 (EI). 
((1R,3R,5R,7R,8S,9R,10S)-rel-3-Ethyl-8,9,10-trimethyl-5-(1-methyl)ethyl-2,4,6-
trioxatricyclo[3.3.1.13,7]decan-1-ol (121) 
O
O
O
HO
3
7
1
9
5
10
H
1'
2'
1''
2''
2''    121 
DMP (65 mg, 0.154 mmol) was added to a solution of diol 136 (30 mg, 0.11 mmol) in 
CH2Cl2 (8 mL) at room temperature. After 1 h, the mixture was diluted with ethyl acetate and 
washed sequentially with a 1:1 (v/v) mixture of saturated aq NaHCO3 and saturated aq Na2SO3, 
distilled water and brine, dried over Na2SO4, and concentrated to produce the crude 
hydroxytrione as a mixture of hemiacetal, enol and triketone tautomers (28 mg). A solution of 
imidazole (24 mg, 0.36 mmol) and crude hydroxytriketone (23 mg, 0.084 mmol) in CDCl3 (0.6 
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mL; previously neutralized by passing through basic alumina) was heated to 40 °C (oil bath 
temperature). After 5 days (reaction monitored by 1H NMR) the mixture was diluted with ethyl 
acetate and washed sequentially with 1% aq citric acid (´3), NaHCO3 and brine, dried over 
Na2SO4, and concentrated, and fractionated by preparative TLC (20% ethyl acetate in toluene) to 
give the title compound (8.5 mg, 34% over 2 steps) in addition to other fractions that contained 
mixtures of retro-Claisen 128, dehydrated 127, and hemiacetal 124. 
IR νmax 3423 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 3.79 (1H, d, J = 3 Hz, HC-7), 2.63 (1H, s, HO), 2.12-2.05 (2H, 
m, HC-9, HC-10), 2.02 (1H, br q, J = 7 Hz, HC-8), 1.85 (1H, qq, J = 7, 7 Hz, HC-1''), 1.67-1.53 
(2H, m, H2C-1'), 1.11 (3H, d, J = 7 Hz, H3CC-8), 1.00-0.87 (15H, m, H3CC-10, H3CC-8, H3C-2', 
H3C-2'''×2). 
13
C NMR (125 MHz, CDCl3) δ 103.0 (s, C-3), 102.9 (s, C-5), 97.9 (s, C-1), 78.0 (d, C-7), 36.7 
(d, C-10), 35.9 (d, C-8), 34.9 (d, C-9), 32.6 (d, C-1''), 29.7 (t, C-1'), 15.2 (q, C-2''), 15.1 (q, C-2''), 
13.3 (q, CH3C-8), 12.6 (q, CH3C-10), 6.8 (q, CH3C-9), 6.6 (q, C-2'). 
LRMS (CI, NH3), m/z (relative intensity): 271 ([M+1]+, 100), 253 (99), 165 (66), 127 (46), 71 
(58). 
HRMS m/z calcd for C15H26O4+H: 271.1909; found: 271.1905 (CI, NH3). 
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(3S,4R,6S,7R,8S)-rel-8-(2-Ethyl-1,3-dioxolan-2-yl)-3-hydroxy-2,4,6-trimethyl-7-
(triethylsilyloxy)non-1-en-5-one (138) 
SiEt3
O OOO
HO
6
8
4
4' 5'
1
1''
2''
2'
   138 
(c-C6H11)2BCl (1 M in hexane; 0.56 mL, 0.56 mmol) was added via syringe to a stirred 
solution of Et3N (0.078 mL, 59 mg, 0.58 mmol) CH2Cl2 (3 mL) at –78 °C under Ar. After 2 min, 
a solution of ketone 109 (100 mg, 0.279 mmol) in CH2Cl2 (2 mL) was added via syringe. After 2 
h, a solution of methacrolein (0.048 mL, 39 mg, 0.56 mmol) CH2Cl2 (0.5 mL) was added 
dropwise via syringe. After 19.5 h, the reaction was quenched by sequential addition of 
phosphate buffer(pH 7; 5 mL), MeOH (1 mL) and 30% aq H2O2 (1.5 mL) with vigorous stirring. 
The mixture was warmed to 0 °C and after 10 min, was diluted with ice-water and saturated 
aqueous Na2SO3 and extracted with CH2Cl2. The combined organic layers were died over 
Na2SO4 and concentrated to give the crude product whose 1H NMR spectrum suggest the 
presence of a single adduct. Fractionation of the crude by FCC (10-20% ethyl acetate in hexanes) 
afforded recovered 109 (49 mg, 49%) and the title compound (51 mg, 40%). 
IR νmax 3470 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 4.94 (1H, br s, HC-1), 4.92 (1H, br s, HC-1), 4.30-4.22 (2H, m, 
HC-3, HC-7), 3.96-3.82 (4H, m, H2C-4', H2C-5'), 3.38 (1H, br s, HO), 3.08 (1H, dq, J = 4, 7 Hz, 
HC-6), 2.87 (1H, dq, J = 9, 7 Hz, HC-4), 2.04 (1H, br q, J = 7 Hz, HC-8), 1.74 (3H, s, H3CC-2), 
1.71-1.53 (2H, m, H2C-1"), 1.07 (3H, d, J = 7 Hz, H3CC-6), 0.99 (9H, t, J = 8 Hz, H3CCSi ×3), 
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0.94 (3H, d, J = 7 Hz, HC-9), 0.92 (3H, d, J = 7 Hz, H3CC-4), 0.83 (3H, t, J = 7.5 Hz, HC-2"), 
0.65 (6H, ap q, J = 8 Hz, H2CSi ×3). 
13
C NMR (125 MHz, CDCl3) δ 215.9 (s, C-5), 144.2 (s, C-2), 114.6 (t, C-1), 114.3 (s, C-2'), 77.7 
(d, C-3), 69.2 (d, C-7), 65.0 (t, C-4'), 64.8 (t, C-5'), 53.9 (d, C-6), 50.7 (d, C-4), 39.9 (d, C-8), 
26.2 (t, C-1"), 16.6 (q, CH3C-2), 14.7 (q, CH3C-4), 11.11 (q, CH3C-6), 11.06 (q, C-9), 7.4 (q, C-
2"), 7.2 (q ×3, CH3CSi), 5.5 (t ×3, CH2Si). 
LRMS (CI, NH3), m/z (relative intensity): 429 ([M+1]+, 13), 367 (82), 302 (63), 297 (52), 285 
(100), 273 (35), 199 (58). 
HRMS m/z calcd for C23H44O5Si+H: 429.3036; found: 429.3029 (CI, NH3). 
(4S,5S,6S,8R,9S)-5,9-Dihydroxy-4,6,8,10-tetramethylundec-10-ene-3,7-dione (139) 
HO O HO
9
11
75
1
3
O
   139 
FeCl3·6H2O (43 mg, 0.158 mmol) was added to a stirred solution of aldol 138 (48 mg, 
0.11 mmol) acetone (26 mL) and the mixture was heated under reflux. After 10 min, the mixture 
was diluted with ethyl acetate and washed sequentially with saturated aq NaHCO3, water and 
brine, dried over Na2SO4, concentrated, and fractionated by PTLC (50% ethyl acetate in hexane; 
developed twice) to provide the titled compound (21 mg, 52%). 
IR νmax 3468 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 4.94 (1H, br s, HC-11), 4.91 (1H, br s, HC-11), 4.19 (1H, d, J = 
9.5 Hz, HC-9), 4.16 (1H, dd, J = 3, 8.5 Hz, HC-5), 3.68 (1H, br s, HOC-5), 3.15 (1H, br s, HOC-
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9), 3.04-2.92 (2H, m, HC-6, HC-8), 2.67 (1H, dq, J = 3, 7 Hz, HC-4), 2.62-2.45 (2H, m, H2C-2), 
1.73 (3H, s, H3CC-10), 1.17 (3H, d, J = 7 Hz, H3CC-4), 1.04 (3H, t, J = 7.5 Hz, HC-1,), 1.02 
(3H, d, J = 7 Hz, H3CC-6), 0.90 (3H, d, J = 7 Hz, H3CC-8). 
13
C NMR (125 MHz, CDCl3) δ 219.4 (s, C-7), 215.9 (s, C-3), 144.4 (s, C-10), 114.8 (t, C-11), 
80.0 (d, C-9), 74.4 (d, C-5), 50.4 (d, C-8), 49.4 (d, C-6), 47.0 (d, C-4), 34.9 (t, C-2), 16.5 (q, 
CH3C-10), 14.2 (q, CH3C-8), 13.7 (q, CH3C-6), 9.8 (q, CH3C-4), 7.9 (q, C-1). 
LRMS (CI, NH3), m/z (relative intensity): 271 ([M+1]+, 51), 253 (100), 201 (70), 200 (51), 183 
(50), 171 (22), 167 (27), 153 (18). 
HRMS m/z calcd for C15H26O4+H: 271.1909; found: 271.1904 (CI, NH3). 
(4S,6S)-rel-4,6-Dimethyl-3,7-dioxononan-5-yl 2-Methylpropenoate (141) 
   141 
DMP (20 mg, 0.047 mmol) was added to a stirred solution of diol 139 (9 mg, 0.03 mmol) 
in CH2Cl2 (2.3 mL). After 3 h, the reaction was washed sequentially with a 1:1 (v/v) mixture of 
saturated aq solution of NaHCO3 and saturated aq Na2SO3 and brine, dried over Na2SO4, and 
concentrated to give the crude product (11 mg) that was mixture of at least 4 major components 
by 1H NMR. Imidazole (42 mg, 0.62 mmol) was added to a solution of the above crude (11 mg) 
in CDCl3 (0.6 mL; previously passed through basic alumina) at room temperature. After 19.5 h, 
the mixture was diluted in ethyl acetate, washed sequentially with 1% aq citric acid, saturated aq 
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NaHCO3 and brine, dried over Na2SO4, and fractionated by PTLC (20% ethyl acetate in hexanes; 
developed twice) to give the title compound (2.4 mg, 24%). 
IR νmax 1720 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 6.04 (1H, br s, HC-3), 5.55 (1H, br s, HC-3), 5.53 (1H, dd, J = 6, 
7 Hz, HC-5'), 2.97-2.83 (2H, m, HC-4', HC-6'), 2.71 (1H, dq, J = 18, 7 Hz, HC-2 or HC-8), 2.54-
2.39 (3H, m, HC-2, H2C-8), 1.90 (3H, s, H3CC-2), 1.13 (3H, d, J = 7 Hz, HC3C-4' or H3CC-6'), 
1.07 (3H, d, J = 7 Hz, HC3C-4' or H3CC-6'), 1.04 (3H, t, J = 7 Hz, HC3C-1' or H3CC-9'), 1.01 
(3H, t, J = 7 Hz, HC3C-1' or H3CC-9'). 
13
C NMR (125 MHz, CDCl3) δ 212.2 (s, C-3' or C-7'), 211.9 (s, C-3' or C-7'), 166.4 (s, C-1), 
136.0 (s, C-2), 126.1 (t, C-3), 75.0 (d, C-5'), 48.2 (d, C-4' or C-6'), 46.8 (d, C-4' or C-6'), 35.4 (t, 
C-2' or C-8'), 35.1 (t, C-2' or C-8'), 18.5 (q, CH3C-2), 13.2 (q, CH3C-4' or CH3C-6'), 11.6 (q, 
CH3C-4' or CH3C-6'), 7.9 (q, CH3C-1' or CH3C-9'), 7.8 (q, CH3C-1' or CH3C-9'). 
LRMS (CI, NH3), m/z (relative intensity): 269 ([M+1]+, 13), 183 (61), 165 (100), 139 (18), 126 
(14), 125 (18), 69 (44), 57 (64). 
HRMS m/z calcd for C15H24O4+H: 269.1753; found: 269.1749 (CI,NH3). 
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(2S,3R,4S,8S)-2-(2-Ethyl-1,3-dioxolan-2-yl)-3-triethylsilyloxy-7-hydroxy-4,6,8-trimethyl-9-
(phenylmethoxy)nonan-5-one (142). 
 
OBnOHO
SiEt3
O
OO
7 9
1
32' 5
4' 5'
1''
2''     142  
LHMDS (1 M in THF; 0.21 mL, 0.21 mmol) was added to a solution of (+)-109 (50 mg, 0.14 
mmol) in THF (0.7 mL) at –50 °C. After 1 h, the reaction mixture was cooled to –78 °C and a 
solution of freshly prepared (S)-29 (28 mg, 0.16 mmol) in THF (0.7 mL) was added slowly via 
syringe. After 1 h, the reaction was quenched by addition of aq. phosphate buffer (pH= 7) and 
the mixture was extracted with ethyl acetate. The combined organic layers were dried over 
Na2SO4, concentrated, and fractionated by FCC (2-100% ethyl acetate in CH2Cl2) to give 
recovered (+)-109 (8 mg, 16%) and the title compound as a ca. 43:25:18:15 mixture of 
diastereomers (60 mg, 80%). 
IR νmax: 3513, 1697 cm-1 
1H NMR (500 MHz, CDCl3) δ: 7.38-7.24 (5H, m, Ph), 4.60-4.43 (2H, m, H2CPh), 4.29 (0.25H, 
dd, J = 1, 5 Hz, HC-3), 4.25 (0.60H, ap dd, J = 1, 5 Hz, HC-3), 4.23 (0.18H, dd, J = 1.5, 5 Hz, 
HC-3), 4.01 (0.15H, br d, J = 9.5 Hz, HC-7), 3.93 (0.18H, br d, J = 10 Hz, HC-7), 3.91-3.72 
(4.5H, m, H2C-4', H2C-5', HC-7), 3.69-3.39 (2.2H, m, HC-7, H2C-9), 3.21 (0.25H, d, J = 7 Hz, 
HO), 3.12-2.89 (1.7H, m, HC-4, HC-6), 2.85 (0.15H, br q, J = 7.5 Hz, HC-6), 2.83 (0.43H, d, J = 
2 Hz, HO), 2.79 (0.18H, dq, J = 1.5, 7.5 Hz, HC-6), 2.02 (0.15H, dq, J = 1, 7 Hz, HC-2), 1.99-
1.75 (1.8H, m, HC-2, HC-8), 1.75-1.53 (2H, m, H2C-1''), 1.15 (1.8H, br d, J = 7.5 Hz, H3CC-6), 
1.10-0.90 (19.2H, m), 0.87-0.80 (3H, m, H3C-2''), 0.68-0.58 (6H, m, H2CSi × 3)  
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13C NMR (125 MHz, CDCl3) δ (major diastereomer*): 218.1, 216.8, 216.5, 216.2*, 138.9, 
138.8, 138.3*, 138.2, 128.62, 128.60*, 128.53, 128.46, 127.9, 127.8*, 127,78, 127,74, 127.69*, 
127.63, 114.2, 113.99, 113.91*, 78.7, 74.7*, 74.6*, 74.3, 73.69, 73.55, 73.48, 73.44, 72.6, 72.4, 
71.9, 70.4, 70.2*, 69.51, 69.45, 65.2*, 65.1, 64.95*, 64.93, 64.8, 55.7, 53.7*, 53.6, 52.5, 50.6, 
49.7, 49.1*, 47.2, 40.8*, 40.7, 40.5, 40.0, 36.3*, 36.2, 35.6, 34.9, 26.5*, 26.3, 15.7, 14.0, 13.8, 
13.3, 12.9*, 11.8*, 11.4, 10.99, 10.95, 10.93, 10.92, 10.8*, 10.7*, 9.4, 8.9, 7.4, 7.31, 7.26*, 7.21, 
7.18, 5.55, 5.48*, 5.43 
LRMS (CI, NH3), m/z (relative intensity): 537 ([M+1]+, 1), 359 (36), 227 (37), 196 (23), 179 
(10), 101 (100), 91 (23) 
HRMS m/z calcd for C30H52O6Si+H: 537.3611; found: 537.3592 (CI, NH3) 
(2R,3S,5S,6S)-Tetrahydro-2-hydroxy-3,5-dimethyl-6-((S)-1-methyl-2-oxobutyl)-2-((S)-1-
methyl-2-(phenylmethoxy)ethyl)-tetrahydro-4H-pyran-4-one (134). 
35
1'
3'
2''
1''2' 2
OBnOOHOO
O
OH OBn
O
O
6
    134  
FeCl3·6H2O (10.5 mg, 0.039 mmol) was added to a stirred solution of aldol adducts 142 (20 mg, 
0.037 mmol) in acetone (1.3 mL) at room temperature. After 1 h, the mixture was diluted with 
ethyl acetate and washed sequentially with saturated aq NaHCO3, H2O and brine, dried over 
Na2SO4, and concentrated. The residue was taken up in CH2Cl2 (2.6 mL) and DMP (16 mg, 0.038 
mmol) was added to the stirred solution. After 3 h, the reaction was washed sequentially with a 
1:1 (v/v) mixture of saturated aq NaHCO3 and saturated aq Na2SO3, H2O and brine, dried over 
Na2SO4, and concentrated. The residue was dissolved in a solution of imidazole (22 mg, 0.32 
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mmol) in CDCl3 (0.6 mL; previously passed over basic alumina) and heated at 40 °C in an NMR 
tube. After 19 h, the mixture was diluted in ethyl acetate, washed sequentially with citric acid 
1%, saturated aq NaHCO3 and brine, dried over Na2SO4, concentrated, and fractionated by PTLC 
(20% ethyl acetate in hexanes; multiple elutions) to afford of the titled compound (4.5 mg, 32% 
over 3 steps). [α]D +30 (c 0.4, CHCl3) 
IR νmax: 3408, 1719 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 5.58 (1H, d, J = 2.5 Hz, HO), 4.51 (1H, d, J = 11.5 Hz, HCPh), 
4.45 (1H, dd, J = 2.5, 10.5 Hz, HC-6), 4.34 (1H, d, J = 11.5 Hz, HCPh), 3.70 (1H, dd, J = 9, 11 
Hz, HC-2''), 3.42 (1H, dd, J = 4, 9 Hz, HC-2''), 2.73 (1H, dq, J = 2.5, 7 Hz, HC-1'), 2.61 (1H, br 
q, J = 6.5 Hz, HC-3), 2.57-2.42 (3H, m, H2C-3', HC-5), 2.22 (1H, ddq, J = 4, 9, 7 Hz, HC-1''), 
1.18 (3H, d, J = 7 Hz, H3CC-1'), 1.04 (3H, t, J = 7.5 Hz, H3C-4'), 104 (3H, d, J = 6.5 Hz, H3CC-
3), 103 (3H, d, J = 7 Hz, H3CC-5), 0.88 (3H, d, J = 7 Hz, H3CC-1'') 
13C  NMR (125 MHz, CDCl3) δ: 211.2 (s, C-2'), 209.0 (s, C-4), 137.1 (s, Ph), 128.8 (d ×2, Ph), 
128.2 (d, Ph), 127.8 (d ×2, Ph), 104.0 (s, C-2), 74.4 (d, C-6), 73.8 (t, CH2Ph), 73.4 (t, C-2''), 51.1 
(d, C-3), 48.0 (d, C-1'), 46.6 (d, C-5), 38.4 (d, C-1''), 33.3 (t, C-3'), 12.3 (q, CH3C-1''), 9.4 (q, 
CH3C-5), 8.29 (q, C-4' or CH3C-3), 8.29 (q, C-4' or CH3C-3), 7.8 (q, CH3C-1') 
LRMS  (CI, NH3), m/z (relative intensity): 394 ([M+18]+, 26), 377 ([M+1]+, 17), 360 (27), 359 
(93), 212 (21), 195 (26), 193 (39), 183 (82), 108 (20), 91 (100) 
HRMS m/z calcd for C22H32O5+NH4: 394.2593; found: 394.2603 (CI, NH3). 
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(2R,3S,4R,8S)-2-(2-Ethyl-1,3-dioxolan-2-yl)-3-triethylsilyloxy-7-hydroxy-4,6,8-trimethyl-9-
(phenylmethoxy)nonan-5-one (149). 
 
OBnOHO
SiEt3
O
OO
7 9
1
32' 5
4' 5'
1''
2''     149  
A solution of freshly prepared LDA (0.17 M in THF; 9.5 mL, 1.6 mmol) at 0 °C was added via 
cannula to a stirred solution of (-)-109 (ent-109) (527 mg, 1.47 mmol) in dry THF (26 mL) at –
78 °C under argon. After 15 min, Ti(OiPr)4 (0.99 mL, 0.92 g, 3.2 mmol) was added. The reaction 
mixture was stirred for 10 min at –78 °C, 30 min at –50 °C, and finally 5 min at –78 °C. A 
solution of freshly prepared (S)-29 (283 mg, 1.59 mmol) in THF (10 mL) was added over 10 min 
via syringe. After 19 h, the reaction was quenched by addition of H2O (14 mL), and the mixture 
was extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, 
concentrated, and fractionated by FCC (5% ethyl acetate in CH2Cl2) to give recovered ent-109 
(85 mg, 16%) and a 82:14:4 mixture of aldol adducts (646 mg, 81%). 
[α]D –59 (c 1.0, CHCl3) 
IR  νmax: 3508, 1699 cm-1 
1H  NMR (500 MHz, CDCl3) δ (major diastereomer only): 7.39-7.21 (5H, m, Ph), 4.52-4.48 (2H, 
m, CH2Ph), 4.17 (1H, dd, J = 1.5, 4 Hz, HC-3), 3.93 (1H, ddd, J = 2, 3, 7 Hz, HC-7), 3.89-3.71 
(4H, m, H2C-4', H2C-5'), 3.43-3.37 (2H, dd, J = 5,2.5 Hz, H2C-9), 3.36 (1H, d, J = 2 Hz, HO), 
3.04 (1H, dq, J = 4, 7 Hz, HC-4), 2.88 (1H, dq, J = 3, 7 Hz, HC-6), 1.98 (1H, dq, J = 1.5, 7 Hz, 
HC-2), 1.94-1.85 (1H, m, HC-8), 1.66 (1H, dq, J = 14.5, 7.5 Hz, HC-1''), 1.56 (1H, dq, J = 14.5, 
7.5 Hz, HC-1''), 1.17 (3H, d, J = 7 Hz, H3CC-6), 1.09 (3H, d, J = 7 Hz, H3CC-8), 1.04 (3H, d, J = 
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7 Hz, H3CC-4), 0.96 (9H, t, J = 8 Hz, H3CCSi ×3), 0.93 (3H, d, J = 7 Hz, H3C-1), 0.82 (3H, t, J = 
7.5 Hz, H3C-2''), 0.61 (6H, ap q, J = 8 Hz, H2CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ (major diastereomer only): 217.5 (s, C-5), 138.5 (s, Ph), 128.5 
(d ×2, Ph), 127.8 (d, Ph), 127.6 (d ×2, Ph), 114.0 (s, C-2'), 73.9 (t, C-9), 73.5 (t, CH2Ph), 73.1 (d, 
C-7), 70.1 (d, C-3), 65.2 (t, C-4' or C-5'), 64.9 (t, C-5' or C-4'), 52.6 (d, C-4), 48.9 (d, C-6), 40.4 
(d, C-2), 36.3 (d, C-8), 26.2 (t, C-1''), 14.0 (q, CH3C-8), 11.2 (q, C-1 or CH3C-4), 11.1 (q, C-1 or 
CH3C-4), 10.6 (q, CH3C-6), 7.3 (q, C-2''), 7.2 (q ×3, CH3CSi), 5.5 (t ×3, CH2Si) 
LRMS  (EI), m/z (relative intensity): 507 ([M-29]+, 20), 378 (16), 377 (48), 364 (11), 349 (12), 
330 (27), 329 (100) 
HRMS  m/z calcd for C30H52O6Si+H: 537.3611; found: 537.3591 (CI, NH3). 
(2R,3S,4R,8S)-2-(2-Ethyl-1,3-dioxolan-2-yl)-3-triethylsilyloxy-7-hydroxy-4,6,8-trimethyl-9-
(phenylmethoxy)nonan-5-one (149).  
OBnOHO
SiEt3
O
OO
7 9
1
32' 5
4' 5'
1''
2''     149  
LHMDS (1 M in THF; 2.2 mL, 2.2 mmol) was added to a solution of (-)-109 (1.31 g, 3.65 
mmol) in THF (31 mL) at –50 °C. After 1 h, the reaction mixture was cooled to –78 °C and a 
solution of freshly prepared (S)-29 (677 mg, 3.80 mmol) in THF (2 mL) was added slowly via 
syringe over 5 min. After 1 h, the reaction was quenched by addition of aq phosphate buffer 
(pH= 7) and the mixture was extracted with ethyl acetate. The combined organic layers were 
dried over Na2SO4, concentrated, and fractionated by FCC (2% ethyl acetate in CH2Cl2) to give 
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recovered 29 (110 mg, 16%), ent-109 (262 mg, 20%), and a 73:10:9:8 mixture of aldol adducts 
(1.51 mg, 77%). [α]D –51 (c 0.95, CHCl3) 
IR  νmax: 3491, 1706 cm-1 
1H  NMR (500 MHz, CDCl3) δ (major diastereomer only): 7.39-7.23 (5H, m, Ph), 4.57-4.47 (2H, 
m, H2CPh), 4.25 (1H, dd, J = 1.5, 5 Hz, HC-3), 3.92 (1H, ddd, J = 2, 2, 9 Hz, HC-7), 3.90-3.73 
(4H, m, H2C-4', H2C-5'), 3.62 (1H, dd, J = 5, 9 Hz, HC-9) 3.58 (1H, dd, J = 7, 9 Hz, HC-9), 3.51 
(1H, d, J = 2 Hz, HO), 3.11 (1H, d7, J = 5, 7 Hz, HC-4), 2.85 (1H, dq, J = 2, 7 Hz, HC-6), 2.00-
1.90 (1H, m, HC-8), 1.87 (1H, dq, J = 1.5, 7 Hz, HC-2), 1.68 (1H, dq, J = 14.5, 7.5 Hz, HC-1''), 
1.59 (1H, dq, J = 14.5, 7.5 Hz, HC-1''), 1.06 (3H, d, J = 7 Hz, H3CC-6), 1.05 (3H, d, J = 7 Hz, 
H3CC-4), 0.97 (9H, t, J = 8 Hz, H3CCSi ×3), 0.93 (3H, d, J = 7 Hz, H3C-1), 0.92 (3H, d, J = 7 
Hz, H3CC-8), 0.83 (3H, t, J = 7.5 Hz, H3C-2''), 0.63 (6H, q, J = 8 Hz, H2CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 214.5 (s, C-5), 138.0 (s, Ph), 128.6 (d ×2, Ph), 127.9 (d, Ph), 
127.8 (d ×2, Ph), 114.0 (s, C-2'), 75.6 (d, C-7), 75.2 (t, C-9), 73.7 (d, C-3), 65.2 (t, C-4' or C-5'), 
64.9 (t, C-5' or C-4'), 51.9 (d, C-4), 48.5 (d, C-6), 40.7 (d, C-2), 36.4 (d, C-8), 26.3 (t, C-1''), 13.9 
(q, CH3C-8), 11.1 (q, CH3C-4), 10.8 (q, C-1), 7.7 (q, CH3C-6), 7.2 (q ×3, CH3CSi), 7.2 (q, C-2''), 
5.5 (t ×3, CH2Si) 
LRMS  (CI, NH3), m/z (relative intensity): 537 ([M+1]+, 21), 476 (36), 475 (100), 424 (21), 405 
(42), 387 (32), 379 (17), 377 (11) 
HRMS  m/z calcd for C30H52O6Si+H: 537.3611; found: 537.3601 (CI, NH3). 
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(4R,5R,6R,10S)-5,9-Dihydroxy-4,6,8,10-tetramethyl-11-(phenylmethoxy)undecan-3,7-dione 
(150).  
OBnOHOOH
7 9
1
3 5
O
11
   150 
FeCl3·6H2O (43 mg, 0.16 mmol) was added to a stirred solution of aldol adducts 149 (coming 
from the reaction with Ti ‘ate’ enolate) (123 mg, 0.230 mmol) in acetone (52 mL) at room 
temperature. After 1.5 h, the mixture was diluted with ethyl acetate and washed sequentially with 
saturated aq NaHCO3, H2O and brine, dried over Na2SO4, concentrated, and fractionated by FCC 
(30% ethyl acetate in hexane) to afford the titled compound (80 mg, 92%). Usually, the crude 
from this reaction mixture was used in the following reaction without further purification. [α]D –
20 (c 0.05, CHCl3) 
IR  νmax: 3489, 1709 cm-1 
1H  NMR (500 MHz, CDCl3) δ (major diastereomer only): 7.39-7.24 (5H, m, Ph), 4.50 (1H, d, J 
= 12, CHPh), 4.48 (1H, d, J = 12 Hz, CHPh), 4.09 (1H, ddd, J = 2.5, 3, 9 Hz, HC-5), 4.05 (1H, 
ddd, J = 3, 4.5, 7 Hz, HC-9), 3.48 (1H, dd, J = 4.5, 9.5 Hz, HC-11), 3.43 (1H, dd, J = 4.5, 9.5 Hz, 
HC-11), 3.38 (1H, d, J = 3 Hz, HOC-5), 3.08 (1H, d, J = 3 Hz, HOC-9), 2.89 (1H, dq, J = 9, 7 
Hz, HC-6), 2.85 (1H,, J = 4.5, 7 Hz, HC-8), 2.65 (1H, dq, J = 2.5, 7 Hz, HC-4), 2.56 (1H, dq, J = 
18, 7.5 Hz, HC-2), 2.50 (1H, dq, J = 18, 7.5 Hz, HC-2), 1.96-1.84 (1H, m, HC-10), 1.13 (3H, d, J 
= 7 Hz, H3CC-4), 1.11 (3H, d, J = 7 Hz, H3CC-8), 1.09 (3H, d, J = 7 Hz, H3CC-10), 1.05 (3H, t, 
J = 7.5 Hz, H3C-1), 0.94 (3H, d, J = 7 Hz, H3C-6) 
13C  NMR (125 MHz, CDCl3) δ (major diastereomer only): 217.9 (s, C-7), 216.5 (s, C-3), 138.6 
(s, Ph), 128.6 (d ×2, Ph), 127.8 (d, Ph), 127.7 (d ×2, Ph), 74.3 (t, C-11), 73.6 (d, C-5), 73.5 (t, 
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CH2Ph), 73.0 (d, C-9), 50.5 (d, C-8), 46.2 (d ×2, C-4, C-6), 36.1 (d, C-10), 35.0 (t, C-2), 14.0 (q, 
CH3C-6), 13.6 (q, CH3C-10), 10.0 (q, CH3C-8), 9.3 (q, CH3C-4), 7.8 (q, C-1) 
LRMS  (EI), m/z (relative intensity): 378 ([M]+, 4), 361 (81), 360 (100), 345 (45), 343 (47), 342 
(38) 
HRMS  m/z calcd for C22H34O5+H: 379.2485; found: 379.2490 (CI, NH3). 
(4R,5R,6R,10S)-5,9-Dihydroxy-4,6,8,10-tetramethyl-11-(phenylmethoxy)undecan-3,7-dione 
(150). 
 
OBnOHOOH
7 9
1
3 5
O
11
    150  
FeCl3·6H2O (532 mg, 1.97 mmol) was added to a stirred solution of aldol adducts 149 (coming 
from the reaction with Li enolate)(1.51 g, 2.81 mmol) in acetone (63 mL) at room temperature. 
After 1.5 h, the mixture was diluted with ethyl acetate and washed sequentially with a saturated 
aq NaHCO3, H2O and brine, dried over Na2SO4, concentrated to afford the crude titled compound 
(1.26 g) that was used directly in the next step. The crude from a smaller scale reaction as above 
was fractionated by FCC (30% ethyl acetate in hexane) to give the titled compound (90%). [α]D 
+14 (c 1.1, CHCl3) 
IR  νmax: 3479, 1706 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 7.40-7.21 (5H, m, Ph), 4.53 (1H, d, J = 12 Hz, HCPh) 4.50 (2H, 
d, J = 12 Hz, HCPh), 4.11 (1H, ddd, J = 3, 3.5, 8.5 Hz, HC-5), 3.90 (1H, br d, J = 9 Hz, HC-9), 
3.82 (1H, br s, HOC-9), 3.61-3.54 (2H, m, H2C-11), 3.40 (1H, d, J = 3.5 Hz, HOC-5), 2.99 (1H, 
dq, J = 8.5, 7 Hz, HC-6), 2.73 (1H, dq, J = 2.5, 7 Hz, HC-8), 2.64 (1H, dq, J = 3, 7 Hz, HC-4), 
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2.61-2.44 (2H, m, H2C-2), 1.99-1.85 (1H, m, HC-10), 1.14 (3H, d, J = 7 Hz, H3CC-4), 1.14 (3H, 
d, J = 7 Hz, H3CC-8), 1.04 (3H, t, J = 7.5 Hz, H3C-1), 1.01 (3H, d, J = 7 Hz, H3CC-6), 0.89 (3H, 
d, J = 7 Hz, H3CC-10) 
13C  NMR (125 MHz, CDCl3) δ: 218.6 (s, C-7), 215.9 (s, C-3), 138.1 (s, Ph), 128.6 (d ×2, Ph), 
127.9 (d, Ph), 127.9 (d ×2, Ph), 75.3 (d, C-9), 74.9 (t, C-11), 73.9 (d, C-5), 73.6 (t, CH2Ph), 50.1 
(d, C-8), 47.0 (d, C-4), 45.7 (d, C-6), 36.2 (d, C-10), 34.9 (t, C-2), 14.3 (q, CH3C-6), 13.9 (q, 
CH3C-10), 9.7 (q, CH3C-4), 8.1 (q, CH3C-8), 7.9 (q, C-1) 
LRMS  (CI, NH3), m/z (relative intensity): 379 ([M+1]+, 43), 265 (51), 218 (27), 201 (39), 196 
(50), 183 (38), 179 (28), 108 (27), 91 (100) 
HRMS  m/z calcd for C22H34O5+H: 379.2485; found: 379.2487 (CI, NH3). 
(2S,3R,5R,6R)-Tetrahydro-2-hydroxy-3,5-dimethyl-6-((R)-1-methyl-2-oxobutyl)-2-((S)-1-
methyl-2-(phenylmethoxy)ethyl)-4H-pyran-4-one (151). 
O
O
OH
OBn
O
H
3
5
1'
3'
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2
OBnOOHOO
+ other tautomers     151  
DMP (1.25 g, 2.95 mmol) was added to a stirred solution of the above crude diols (1.26 g; from 
1.51 g of aldol adducts) in CH2Cl2 (200 mL) at room temperature. After 3 h, the reaction was 
washed sequentially with a 1:1 (v/v) mixture of saturated aq NaHCO3 and 10% aq Na2SO3, H2O 
and brine, dried over Na2SO4, concentrated, and fractionated by FCC (20-50% ethyl acetate in 
hexane) to give recovered 150 (200 mg, 19% from 149) and the titled compound as the 
predominant component in a mixture of ring-chain tautomers (842 mg, 80% from 149). 
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Resubjecting recovered 150 to the above reaction conditions gave additional 151 (148 mg, 14% 
from 149).  
IR νmax: 3429, 1717 cm-1 
1H  NMR (500 MHz, CDCl3) δ (major diastereomer only): 7.40-7.20 (5H, m, Ph), 4.15 (1H, d, J 
= 12 Hz, HCPh), 4.41 (1H, d, J = 12 Hz, HCPh), 4.32 (1H, dd, J = 3, 10.5 Hz, HC-6), 3.59 (1H, 
dd, J = 6.5, 9.5 Hz, HC-2''), 3.49 (1H, dd, J = 5, 9.5 Hz, HC-2''), 3.33 (1H, s, HO), 2.77 (1H, br 
q, J = 6.5 Hz, HC-3), 2.64 (1H, dq, J = 3, 7 Hz, HC-1'), 2.58-2.35 (3H, m, H2C-3', HC-5), 2.18 
(1H, ddq, J = 5, 6.5, 7 Hz, HC-1''), 1.14 (3H, d, J = 7 Hz, H3CC-1'), 1.09 (3H, d, J = 6.5 Hz, 
H3CC-3), 1.02 (3H, t, J = 7.5 Hz, H3C-4'), 0.99 (3H, d, J = 6.5 Hz, H3CC-5), 0.98 (3H, d, J = 7 
Hz, H3CC-1'') 
13C  NMR (125 MHz, CDCl3) δ (major diastereomer only): 211.5 (s, C-2'), 209.0 (s, C-4), 138.0 
(s, Ph), 128.6 (d ×2, Ph), 127.9 (d, Ph), 127.7 (d ×2, Ph), 102.2 (s, C-2), 74.5 (d, C-6), 73.4 (t, 
CH2Ph), 72.8 (t, C-2''), 51.4 (d, C-3), 47.8 (d, C-1'), 46.5 (d, C-5), 41.4 (d, C-1''), 33.4 (t, C-3'), 
12.0 (q, CH3C-1''), 9.4 (q, CH3C-3 or CH3C-5), 9.3 (q, CH3C-3 or CH3C-5), 8.07 (q, C-4' or 
CH3C-1''), 8.06 (q, C-4' or CH3C-1'') 
LRMS  (CI, NH3), m/z (relative intensity): 394 ([M+18]+, 76), 377 ([M+1]+, 21), 359 (31), 212 
(45), 200 (49), 183 (100), 108 (28), 91 (46) 
HRMS  m/z calcd for C22H32O5+NH4: 394.2593; found: 394.2596 (CI, NH3). 
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(1S,3S,5S,7S,8R,9S,10R)-3-Ethyl-8,9,10-trimethyl-5-[(S)-1-methyl-2-(phenylmethoxy)ethyl]-
2,4,6-trioxatricyclo[3.3.1.13,7]decan-1-ol (ent-10-epi-116).  
O
O
O
O
H
3
7
19
5
10
BnO
2'
1'
    ent-10-epi-116  
A solution of imidazole (539 mg, 7.92 mmol) and hemiacetals 151 (432 mg, 1.15 mmol) in 
CHCl3 (14.4 mL; previously neutralized by passing through basic alumina) was stirred at 40 °C. 
After 50 h, the mixture was diluted in ethyl acetate, washed sequentially with 1% aq citric acid 
(×3), saturated aq NaHCO3 and brine, dried over Na2SO4, concentrated, and fractionated by FCC 
(20% ethyl acetate in hexane) to crude ent-10-epi-116 (234 mg) and recovered hemiacetals 151 
(113 mg, 26%). The hemiacetal fraction was resubjected to the isomerization conditions and the 
crude ent-10-epi-116 was fractioned by FCC (5% ethyl acetate in toluene) to yield the titled 
compound (225 mg, 51%). [α]D –41 (c 1.1, CHCl3) 
IR νmax: 3424 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 7.37-7.23 (5H, m, Ph), 4.56 (1H, d, J = 12 Hz, HCPh), 4.46 (1H, 
d, J = 12 Hz, HCPh), 3.90 (1H, dd, J = 2.5, 9 Hz, HC-2'), 3.73 (1H, d, J = 3.5 Hz, HC-7), 3.35 
(1H, dd, J = 9, 9.5 Hz, HC-2'), 2.63 (1H, s, HO), 2.10-1.97 (4H, m, HC-1', HC-8, HC-9, HC-
10,), 1.63 (1H, dq, J = 14.5, 7.5 Hz, HCC-3), 1.55 (1H, dq, J = 14.5, 7.5 Hz, HCC-3), 1.11 (3H, 
d, J = 7 Hz, H3CC-8), 1.04 (3H, d, J = 7 Hz, H3CC-1'), 0.97 (3H, d, J = 6.5 Hz, H3CC-9), 0.92 
(3H, t, J = 7.5 Hz, H3CCC-3), 0.89 (3H, d, J = 7 Hz, H3CC-10) 
13C  NMR (125 MHz, CDCl3) δ: 139.1 (s, Ph), 128.5 (d ×2, Ph), 127.8 (d, Ph), 127.5 (d ×2, Ph), 
103.0 (s, C-3), 102.9 (s, C-5), 97.6 (s, C-1), 78.1 (d, C-7), 73.3 (t, CH2Ph), 71.3 (d, C-2'), 38.8 (d, 
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C-1'), 36.9 (d, C-10), 35.8 (d, C-8), 34.9 (d, C-9), 29.6 (t, CH2C-3), 13.3 (q, CH3C-8), 12.5 (q, 
CH3C-10), 11.1 (q, CH3C-1'), 6.8 (q, CH3C-9), 6.5 (q, CH3CC-3) 
LRMS  (CI, NH3), m/z (relative intensity): 394 ([M+18]+, 70), 377 ([M+1]+, 33), 376 (15), 359 
(100), 227 (33), 212 (33), 183 (69), 165 (34), 101 (56), 91 (57) 
HRMS  m/z calcd for C22H32O5+NH4: 394.2594; found: 394.2593 (CI, NH3). 
Methyl (3R,4S)-Tetrahydro-4-hydroxy-2H-thiopyran-3-carboxylate (155) 
S
OH
2 6
3
MeO
O
4 5
   155 
Procedure adapted from Hayakawa R.; Shimizu M. Synlett 1999, 1328-1330. A 
suspension of Bakers' yeast (Fleischmann's; 5.59 g) in distilled water (55.5 mL) was stirred 
(orbital shaker at 150 rpm) at room temperature. After 30 min, DMSO (0.40 mL) was added and 
stirring continued for 30 min. A solution of 2-ketoester 154 (326 mg, 1.87 mmol) in absolute 
ethanol (5.5 mL) was added. After stirring for 1 day, Celite® (40 mL) and ethyl acetate (40 mL) 
were added and stirring continued for 30 min. The resulting mixture was filtered through a bed 
of Celite® in a sintered glass funnel rinsing with ethyl acetate and the combined filtrate and 
washings were extracted with ethyl acetate. The combined organic layers were dried over 
Na2SO4, concentrated, and fractionated by FCC (50% ethyl acetate in hexanes) to yield the title 
compound (250 mg, 75%; 93% ee by HPLC analysis of the benzoyl derivative). A similar 
experiment conducted with 7.3 g of 154 and 130 g of Baker’s yeast (distributed in 15 × 250 mL 
Erlenmeyer flasks) gave the title compound (4.24 g, 57%; 93% ee). 
[α]D +35 (c 1.3, benzene) 
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IR νmax 3504 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 4.18 (1H, ddd, J = 2.5, 2.5, 5 Hz, HC-4), 3.72 (3H, s, H3CO), 
3.16 (1H, dd, J = 10.5, 13.5 Hz, HC-2), 2.98 (1H, ddd, J = 2.5, 11, 13.5 Hz, HC-6), 2.85 (1H, dt, 
J = 2.5, 2.5, 10.5 Hz, HC-3), 2.57 (1H, br d, J = 13.5 Hz, HC-2), 2.32 (1H, ddd, J = 3.5, 4, 13.5 
Hz, HC-6), 2.19 (1H, m, J = 2.5, 4, 5, 14 Hz, HC-5), 1.89 (1H, ddt, J = 2.5, 3, 11, 14 Hz, HC-5). 
13
C NMR (125 MHz, CDCl3) δ 174.3 (s, C=O), 65.9 (d, C-4), 52.2 (q, CH3O), 47.6 (d, C-3), 
33.5 (t, C-5), 25.1 (t, C-2), 22.9 (t, C-6). 
LRMS (EI), m/z (relative intensity): 176 ([M]+, 84), 158 (38), 126 (18), 99 (100), 98 (60), 87 
(66), 55 (27). 
HRMS m/z calcd for C7H12O3S: 176.0507; found: 176.0510 (EI). 
(3S,4S)-3-(Hydroxymethyl)-tetrahydro-2H-thiopyran-4-ol (156) 
S
OH
2 6
3
OH
4 5
1'
   156 
NaBH4 (1.77 g, 45.4 mmol) was added slowly in small portions to a stirred solution of 
155 (2.05 g, 11.3 mmol) in methanol (28.3 mL) at room temperature . After 35 min, the mixture 
was neutralized to pH 7 by addition of 10% aq HCl. The mixture was diluted with MeOH and 
filtered though a plug of silica gel rinsing with 20% (v/v) methanol in CH2Cl2. The combined 
filtrate and washings were concentrated. The residue was taken up in 1 M aq NaOH and after 
stirred for 1 h, the aqueous layer was extracted with CH2Cl2, dried over Na2SO4, concentrated, 
and fractionated by FCC (50% ethyl acetate in hexanes to 100% ethyl acetate) to yield the title 
  118 
compound (1.23 g, 73%).[known compound: Hayakawa, R.; Shimizu, M. Synlett 1999, 1298-
1300.] 
[α]D +17 (c 0.7, CHCl3) 
IR νmax 3372 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 4.16 (1H, ddd, J = 2.5, 3, 5.5 Hz, HC-4), 3.84 (1H, dd, J = 5.5, 11 
Hz, HC-1'), 3.82 (1H, dd, J = 4.5, 11 Hz, HC-1'), 3.03 (1H, dd, J = 105., 13.5 Hz, HC-2), 2.99 
(1H, ddd, J = 2.5, 11, 14 Hz, HC-6), 2.85 (1H, br s, HOC-4), 2.59 (1H, br s, HOC-7), 2.37-2.30 
(2H, m, HC-2, HC-6), 2.08 (1H, dddd, J = 3, 5.5, 5.5, 14 Hz, HC-5), 2.00 (1H, ddddd, J = 2.5, 3, 
4.5, 5.5, 10.5 Hz, HC-3), 1.91 (1H, dddd, J = 3, 3.5, 11, 14 Hz, HC-5). 
13
C NMR (125 MHz, CDCl3) δ 69.2 (d, C-4), 66.3 (t, C-1'), 43.2 (d, C-3), 34.4 (t, C-5), 25.6 (t, 
C-2), 23.1 (t, C-6). 
LRMS (EI), m/z (relative intensity): 148 ([M]+, 81), 130 (24), 112 (25), 99 (100), 87 (40), 79 
(31), 74 (39), 57 (43). 
HRMS m/z calcd for C6H12O2S: 148.0558; found: 148.0552 (EI). 
(2R,4aS,8aS)-Hexahydro-2-phenylthiopyrano[4,3-d][1,3]dioxine (157) 
S
O2
8a4a
O
4
5
Ph
7
   157 
Benzaldehyde dimethyl acetal (2.65 mL, 18.135 mmol) and p-TsOH (58 mg, 0.30 mmol) 
were added to a stirred solution of diol 156 (896 mg, 6.04 mmol) in CH2Cl2 (60.5 mL) at room 
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temperature under Ar at rt. After 20 min, the mixture was washed with saturated aq NaHCO3, 
dried over Na2SO4, and concentrated to provide the title compound that was homogeneous by 
TLC and 1H NMR (1.38 g, 97%). 
[α]D +6 (c 0.9, CHCl3) 
IR νmax 2914 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 7.51 (2H, app d, J = 7.5 Hz, Ph), 7.42-7.32 (3H, m, Ph), 5.54 
(1H, s, HC-2), 4.21 (1H, br s, HC-8a), 4.06 (1H, dd, J = 2.5, 11.5 Hz, HC-4), 3.99 (1H, d, J = 
11.5 Hz, HC-4), 3.57 (1H, dd, J = 12.5, 13 Hz, HC-5), 3.07-3.00 (1H, m, J = 13.5 Hz, HC-7), 
2.36 (1H, br d, J = 13 Hz, HC-5), 2.33-2.24 (2H, m, HC-7, HC-8), 2.02-1.92 (1H, m, HC-8), 
1.80 (1H, br d, J = 12.5 Hz, HC-4a). 
13
C NMR (125 MHz, CDCl3) δ 138.7 (s, Ph), 129.2 (d, Ph), 128.5 (d ×2, Ph), 126.4 (d ×2, Ph), 
102.4 (d, C-2), 74.1 (d, C-8a), 72.8 (t, C-4), 36.4 (d, C-4a), 33.6 (t, C-8), 26.3 (t, C-5), 22.5 (t, C-
7). 
LRMS (EI), m/z (relative intensity): 236 ([M]+, 100), 205 (24), 130 (94), 105 (68), 99 (61), 74 
(81). 
HRMS m/z calcd for C13H16O2S: 236.0871; found: 236.0869 (EI). 
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((3S,4S)-4-Benzyloxy-tetrahydro-2H-thiopyran-3-yl)methanol (158) 
S
OBnOH
2' 6'
3'
4' 5'
1
   158 
Procedure adapted from Takano et al, Chem Lett. 1983, 12, 1593-1596. DIBALH (1 M in 
toluene; 10.6 mL, 10.6 mmol) was added slowly via syringe (ca. 3 min) to a stirred solution of 
benzylidene acetal 157 (1.0 g, 4.2 mmol) in CH2Cl2 (42 mL) at 0 °C under Ar. After 5 min, the 
cooling bath was removed and the mixture was allowed to reach ambient temperature. After 13.5 
h, the mixture was cooled to 0 °C and a saturated solution of Rochelle's salt (30 mL) was added. 
The mixture was allowed to warm to ambient temperature and after 2 h, was extracted with 
CH2Cl2. The combined organic layers were dried over Na2SO4 and concentrated to yield the title 
compound that was homogeneous by TLC and 1H NMR (1.0 g, 99%). 
[α]D +62 (c 1.2, CHCl3) 
IR νmax 3405 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 7.39-7.27 (5H, m, Ph), 4.64 (1H, d, J = 11.5 Hz, HCPh), 4.41 
(1H, d, J = 11.5 Hz, HCPh), 3.81 (1H, ddd, J = 2.5, 2.5, 5 Hz, HC-4'), 3.73 (1H, dd, J = 6.5, 11 
Hz, HC-1), 3.67 (1H, dd, J = 5, 11 Hz, HC-1), 3.02-2.90 (2H, m, HC-2', HC-6'), 2.41-2.29 (3H, 
m, HC-2', HC-5', HC-6'), 2.20 (1H, br s, HO), 2.05 (1H, dddd, J = 5, 6.5 Hz, HC-3'), 1.84-1.75 
(1H, m, HC-5'). 
13
C NMR (125 MHz, CDCl3) δ 138.4 (s, Ph), 128.7 (d ×2, Ph), 128.0 (d, Ph), 127.9 (d ×2, Ph), 
75.2 (d, C-4'), 70.6 (t, CH2Ph), 65.3 (t, C-1), 43.8 (d, C-3'), 29.8 (t, C-5'), 26.1 (t, C-2'), 23.4 (t, 
C-6 '). 
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LRMS (EI), m/z (relative intensity): 238 ([M]+, 10), 132 (38), 129 (27), 99 (30), 91 (100), 65 
(15). 
HRMS m/z calcd for C13H18O2S: 238.1028; found: 238.1023 (EI). 
(3R,4S)-Tetrahydro-4-benzyloxy-2H-thiopyran-3-carbaldehyde (159) 
S
OBnO
2' 6'
3'
4' 5'
1
   159 
IBX (32 mg, 0.11 mmol) was added to a stirred solution of alcohol 158 (12.5 mg, 0.052 
mmol) in dry DMSO (0.4 mL) at room temperature under Ar. After 2 h, the mixture was diluted 
in ethyl acetate, washed sequentially with saturated aq NaHCO3, H2O and brine, dried over 
Na2SO4, concentrated, and fractionated by FCC (20% ethyl acetate in hexanes) to provide the 
title compound as a colorless oil that was homogeneous by TLC and 1H NMR (9.5 mg, 77%). 
[α]D –14 (c 1.0, C6H6) 
IR νmax 1727 cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 9.55 (1H, s, HC-1), 7.39-7.23 (5H, m, Ph), 4.62 (1H, d, J = 12 
Hz, HCPh), 4.42 (1H, d, J = 12 Hz, HCPh), 4.23 (1H, ddd, J = 2.5, 2.5, 4.5 Hz, HC-4'), 3.13 (1H, 
dd, J = 12, 14.5 Hz, HC-2'), 2.98 (1H, ddd, J = 2.5, 12, 13.5 Hz, HC-6'), 2.68-2.59 (2H, m, HC-
2', HC-3'), 2.43 (1H, dddd, J = 2.5, 4, 4.5, 14.5 Hz, HC-5'), 2.35 (1H, dddd, J = 1.5, 3.5, 4, 13.5 
Hz, HC-6'), 1.84 (1H, dddd, J = 2.5, 3.5, 12, 14.5 Hz, HC-5'). 
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13
C NMR (125 MHz, CDCl3) δ 202.4 (s, C-1), 138.0 (s, Ph), 128.7 (d ×2, Ph), 128.1 (d, Ph), 
127.8 (d ×2, Ph), 71.7 (d, C-4'), 70.6 (t, CH2Ph), 54.0 (d, C-3'), 29.8 (t, C-5'), 23.0 (t, C-2'), 23.0 
(t, C-6'). 
LRMS (EI), m/z (relative intensity): 236 ([M]+, 11), 157 (17), 99 (31), 91 (100), 65 (17). 
HRMS m/z calcd for C13H16O2S: 236.0871; found: 236.0865 (EI). 
(1R,2S,4S,5R,6S)-6-(2-Ethyl-1,3-dioxolan-2-yl)-1-[(3S,4S)-tetrahydro-4-(benzyloxy)-2H-
thiopyran-3-yl]-1-hydroxy-2,4-dimethyl-5-(triethylsilyloxy)heptan-3-one (160) 
SiEt3
O O
OO
HO OBn
S2'
3'
4' 5'
6'
1'
1
24
6
7
2''
4'' 5''
1'''
2'''
   160 
LHMDS (1 M in THF; 0.21 mL, 0.21 mmol) was added to a solution of (+)-109 (50 mg, 
0.139 mmol) in THF (0.7 mL) at –50 °C. After 1 h, the reaction mixture was cooled to –78 °C 
and a solution of freshly prepared aldehyde 159 (40 mg, 0.169 mmol) was added dropwise in 
THF (0.7 mL). After 1 h, the reaction was quenched by addition of phosphates buffer pH= 7 (1 
mL), extracted with ethyl acetate, dried over Na2SO4, concentrated and fractionated by FCC (2% 
ethyl acetate in CH2Cl2) to provide a mixture of at least 3 diastereomers by TLC (62 mg, 77%). 
The mixture was used in the next reaction. 
IR νmax 3489 cm
-1
. 
1H NMR (500 MHz, CDCl3) - complex 
13
C NMR (125 MHz, CDCl3) - complex 
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HRMS m/z calcd for C32H54O6SiS+Na: 617.3302; found: 617.3294 (ESI). 
(2S,3S,5S,6S)-2-((3R,4S)-4-(Benzyloxy)tetrahydro-2H-thiopyran-3-yl)-2-hydroxy-3,5-
dimethyl-6-((S)-1-methyl-2-oxobutyl)tetrahydro-4H-pyran-4-one (161) 
OH O O OBn
S
O
O
O
O
O
H
35
2'
3'
2''
1''
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S
OBn
4' 5'
6'
3''
   161 
FeCl3 6H2O (6.5 mg, 0.024 mmol) was added to a stirred solution of aldol adducts 160 
(20 mg, 0.034 mmol) in acetone (0.8 mL) at room temperature. After 1 h, the mixture was 
diluted with ethyl acetate and washed sequentially with saturated aq NaHCO3, H2O and brine, 
dried over Na2SO4, and concentrated. The residue (14 mg) was taken up in CH2Cl2 (2.4 mL) and 
DMP (15 mg, 0.035 mmol) was added to the stirred solution. After 3 h, the mixture was washed 
sequentially with a 1:1 mixture (v/v) of saturated aq NaHCO3 and saturated aq Na2SO3, H2O and 
brine, dried over Na2SO4, and concentrated. The residue (16 mg) was taken up in CDCl3 (0.6 
mL; previously passed through basic alumina), imidazole (22 mg, 0.32 mmol) was added, and 
the mixture was heated to 40 °C (oil bath temperature). After 19.5 h (reaction monitored by 1H 
NMR), the mixture was diluted with ethyl acetate, washed sequentially with 1% aq citric acid, 
NaHCO3, and brine, dried over Na2SO4, concentrated, and fractionated by PTLC (20% ethyl 
acetate in hexanes; multiple development) to give the title compound (5.1 mg, 31%). 
[α]D +90 (c 0.35, CHCl3) 
IR νmax 3384 cm
-1
. 
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1H NMR (500 MHz, CDCl3) δ 7.39-7.22 (5H, m, Ph), 5.51 (1H, s, HO), 4.57 (1H, d, J = 11 Hz, 
HCPh), 4.38 (1H, dd, J = 2.5, 10.5 Hz, HC-6), 4.35 (1H, br s, HC-4'), 4.25 (1H, d, J = 11 Hz, 
HCPh), 3.09 (1H, dd, J = 13.5,13.5 Hz, HC-2'), 2.96 (1H, dt, J = 2, 13, 13.5 Hz, HC-6'), 2.76 
(1H, dq, J = 2.5, 7 Hz, HC-1''), 2.65 (1H, dq, J = 10.5, 6.5 Hz, HC-5), 2.58 (1H, q, J = 7 Hz, HC-
3), 2.54-2.47 (3H, m, H2C-3'', HC-5'), 2.26 (1H, br d, J = 13.5 Hz, HC-6'), 2.17-2.09 (2H, m, 
HC-2', HC-3'), 1.72 (1H, dddd, J = 1.5, 3.5, 13, 13.5 Hz, HC-5'), 1.24 (3H, d, J = 7 Hz, H3CC-
1''), 1.12 (3H, d, J = 7 Hz, H3CC-3), 1.04 (3H, t, J = 7.5 Hz, H3CC-4''), 1.02 (3H, d, J = 6.5 Hz, 
H3CC-5). 
13
C NMR (125 MHz, CDCl3) δ 211.3 (s, C-3''), 210.7 (s, C-4), 137.4 (s, Ph), 128.9 (d ×2, Ph), 
128.3 (d, Ph), 127.4 (d ×2, Ph), 102.3 (s, C-2), 74.2 (d, C-6), 73.8 (d, C-4'), 70.1 (t, CH2Ph), 51.5 
(d, C-3), 47.6 (d, C-1''), 45.3 (d, C-3'), 41.8 (d, C-5), 34.0 (t, C-3''), 29.9 (t, C-5'), 22.3 (t, C-2'), 
21.9 (t, C-6'), 14.0 (q, CH3C-3), 9.3 (q, CH3C-5), 8.3 (q, C-4''), 8.1 (q, CH3C-1''). 
LRMS (EI), m/z (relative intensity): 434 ([M]+, 1), 245 (18), 100 (19), 91 (100), 69 (11), 57 (25). 
HRMS m/z calcd for C24H34O5S: 434.2127; found: 434.2117 (EI). 
(1R,3R,5S,7R,8R,9R,10R)-3-Ethyl-8,9,10-trimethyl-5-[(S)-1-methyl-2-
(phenylmethoxy)ethyl]-1-trimethylsilyloxy-2,4,6-trioxatricyclo[3.3.1.13,7]decane (ent-10-epi-
163).  
O
O
O
O
TMS
3
7
19
5
10
BnO
2'
1'
    ent-10-epi-163  
2,6-Lutidine (0.34 mL, 0.31 mg, 2.9 mmol) and TMSOTf (0.21 mL, 0.26 g, 1.2 mmol) were 
sequentially added to a stirred solution of trioxaadamantane ent-10-epi-116 (220 mg, 0.584 
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mmol) in CH2Cl2 (7.3 mL) at 0 °C under argon. After 10 min, additional TMSOTf (0.21 mL, 
0.26 g, 1.2 mmol) was added. After a further 10 min, the reaction was quenched by addition of 
1% aq citric acid (1 mL) and the mixture was diluted with ethyl acetate, washed sequentially 
with 1% citric acid, saturated aq NaHCO3 and brine, dried over Na2SO4, concentrated, and 
fractionated by FCC (20% ethyl acetate in hexane) to provide the titled compound (229 mg, 
87%). [α]D –27 (c 1.0, CHCl3) 
IR  νmax: 2973, 2941, 2883, 1454, 1249, 1045, 906, 877, 842 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 4.56 (1H, d, J = 12 Hz, CHPh), 4.45 (1H, d, J = 12 Hz, CHPh), 
3.90 (1H, dd, J = 2.5, 9 Hz, HC-2'), 3.70 (1H, d, J = 3.5 Hz, HC-5), 3.33 (1H, dd, J = 9, 9.5 Hz, 
HC-2'), 2.07-1.92 (4H, m, HC-1', HC-8, HC-9, HC-10), 1.62 (1H, dq, J = 14.5, 7.5 Hz, HCC-3), 
1.52 (1H, dq, J = 14.5, 7.5 Hz, HCC-3), 1.06 (3H, d, J = 7 Hz, H3CC-8), 1.02 (3H, d, J = 7 Hz, 
H3CC-5), 0.93 (3H, t, J = 7.5 Hz, H3CC-1'), 0.90 (3H, d, J = 7 Hz, H3CC-9), 0.88 (3H, d, J = 7 
Hz, H3CC-10), 0.16 (9H, s, H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 139.2 (s, Ph), 128.5 (d ×2, Ph), 127.8 (d ×2, Ph), 127.5 (d, Ph), 
103.5 (s, C-5), 102.8 (s, C-3), 99.8 (s, C-1), 78.3 (d, C-7), 73.3 (t, CH2Ph), 71.4 (t, C-2'), 39.1 (d, 
C-1'), 37.4 (d, C-10), 36.9 (d, C-8), 35.5 (d, C-9), 29.6 (t, CH2C-3), 13.3 (q, CH3C-8), 12.6 (q, 
CH3C-10), 11.1 (q, CH3C-1'), 7.7 (q, CH3C-9), 6.5 (q, CH3CC-3), 2.2 (q ×3, CH3Si) 
LRMS  (EI), m/z (relative intensity): 448 ([M]+, 15), 379 (100), 364 (5), 363 (14), 324 (17), 323 
(61) 
HRMS  m/z calcd for C25H40O5Si: 448.2645; found: 448.2644 (EI). 
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(S)-2-[(1R,3R,5S,7R,8R,9R,10R)-3-Ethyl-8,9,10-trimethyl-1-trimethylsilyloxy-2,4,6-
trioxatricyclo[3.3.1.13,7]dec-5-yl]propanol (ent-10-epi-164).  
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10% Pd/C (163 mg, 0.153 mmol) was added to a solution of trioxaadamantane ent-10-epi-163 
(228 mg, 0.510 mmol) in ethanol (64 mL) at room temperature. After purging the flask with H2, 
the mixture was stirred under an atmosphere of H2 (balloon). After 15 min, the mixture was 
filtered through wet Celite® and the combined filtrate and EtOH washings were concentrated, 
and fractionated by FCC (20% ethyl acetate in hexane) to yield the titled compound (158 mg, 
86%). [α]D –9 (c 1.2, CHCl3) 
IR  νmax: 3469, 2972, 2942, 2884, 1465, 1249, 1193, 903, 877, 843 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 3.82 (1H, dd, J = 3.5,1 Hz, HC-7'), 3.75 (2H, ap dd, J = 5, 6 Hz, 
H2C-1), 3.07 (1H, t, J = 6 Hz, HO), 2.11 (1H, dq, J = 3.5, 7 Hz, HC-10'), 2.03-1.96 (2H, m, HC-
8', HC-9'), 1.92 (1H, ddq, J = 5, 5, 7 Hz, HC-2), 1.66 (1H, dq, J = 14, 7.5 Hz, HCC-3'), 1.54 (1H, 
dq, J = 14, 7.5 Hz, HCC-3'), 1.07 (3H, d, J = 7 Hz, H3CC-8'), 0.94 (3H, t, J = 7.5 Hz, H3CCC-3'), 
0.92 (3H, d, J = 7 Hz, H3C-3 or H3CC-10), 0.91 (3H, d, J = 7 Hz, H3C-3 or H3CC-10), 0.91 (3H, 
d, J = 6.5 Hz, H3CC-9'), 0.17 (9H, s, H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 105.5 (s, C-5'), 103.1 (s, C-3'), 99.6 (s, C-1'), 78.4 (d, C-7'), 
64.3 (t, C-1), 39.2 (d, C-2), 37.7 (d, C-2), 36.8 (d, C-8'), 35.5 (d, C-9'), 29.6 (t, CH2C-3'), 13.3 (q, 
CH3C-8'), 12.6 (q, CH3C-10'), 10.1 (q, C-3), 7.6 (q, CH3C-9'), 6.5 (q, CH3CC-3'), 2.2 (q ×3, 
CH3Si) 
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LRMS  (EI), m/z (relative intensity): 358 ([M]+, 6), 239 (19), 215 (94), 197 (30), 187 (25), 143 
(34), 125 (28), 73 (45), 69 (23), 57 (100) 
HRMS  m/z calcd for C18H34O5Si: 358.2176; found: 358.2180 (EI). 
(S)-2-[(1R,3R,5S,7R,8R,9R,10R)-3-Ethyl-8,9,10-trimethyl-1-trimethylsilyloxy-2,4,6-
trioxatricyclo[3.3.1.13,7]dec-5-yl]propanal (ent-10-epi-167).  
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IBX (256 mg, 0.912 mmol) was added to a stirred solution of adamantane ent-10-epi-164 (294 
mg, 0.820 mmol) in dry DMSO (13 mL) at room temperature under argon. After 12 h, the 
reaction mixture was diluted with ethyl acetate, washed sequentially with saturated aq NaHCO3, 
water and brine, dried over Na2SO4, and concentrated to yield the titled compound (292 mg, 
99%). [α]D –70 (c 0.8, CHCl3) 
IR  νmax: 1733 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 9.97 (1H, s, HC-1), 3.79 (1H, d, J = 3.5 Hz, HC-5'), 2.53 (1H, q, 
J = 7 Hz, HC-2), 2.08 (1H, dddd, J = 3.5, 7 Hz, HC-10'), 2.00 (1H, br q, J = 7 Hz, HC-8'), 1.96 
(1H, q, J = 6.5 Hz, HC-9'), 1.68 (1H, dq, J = 14, 7.5 Hz, HCC-3'), 1.57 (1H, dq, J = 14, 7.5 Hz, 
HCC-3'), 1.07 (3H, d, J = 7 Hz, H3CC-8'), 1.04 (3H, d, J = 7 Hz, H3C-3), 0.96 (3H, t, J = 7.5 Hz, 
H3CCC-3'), 0.95 (3H, d, J = 6.5 Hz, H3CC-9'), 0.92 (3H, d, J = 7 Hz, H3CC-10'), 0.18 (9H, s, 
H3CSi ×3)  
13C NMR (125 MHz, CDCl3) δ: 204.3 (s, C-1), 103.8 (s, C-5'), 103.4 (s, C-3'), 99.7 (s, C-1'), 
78.6 (d, C-7'), 50.6 (d, C-2), 37.6 (d, C-10'), 36.9 (d, C-8'), 35.5 (d, C-9'), 29.6 (t, CH2C-3'), 13.2 
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(q, CH3C-8'), 12.6 (q, CH3C-10'), 7.9 (q, CH3C-9'), 6.8 (q, C-3), 6.4 (q, CH3CC-3'), 2.2 (q ×3, 
CH3Si) 
LRMS  (EI), m/z (relative intensity): 356 ([M]+, 3), 231 (40), 187 (20), 173 (13), 149 (13), 141 
(16), 75 (14), 73 (31), 69 (17), 57 (100) 
HRMS  m/z calcd for C18H32O5Si: 356.2019; found: 356.2020 (EI). 
(2S,3R*)-2-[(1R,3R,5S,7R,8R,9R,10R)-3-Ethyl-8,9,10-trimethyl-1-trimethylsilyloxy-2,4,6-
trioxatricyclo[3.3.1.13,7]dec-5-yl]pentan-3-ol (ent-10-epi-169).  
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EtMgBr (3 M in diethyl ether; 0.071 mL, 0.21 mmol) was added to a stirred solution of aldehyde 
ent-10-epi-167 (63 mg, 0.18 mmol) in THF (3.3 mL) at –78 °C under argon. After 10 min, the 
reaction was quenched by addition of phosphates buffer (pH=7; 1 mL), diluted with ethyl acetate 
and washed with phosphate buffer (pH=7). The aqueous layer was extracted with ethyl acetate 
and the combined organic layers were dried over Na2SO4, and concentrated to yield the titled 
compound as a single diastereomer (62 mg, 88%). [α]D –13 (c 0.8, CHCl3) 
IR  νmax: 3554 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 4.19 (1H, ap dd, J = 6, 8 Hz, HC-3), 3.82 (1H, d, J = 3.5 Hz, 
HC-7'), 3.43 (1H, s, HO), 2.14 (1H, dq, J = 3.5, 7 Hz, HC-10'), 2.03 (1H, q, J = 6.5 Hz, HC-9'), 
1.99 (1H, br q, J = 7 Hz, HC-8'), 1.69-1.52 (4H, m, HC-2, H2CC-3', H2C-4), 1.30 (1H, ddq, J = 8, 
14.5, 7.5 Hz, HC-4), 1.07 (3H, d, J = 7 Hz, H3CC-8'), 0.94 (12H, t, J = 7.5 Hz, H3CCC-3'), 0.93 
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(3H, t, J = 7.5 Hz, H3C-5), 0.90 (3H, d, J = 7 Hz, H3CC-10'), 0.89 (3H, d, J = 7 Hz, H3C-1), 0.87 
(3H, d, J = 6.5 Hz, H3CC-8), 0.17 (9H, s, H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 105.5 (s, C-5'), 102.9 (s, C-3'), 99.5 (s, C-1'), 78.6 (d, C-7'), 
70.9 (d, C-3), 40.9 (d, C-2), 37.4 (d, C-10'), 36.9 (d, C-8'), 35.5 (d, C-9'), 29.6 (t, CH2C-3'), 27.6 
(t, C-4), 13.2 (q, CH3C-8'), 12.6 (q, CH3C-10'), 11.0 (q, C-5), 7.7 (q, CH3C-9'), 6.5 (q, CH3CC-
3'), 5.3 (q, C-1), 2.2 (q ×3, CH3Si) 
LRMS  (EI), m/z (relative intensity): 386 ([M]+, 0.4), 243 (99), 197 (46), 187 (42), 153 (40), 129 
(36), 97 (71), 73 (77), 57 (100) 
HRMS  m/z calcd for C20H38O5Si: 386.2489; found: 386.2490 (EI). 
(S)-2-[(1R,3R,5S,7R,8R,9R,10R)-3-Ethyl-8,9,10-trimethyl-1-trimethylsilyloxy-2,4,6-
trioxatricyclo[3.3.1.13,7]dec-5-yl]pentan-3-one (ent-10-epi-95).  
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IBX (90 mg, 0.32 mmol) was added to a solution of adamantane ent-10-epi-169 (62 mg, 0.16 
mmol) in dry DMSO (2.6 mL) at room temperature under argon. After 12.5 h, the reaction 
mixture was diluted with ethyl acetate, washed sequentially with saturated aq NaHCO3, distilled 
water and brine, dried over Na2SO4, concentrated, and fractionated by FCC (10% ethyl acetate in 
hexane) to yield the titled compound (61 mg, 99%). [α]D –67 (c 1.1, CHCl3) 
IR  νmax: 1718 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 3.80 (1H, d, J = 3.5 Hz, HC-7'), 2.87 (1H, q, J = 7 Hz, HC-2), 
2.76 (1H, dq, J = 18, 7.5 Hz, HC-4), 2.46 (1H, dq, J = 18, 7.5 Hz, HC-4), 2.02-1.92 (3H, m, HC-
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8', HC-9',HC-10'), 1.65 (1H, dq, J = 14, 7.5 Hz, HCC-3'), 1.52 (1H, dq, J = 14, 7.5 Hz, HCC-3'), 
1.05 (3H, d, J = 7 Hz, H3CC-8'), 1.03 (3H, d, J = 7 Hz, H3C-1), 1.01 (3H, t, J = 7.5 Hz, H3C-5), 
0.95 (3H, d, J = 6.5 Hz, H3CC-9'), 0.94 (3H, t, J = 7.5 Hz, H3CCC-3'), 0.87 (3H, d, J = 7 Hz, 
H3CC-10'), 0.16 (9H, s, H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 211.8 (s, C-3), 103.2 (s, C-3'), 103.1 (s, C-5'), 99.8 (s, C-1'), 
78.2 (d, C-7'), 50.6 (d, C-2), 37.4 (t, C-4), 37.2 (d, C-10'), 36.8 (d, C-8'), 35.6 (d, C-9'), 29.6 (t, 
CH2C-3'), 13.2 (q, CH3C-8'), 12.5 (q, CH3C-10'), 9.7 (q, C-1), 8.1 (q, C-5 or CH3C-9'), 8.0 (q, C-
5 or CH3C-9'), 6.5 (q, CH3CC-3'), 2.2 (q ×3, CH3Si) 
LRMS  (EI), m/z (relative intensity): 384 ([M]+, 5), 259 (60), 203 (18), 187 (21), 169 (67), 101 
(19), 75 (17), 73 (37), 57 (100) 
HRMS  m/z calcd for C20H36O5Si: 384.2332; found: 384.2334 (EI). 
(R)-2-[(1R,3R,5S,7R,8R,9R,10R)-3-Ethyl-8,9,10-trimethyl-5-[(S)-1-methyl-2-
(phenylmethoxy)ethyl]-1-trimethylsilyloxy-2,4,6-trioxatricyclo[3.3.1.13,7]dec-5-yl]propanal 
(ent-167).  
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Imidazole (552 mg, 8.11 mmol) was added to a stirred solution of aldehyde ent-10-epi-167 (419 
mg, 1.18 mmol) in CHCl3 (14.8 mL) that was previously neutralized by passing through basic 
alumina. After stirring at 40 °C for 1 day, the mixture was diluted with ethyl acetate, washed 
sequentially with 1% aq citric acid (x3), saturated aq NaHCO3 and brine, dried over Na2SO4, 
concentrated, and fractionated by FCC (5% diethyl ether in hexanes) to yield the titled 
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compound (62 mg, 14%; dr 16-18) and recovered ent-10-epi-167 (338 mg, 80%; dr 16-18). The 
latter fraction was re-subjected to the isomerization conditions and after a total of six 
isomerization cycles, recovered ent-10-epi-167 (119 mg, 28%; dr 16-18) and the titled compound 
were obtained (208 mg, 49%; dr 16-18). A similar experiment conducted in CDCl3 for several 
days resulted in a 4:1 ratio of ent-10-epi-167 and ent-167, respectively. [α]D +5 (c 0.5, CHCl3) 
IR  νmax: 1727 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 9.74 (1H, d, J = 2.5 Hz, HC-1), 3.80 (1H, d, J = 3 Hz, HC-7'), 
2.62 (1H, dq, J = 2.5, 7 Hz, HC-2), 2.13 (1H, dq, J = 3.5, 7 Hz, HC-10'), 2.03-1.99 (2H, m, HC-
8', HC-9'), 1.66 (1H, dq, J = 14, 7.5 Hz, HCC-3'), 1.56 (1H, dq, J = 14, 7.5 Hz, HCC-3'), 1.15 
(3H, d, J = 7 Hz, H3C-3), 1.05 (3H, d, J = 7 Hz, H3CC-8'), 0.96 (3H, t, J = 7.5 Hz, H3CCC-3'), 
0.92 (3H, d, J = 7 Hz, H3CC-10'), 0.91 (3H, d, J = 6.5 Hz, H3CC-9'), 0.16 (9H, s, H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 203.0 (s, C-1), 103.2 (s, C-3'), 101.9 (s, C-5'), 99.6 (s, C-1'), 
78.6 (d, C-7'), 52.6 (d, C-2), 37.6 (d, C-10'), 37.0 (d, C-9'), 36.7 (d, C-8'), 29.7 (t, CH2C-3'), 13.3 
(q, CH3C-8'), 12.7 (q, CH3C-10'), 7.9 (q, CH3C-9'), 7.5 (q, C-3), 6.4 (q, CH3CC-3'), 2.2 (q ×3, 
CH3Si) 
LRMS  (EI), m/z (relative intensity): 356 ([M]+, 7), 231 (49), 187 (29), 141 (21), 101 (25), 73 
(31), 71 (21), 69 (27), 57 (100) 
HRMS  m/z calcd for C18H32O5Si: 356.2019; found: 356.2019 (EI). 
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(2R,3R*)-2-[(1R,3R,5S,7R,8R,9R,10R)-3-Ethyl-8,9,10-trimethyl-1-trimethylsilyloxy-2,4,6-
trioxatricyclo[3.3.1.13,7]dec-5-yl]pentan-3-ol (ent-170).  
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EtMgBr (3 M in diethyl ether; 0.075 mL, 0.23 mmol) was added to a stirred solution of aldehyde 
ent-167 (62 mg, 0.17 mmol) in THF (3.4 mL) at –78 °C under argon. The reaction was 
monitored by TLC and additional EtMgBr solution (ca. 0.01 mL) was added every 10 min. After 
50 min, the reaction was quenched by addition of phosphates buffer (pH=7; 1 mL), diluted with 
ethyl acetate and washed with phosphate buffer (pH=7). The aqueous layer was extracted with 
ethyl acetate and the combined organic layers were dried over Na2SO4, and concentrated to yield 
the titled compound as a 4:1 mixture of diastereomers (66 mg, 99%). [α]D +5 (c 0.45, CHCl3) 
IR  νmax: 3540 cm-1 
1H  NMR (500 MHz, CDCl3) δ (major diastereomer only): 3.82 (1H, d, J = 3.5 Hz, HC-7'), 3.79 
(1H, ap t, J = 7 Hz, HC-2), 3.31 (1H, s, HO), 2.18 (1H, q, J = 6.5 Hz, HC-9'), 2.08 (1H, dq, J = 
3.5, 7 Hz, HC-10'), 1.98 (1H, br q, J = 7 Hz, HC-8'), 1.82 (1H, q, J = 7 Hz, HC-2), 1.71-1.49 
(3H, m, H2CC-3', HC-4), 1.35 (1H, ddq, J = 7, 14, 7 Hz, HC-4), 1.08 (3H, d, J = 7 Hz, H3CC-8'), 
0.96 (3H, d, J = 7 Hz, H3C-1), 0.94 (3H, t, J = 7.5 Hz, H3CCC-3'), 0.90 (3H, d, J = 7 Hz, H3CC-
10'), 0.89 (3H, t, J = 6 Hz, H3C-5), 0.87 (3H, d, J = 6.5 Hz, H3CC-9'), 0.16 (9H, s, H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ (major diastereomer only): 104.7 (s, C-5'), 102.6 (s, C-3'), 99.7 
(s, C-1'), 78.7 (d, C-7'), 70.8 (d, C-3), 40.0 (d, C-2), 37.0 (d, C-10'), 36.9 (d, C-8'), 35.8 (d, C-9'), 
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29.6 (t, CH2C-3'), 27.4 (t, C-4), 13.5 (q, CH3C-8'), 12.6 (q, CH3C-10'), 10.7 (q, C-5), 7.9 (q, 
CH3C-9'), 6.5 (q, CH3CC-3'), 4.5 (q, C-1), 2.2 (q ×3, CH3Si) 
LRMS  (CI, NH3), m/z (relative intensity): 387 ([M+1]+, 7), 329 (25), 298 (19), 297 (100), 243 
(25), 97 (7), 90 (14) 
HRMS  m/z calcd for C20H38O5Si+H: 387.2567; found: 387.2556 (CI). 
(R)-2-[(1R,3R,5S,7R,8R,9R,10R)-3-Ethyl-8,9,10-trimethyl-1-trimethylsilyloxy-2,4,6-
trioxatricyclo[3.3.1.13,7]dec-5-yl]pentan-3-one (ent-95).  
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IBX (217 mg, 0.775 mmol) was added to a stirred solution of ent-170 (148 mg, 0.382 mmol) in 
dry DMSO (6.4 mL) at room temperature under argon. After 14 h, the reaction mixture was 
diluted with ethyl acetate, washed sequentially with saturated aq NaHCO3, distilled water and 
brine, dried over Na2SO4, concentrated, and fractionated by FCC (10% ethyl acetate in hexane) 
to yield the titled compound (130 mg, 87%) [α]D –20 (c 0.4, CHCl3) 
IR  νmax: 2980, 2940, 1705, 1249, 900, 878, 843 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 3.81 (1H, d, J = 3.5 Hz, HC-7'), 2.81 (1H, q, J = 7 Hz, HC-2), 
2.62 (1H, dq, J = 18, 7.5 Hz, HC-4), 2.48 (1H, dq, J = 18, 7.5 Hz, HC-4), 2.08 (1H, dq, J = 3.5, 7 
Hz, HC-10'), 1.97 (1H, br q, J = 7 Hz, HC-8'), 1.87 (1H, q, J = 6.5 Hz, HC-9'), 1.62 (1H, dq, J = 
14, 7.5 Hz, HCC-3'), 1.53 (1H, dq, J = 14, 7.5 Hz, HCC-3'), 1.21 (3H, d, J = 7 Hz, H3C-1), 1.04 
(3H, d, J = 7 Hz, H3CC-8'), 1.00 (3H, t, J = 7.5 Hz, H3C-5), 0.94 (3H, t, J = 7.5 Hz, H3CCC-3'), 
0.93 (3H, d, J = 6.5 Hz, H3CC-9'), 0.90 (3H, d, J = 7 Hz, H3CC-10'), 0.15 (9H, s, H3CSi ×3) 
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13C  NMR (125 MHz, CDCl3) δ: 212.2 (s, C-3), 103.1 (s, C-3'), 101.5 (s, C-5'), 99.8 (s, C-1'), 
78.5 (d, C-6'), 53.2 (d, C-2), 37.3 (d, C-9'), 37.2 (d, C-10'), 36.8 (d, C-8'), 33.9 (t, C-4), 29.7 (t, 
CH2C-3'), 13.4 (q, CH3C-8'), 12.6 (q, CH3C-10'), 10.4 (q, C-1), 8.1 (q, C-5 or CH3C-9'), 8.0 (q, 
C-5 or CH3C-9'), 6.5 (q, CH3CC-3'), 2.2 (q ×3, CH3Si) 
LRMS  (EI), m/z (relative intensity): 384 ([M]+, 9), 259 (45), 239 (16), 197 (17), 187 (23), 169 
(61), 73 (33), 57 (100) 
HRMS  m/z calcd for C20H36O5Si: 384.2332; found: 384.2328 (EI). 
ent-(10R,12R,13S)-11-Didehydro-13-dihydro-7-O-(trimethylsilyl)caloundrin B (185).  
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9-BBNOTf (0.5 M in hexane; 0.31 mL, 0.16 mmol) was added to a stirred solution of Et3N 
(0.024 mL, 17 mg, 0.17 mmol) in ethyl ether (1 mL) at –78 °C under argon. After 10 min, a 
solution of ketone ent-10-epi-95 (30 mg, 0.078 mmol) in ether (0.3 mL plus 2× 0.1 mL rinses) 
was added via syringe. After 2 h, a solution of freshly prepared aldehyde (±)-30 (49 mg, 0.23 
mmol) via syringe in ether (0.3 mL) was added. After 2 h, the reaction was quenched by 
sequential addition of phosphate buffer (pH=7; 3 mL), methanol (0.5 mL) and 30% aq H2O2 (0.5 
mL) with vigorous stirring. The mixture was warmed to 0 °C and, after 10 min, was extracted 
with CH2Cl2. The combined organic layers were dried over Na2SO4, concentrated, and 
fractionated by FCC (20-50% ethyl acetate in hexane) to provide the titled compound (34.5 mg, 
74%). [α]D –39 (c 1.9, CHCl3) 
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IR  νmax: 3438, 1715, 1656, 1615 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 4.32 (1H, d, J = 10 Hz, HC-13), 3.62 (1H, d, J = 3 Hz, HC-5), 
3.07 (1H, dq, J = 10, 7 Hz, HC-14), 3.05-2.96 (2H, m, HO, HC-10), 2.92 (1H, br q, J = 7 Hz, 
HC-12), 2.61 (1H, dq, J = 15, 7.5 Hz, HC-20), 2.48 (1H, dq, J = 15, 7.5 Hz, HC-20), 1.98 (3H, s, 
H3CC-16), 1.95-1.87 (2H, m, HC-6, HC-8), 1.92 (3H, s, H3CC-18), 1.61-1.42 (2H, m, H2C-2, 
HC-4), 1.34 (3H, d, J = 7 Hz, H3CC-14), 1.18 (3H, t, J = 7.5 Hz, H3C-21), 1.14 (3H, d, J = 7.5 
Hz, H3CC-12), 1.03 (3H, d, J = 7 Hz, H3CC-10), 1.00 (3H, d, J = 7 Hz, H3CC-6), 0.92 (3H, d, J = 
6.5 Hz, H3CC-8), 0.82 (3H, t, J = 7.5 Hz, H3C-1), 0.76 (3H, d, J = 7 Hz, H3CC-4), 0.14 (9H, s, 
H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 215.4 (s, C-11), 179.7 (s, C-17), 164.4 (s, C-15 or C-19), 164.3 
(s, C-15 or C-19), 119.1 (s, C-16), 118.1 (s, C-18), 103.4 (s, C-9), 103.0 (s, C-3), 99.6 (s, C-7), 
78.4 (d, C-5), 71.9 (d, C-13), 48.6 (d, C-12), 48.5 (d, C-10), 38.4 (d, C-14), 38.4 (d, C-4), 36.6 
(d, C-6), 35.6 (d, C-8), 29.5 (t, C-2), 24.9 (t, C-20), 16.0 (q, CH3C-14), 13.1 (q, CH3C-6), 12.7 
(q, CH3C-4), 11.5 (q, C-21), 10.1 (q, CH3C-12), 10.0 (q, CH3C-10), 9.9 (q, CH3C-16), 9.8 (q, 
CH3C-18), 7.9 (q, CH3C-8), 6.0 (q, C-1), 2.1 (q ×3, CH3Si) 
LRMS  (EI), m/z (relative intensity): 592 ([M]+, 4), 467 (22), 259 (29), 180 (40), 179 (41), 73 
(37), 57 (100) 
HRMS  m/z calcd for C32H52O8Si: 592.3432; found: 592.3422 (EI). 
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ent-(10R,11S,12R,13R)-13-Dihydro-7-O-(trimethylsilyl)caloundrin B (189).  
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    189  
NaBH(OAc)3 (32 mg, 0.15 mmol) and acetic acid (77 mg, 73 uL, 1.3 mmol) were added 
sequentially to a stirred solution of aldol adduct 185 (18 mg, 0.030 mmol) in THF (0.7 mL) 
under argon at room temperature. After 3 h, distilled water (1.3 mL) was added. The mixture was 
diluted with ethyl acetate, washed sequentially with saturated aq NaHCO3 and brine, dried over 
Na2SO4, concentrated, and fractionated by FCC (50% ethyl acetate in hexane) to yield the 
desired product (14 mg, 78%). [α]D –5 (c 1.4, CHCl3) 
IR  νmax: 3440, 1655, 1604 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 4.92 (1H, br s, HOC-11), 4.35 (1H, br s, HOC-13), 4.16 (1H, d, 
J = 10 Hz, HC-13), 3.98 (1H, dd, J = 1.5, 9 Hz, HC-11), 3.81 (1H, d, J = 3 Hz, HC-5), 3.09 (1H, 
dq, J = 10, 6.5 Hz, HC-14), 2.64 (1H, dq, J = 15, 7.5 Hz, HC-20), 2.49 (1H, dq, J = 15, 7.5 Hz, 
HC-20), 2.10-1.97 (4H, m, HC-4,HC-6, HC-8, HC-10), 2.00 (3H, s, H3CC-16), 1.92 (3H, s, 
H3CC-18), 1.71-1.62 (1H, dq, J = 14.5, 7.5 Hz, HC-2), 1.54-1.46 (2H, m, HC-2, HC-12), 1.35 
(3H, d, J = 6.5 Hz, H3CC-14), 1.21 (3H, t, J = 7.5 Hz, H3C-21), 1.07 (3H, d, J = 7 Hz, H3CC-12), 
1.03 (3H, d, J = 7 Hz, H3CC-6), 0.93 (9H, d, J = 6.5 Hz, H3CC-8), 0.92 (3H, t, J = 7.5 Hz, H3C-
1), 0.90 (3H, d, J = 7 Hz, H3CC-4), 0.57 (3H, d, J = 7 Hz, H3CC-10), 0.16 (9H, s, H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 180.0 (s, C-10), 164.8 (s, C-15), 164.2 (s, C-19), 119.2 (s, C-
16), 118.3 (s, C-18), 106.1 (s, C-9), 103.6 (s, C-3), 99.7 (s, C-7), 78.4 (d, C-5), 78.0 (d, C-11), 
72.5 (d, C-13), 40.0 (d, C-10), 39.6 (d, C-14), 37.8 (d, C-4), 36.6 (d, C-6), 35.7 (d, C-8 or C-12), 
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35.6 (d, C-8 or C-12), 29.6 (t, C-2), 25.0 (t, C-20), 15.7 (q, CH3C-14), 13.2 (q, CH3C-6), 12.6 (q, 
CH3C-4), 11.8 (q, CH3C-12), 11.4 (q, CH3C-21), 10.1 (q, CH3C-16 ), 9.9 (q, CH3C-10 ), 9.7 (q, 
CH3C-18), 7.5 (q, CH3C-8), 6.3 (q, C-1), 2.1 (q ×3, CH3Si) 
LRMS  (EI), m/z (relative intensity): 594 ([M]+, 5), 525 (10), 469 (24), 267 (14), 209 (12), 181 
(17), 180 (100), 153 (12), 73 (26), 57 (46) 
HRMS  m/z calcd for C32H54O8Si: 594.3588; found: 594.3592 (EI). 
ent-(10R,12S,13S)-11-Didehydro-13-dihydro-7-O-(trimethylsilyl)caloundrin B (186) 
10-epi-anti-aldol-A  
       186  
[α]D −90 (c 0.23, CHCl3) 
IR  νmax: 3364, 1703, 1654, 1612, 1597 (sh) cm-1 
1H  NMR (500 MHz, CDCl3) δ: 3.82 (1H, ddd, J = 4, 8, 9 Hz, HC-13), 3.61 (1H, dd, J = 3.5, 1 
Hz, HC-5), 3.38 (1H, dq, J = 8, 7 Hz, HC-14), 3.04 (1H, dq, J = 4, 7.5 Hz, HC-12), 2.98 (1H, q, 
J = 7 Hz, HC-10), 2.89 (1H, d, J = 9 Hz, HO), 2.63-2.53 (2H, m, H2C-20), 1.97-1.86 (2H, m, 
HC-6, HC-8), 1.93 (3H, s, H3CC-18), 1.88 (3H, s, H3CC-16), 1.66-1.47 (2H, m, HC-2, HC-4), 
1.40-1.29 (1H, m, HC-2), 1.31 (3H, d, J = 7 Hz, H3CC-14), 1.28 (3H, d, J = 7.5 Hz, H3CC-12), 
1.20 (3H, t, J = 7.5 Hz, H3C-21), 1.02 (3H, d, J = 7 Hz, H3CC-10), 1.01 (3H, d, J = 7 Hz, H3CC-
6), 0.93 (3H, d, J = 6.5 Hz, H3CC-8), 0.86 (3H, t, J = 7.5 Hz, H3C-1), 0.74 (3H, d, J = 7 Hz, 
H3CC-4), 0.14 (9H, s, H3CSi ×3) 
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13C  NMR (125 MHz, CDCl3) δ: 215.1 (s, C-11), 179.7 (s, C-17), 165.4 (s, C-15), 164.3 (s, C-
19), 118.8 (s, C-16), 118.1 (s, C-18), 103.7 (s, C-9), 103.2 (s, C-3), 99.7 (s, C-7), 78.1 (d, C-5), 
76.7 (d, C-13), 49.7 (d, C-12), 48.5 (d, C-10), 39.7 (d, C-14), 37.5 (d, C-4), 36.5 (d, C-6), 35.8 
(d, C-8), 29.5 (t, C-2), 24.0 (t, C-20), 16.7 (q, CH3C-12), 15.1 (q, CH3C-14), 13.1 (q, CH3C-6), 
12.5 (q, CH3C-4), 11.4 (q, C-21), 9.8 (q, CH3C-18), 9.3 (q ×2, CH3C-10, CH3C-16), 8.1 (q, 
CH3C-8), 6.3 (q, C-1), 2.1 (q ×3, CH3Si) 
LRMS  (EI), m/z (relative intensity): 592 ([M]+, 9), 468 (18), 467 (54), 349 (32), 181 (17), 180 
(100), 179 (19), 73 (33), 57 (49) 
HRMS  m/z calcd for C32H52O8Si: 592.3431; found: 592.3448 (EI). 
ent-(10R,12R,13R)-11-Didehydro-13-dihydro-7-O-(trimethylsilyl)caloundrin B (188) 
10-epi-anti-aldol-B 
  188  
Et3N (0.008 mL, 6 mg, 0.06 mmol) and BCl(c-C6H12)2 (1 M in hexane; 0.052 mL, 0.052 mmol) 
were added sequentially to a stirred solution of ent-10-epi-95 (9 mg, 0.023 mmol) in ether (0.2 
mL) at 0 °C under argon. After 1 h, the reaction mixture was cooled at –78 °C and a solution of 
freshly prepared aldehyde (±)-30 (16 mg, 0.078 mg) in ether (0.25 mL) was added. After 2 h, the 
reaction was quenched by sequential addition of of phosphate buffer (pH=7, 0.5 mL), MeOH 
(0.5 mL), and 30% aq H2O2 (0.5 mL) with vigorous stirring. After 10 min at 0 °C, the mixture 
was extracted with CH2Cl2 and the combined organic layers were dried over Na2SO4, 
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concentrated, and fractionated by PTLC (50% ethyl acetate in hexane) to provide 186 (anti-aldol, 
3 mg, 16%) and 188 (anti-aldol, 9.3 mg, 67%). [α]D –60 (c 0.9, CHCl3) 
IR  νmax: 3379, 1716, 1651, 1595 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 3.83 (1H, q, J = 6.5, Hz, HC-13), 3.80 (1H, br d, J = 3 Hz, HC-
5), 3.12 (1H, dq, J = 6.5, 7 Hz, HC-12), 2.98 (1H, q, J = 7 Hz, HC-10), 2.91 (1H, dq, J = 6.5, 7 
Hz, HC-14), 2.65 (1H, d, J = 6.5 Hz, HO), 2.60 (2H, ap q, J = 7.5 Hz, H2C-20), 2.02-1.87 (3H, 
m, HC-4, HC-6, HC-8), 1.93 (3H, s, H3CC-16 or H3CC-18), 1.92 (3H, s, H3CC-16 or H3CC-18), 
1.65 (1H, dq, J = 15, 7.5 Hz, HC-2), 1.44 (1H, dq, J = 15, 7.5 Hz, HC-2), 1.30 (3H, d, J = 7 Hz, 
H3CC-14), 1.20 (3H, t, J = 7.5 Hz, H3C-21), 1.13 (3H, d, J = 7 Hz, H3CC-12), 1.03 (3H, d, J = 7 
Hz, H3CC-6), 1.00 (3H, d, J = 7 Hz, H3CC-10), 0.90 (3H, t, J = 7.5 Hz, H3C-1), 0.89 (3H, d, J = 
7 Hz, H3CC-8), 0.86 (3H, d, J = 7 Hz, H3CC-4), 0.16 (9H, s, H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 216.9 (s, C-11), 179.7 (s, C-12), 164.9 (s, C-15), 164.3 (s, C-
19), 118.6 (s, C-18), 118.4 (s, C-16), 104.0 (s, C-9), 103.1 (s, C-3), 99.7 (s, C-7), 78.4 (d, C-5), 
77.4 (d, C-13), 52.5 (d, C-10), 49.4 (d, C-12), 39.9 (d, C-14), 37.9 (d, C-4), 36.6 (d, C-6), 35.6 
(d, C-8), 29.7 (t, C-2), 24.9 (t, C-20), 14.5 (q, CH3C-12), 13.7 (q, CH3C-14), 13.2 (q, CH3C-6), 
12.6 (q, CH3C-4), 11.5 (q, C-21), 9.72 (q, CH3C-16 or CH3C-18), 9.66 (q, CH3C-16 or CH3C-18), 
9.5 (q, CH3C-10), 7.9 (q, CH3C-8), 6.1 (q, C-1), 2.2 (q ×3, H3CSi) 
LRMS  (EI), m/z (relative intensity): 592 ([M]+, 5), 467 (45), 349 (28), 180 (100), 179 (54), 169 
(15), 153 (33), 73 (36), 57 (86) 
HRMS  m/z calcd for C32H52O8Si: 592.3431; found: 592.3418 (EI). 
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ent-(13S)-11-Didehydro-13-dihydro-7-O-(trimethylsilyl)caloundrin B (190) 
syn-aldol-A.  
190  
[α]D –15 (c 0.2, CHCl3) 
IR  νmax: 3421, 1700, 1653, 1616 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 4.08 (1H, d, J = 10 Hz, HC-13), 3.74 (1H, d, J = 3.5 Hz, HC-5), 
1.19 (1H, br s, HO), 3.04 (1H, dq, J = 10, 7 Hz, HC-14), 2.89 (1H, q, J = 7 Hz, HC-10), 2.78 
(1H, br q, J = 7 Hz, HC-12), 2.67 (1H, dq, J = 15, 7.5 Hz, HC-20), 2.51 (1H, dq, J = 15, 7.5 Hz, 
HC-20), 2.08-1.90 (2H, m, HC-4, HC-6), 1.99 (3H, s, H3CC-16), 1.95 (3H, s, H3CC-18), 1.76 
(1H, s, J = 6.5 Hz, HC-8), 1.68-1.42 (2H, m, HC-2), 1.35 (3H, d, J = 7 Hz, H3CC-14), 1.20 (3H, 
t, J = 7.5 Hz, H3C-21), 1.14 (3H, d, J = 7 Hz, H3CC-10), 1.09 (3H, d, J = 7 Hz, H3CC-12), 0.99 
(3H, d, J = 7 Hz, H3CC-6), 0.87 (3H, t, J = 7.5 Hz, H3C-1), 0.87 (3H, d, J = 7 Hz, H3CC-4), 0.81 
(3H, d, J = 6.5 Hz, H3CC-8), 0.14 (9H, s, H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 217.0 (s, C-11), 179.9 (s, C-17), 164.6 (s, C-19), 163.8 (s, C-
15), 119.2 (s, C-16), 118.2 (s, C-18), 103.2 (s, C-3), 101.4 (s, C-9), 99.6 (s, C-7), 78.4 (d, C-5), 
72.4 (d, C-13), 52.0 (d, C-10), 46.4 (d, C-12), 38.7 (d, C-14), 37.4 (d, C-8), 37.0 (d, C-4), 36.6 
(d, C-6), 29.6 (t, C-2), 25.0 (t, C-20), 15.9 (q, CH3C-14), 13.2 (q, CH3C-6), 12.5 (q, CH3C-4), 
11.4 (q, C-21), 10.8 (q, CH3C-10), 10.1 (q, CH3C-12), 9.9 (q, CH3C-16), 9.8 (q, CH3C-18), 8.3 
(q, CH3C-8), 6.4 (q, C-1), 2.2 (q ×3, CH3Si) 
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LRMS  (EI), m/z (relative intensity): 592 ([M]+, 10), 467 (57), 349 (63), 209 (19), 180 (70), 179 
(39), 169 (22), 73 (42), 57 (100) 
HRMS  m/z calcd for C32H52O8Si: 592.3431; found: 592.3446 (EI). 
ent-(13S)-11-Didehydro-13-dihydro-7-O-(trimethylsilyl)caloundrin B (192) 
syn-aldol-B 
 192 
n-BuLi (2.4 M in hexanes; 0.012 mL, 0.027 mmol) was added to a stirred solution of tert-
butyl(trimethylsilyl)amine (0.006 mL, 4 mg, 0.03 mmol) in THF (0.1 mL) at 0 °C under argon. 
After 3 min, the reaction mixture was warmed to room temperature and, after 15 min, was cooled 
0 °C. A solution of ketone ent-95 (7 mg, 0.02 mmol) in THF (0.1 mL plus 3× 0.1 mL rinses) was 
added, After 10 min, the mixture cooled to –78 °C, and a solution of freshly prepared aldehyde 
(±)-30 (11.5 mg, 0.055 mmol) in THF (0.3 mL) was added. After 20 min, the reaction was 
quenched by addition of phosphate buffer (pH=7; 1 mL). The mixture was extracted with ethyl 
acetate. The combined organic layers were dried over Na2SO4, concentrated, and fractionated by 
FCC (20%-100% ethyl acetate in hexanes) to provide recovered starting ketone ent-95 (2 mg, 
28%), and a mixture of aldol adducts that were further fractionated by PTLC (30% ethyl acetate 
in hexane, multiple elution) to provide a 1.5:1 mixture of two anti aldols (2.5 mg, ca. 23%), syn-
aldol-A 190 (2 mg,18%), and syn-aldol-B 192 (3 mg, 28%). [α]D +15 (c 0.3, CHCl3) 
IR  νmax: 3396, 1716, 1653, 1595 cm-1 
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1H  NMR (500 MHz, CDCl3) δ: 4.05 (1H, d, J = 10 Hz, HC-13), 3.77 (1H, d, J = 3.5 Hz, HC-5), 
3.16 (1H, s, HO), 3.03 (1H, dq, J = 10, 7 Hz, HC-14), 2.89 (1H, q, J = 7 Hz, HC-10), 2.73 (1H, 
q, J = 7 Hz, HC-12), 2.63 (1H, dq, J = 15, 7.5 Hz, HC-20), 2.54 (1H, dq, J = 15, 7.5 Hz, HC-20), 
2.13 (1H, q, J = 6.5 Hz, HC-8), 2.01-1.91 (2H, m, HC-4, HC-6), 1.98 (3H, s, H3CC-16), 1.95 
(3H, s, H3CC-18), 1.64-1.50 (1H, m, HC-2), 1.50-1.39 (1H, m, HC-2), 1.34 (3H, d, J = 7 Hz, 
H3CC-14), 1.20 (3H, t, J = 7.5 Hz, H3C-21), 1.15 (3H, d, J = 7 Hz, H3CC-10), 1.10 (3H, d, J = 7 
Hz, H3CC-6), 1.07 (3H, d, J = 7 Hz, H3CC-12), 0.88 (3H, d, J = 7 Hz, H3CC-4), 0.84 (3H, t, J = 
7.5 Hz, H3C-1), 0.81 (3H, d, J = 6.5 Hz, H3CC-8), 0.14 (9H, s, H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 216.5 (s, C-11), 179.9 (s, C-17), 164.5 (s, C-19), 163.9 (s, C-
15), 119.2 (s, C-16), 118.3 (s, C-18), 103.1 (s, C-3), 102.0 (s, C-9), 99.7 (s, C-7), 78.6 (d, C-5), 
72.4 (d, C-13), 51.3 (d, C-10), 46.1 (d, C-12), 38.9 (d, C-14), 37.4 (d, C-4), 36.7 (d, C-6), 36.0 
(d, C-8), 29.6 (t, C-2), 25.0 (t, C-20), 15.9 (q, CH3C-14), 13.3 (q, CH3C-6), 12.6 (q, CH3C-4), 
11.6 (q, C-21), 10.7 (q, CH3C-10), 10.0 (q, CH3C-16), 9.9 (q, CH3C-18), 9.7 (q, CH3C-12), 8.1 
(q, CH3C-8), 6.3 (q, C-1), 2.1 (q ×3, CH3Si) 
LRMS  (EI), m/z (relative intensity): 592 ([M]+, 11), 468 (24), 467 (73), 349 (76), 209 (25), 180 
(97), 179 (44), 73 (64), 57 (100) 
HRMS  m/z calcd for C32H52O8Si: 592.3431; found: 592.3451 (EI). 
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ent-(13S)-11-Didehydro-13-dihydro-7-O-(trimethylsilyl)caloundrin B (191).  
O
O
O
O
TMS
O
H
O
11
9
O
O
1
3
5
7
131517
19
    191  
n-BuLi (2.4 M in hexanes; 0.070 mL, 0.17 mmol) was added to a stirred solution of tert-
butyl(trimethylsilyl)amine (0.035 mL, 26 mg, 0.18 mmol) in THF (0.7 mL) at 0 °C under argon. 
After 1 min, the reaction mixture was warmed to room temperature and, after 15 min, was cooled 
0 °C. A solution of ketone ent-95 (48 mg, 0.12 mmol) in THF (0.6 mL plus 3× 0.2 mL rinses) 
was added, After 10 min, the mixture cooled to –78 °C, and (c-C6H12)2BCl (1 M in hexane; 0.169 
mL, 0.17 mmol) was added. After 15 min, a solution of freshly prepared aldehyde (±)-30 (95 mg, 
0.45 mmol) in THF (0.6 mL) was added. After 7 h, the reaction was quenched by sequential 
addition of phosphate buffer (pH=7; 1 mL), methanol (1 mL) and 30% aq H2O2 (1 mL) with 
vigorous stirring. The mixture was warmed to 0 °C and, after 10 min, was extracted with CH2Cl2. 
The combined organic layers were dried over Na2SO4, concentrated, and fractionated by FCC 
(20-50% ethyl acetate in hexane) to provide the titled compound (38 mg, 51%) and a mixture of 
diastereomers including 191 (24 mg, 31%). Fractionation of the latter mixture by PTLC (30% 
ethyl acetate in hexane, multiple elution) provided a 2:1 mixture of aldol diastereomers (13 mg, 
18%) and additional titled compound (7 mg, 9%; total yield of 191 = 60%). [α]D +15 (c 0.9, 
CHCl3) 
IR  νmax: 3378, 1703, 1652, 1596 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 3.89 (1H, ddd, J = 6, 6.5, 7 Hz, HC-13), 3.77 (1H, br d, J = 3.5 
Hz, HC-5), 3.11 (1H, dq, J = 6, 7 Hz, HC-14), 2.93 (1H, dq, J = 7, 7 Hz, HC-12), 2.88 (1H, q, J 
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= 7 Hz, HC-10), 2.70 (1H, d, J = 6.5 Hz, HO), 2.59 (2H, ap q, J = 7.5 Hz, H2C-20), 2.09-2.00 
(2H, m, HC-4, HC-8), 1.97-1.91 (1H, m, HC-6), 1.93 (3H, s, H3CC-16 or H3CC-18), 1.92 (3H, s, 
H3CC-16,H3CC-18), 1.59 (1H, dq, J = 14.5, 7.5 Hz, HC-2), 1.51 (1H, dq, J = 14.5, 7.5 Hz, HC-
2), 1.29 (3H, d, J = 7 Hz, H3CC-14), 1.20 (3H, t, J = 7.5 Hz, H3C-21), 1.19 (3H, d, J = 7 Hz, 
H3CC-10), 1.12 (3H, d, J = 7 Hz, H3CC-12), 1.03 (3H, d, J = 7 Hz, H3CC-6), 0.92 (3H, t, J = 7.5 
Hz, H3C-1), 0.92 (3H, d, J = 6.5 Hz, H3CC-8), 0.88 (3H, d, J = 7 Hz, H3CC-4), 0.14 (9H, s, 
H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 215.6 (s, C-11), 179.8 (s, C-17), 164.9 (s, C-15), 164.4 (s, C-
19), 118.6 (s, C-16), 118.3 (s, C-18), 103.1 (s, C-3), 102.2 (s, C-9), 99.8 (s, C-7), 78.5 (d, C-13), 
76.6 (d, C-5), 52.1 (d, C-10), 47.5 (d, C-12), 39.0 (d, C-14), 37.2 (d, C-4), 36.9 (d, C-8), 36.8 (d, 
C-6), 29.6 (t, C-2), 24.9 (t, C-20), 15.1 (q, CH3C-12), 13.3 (q, CH3C-6), 13.0 (q, CH3C-14), 12.6 
(q, CH3C-4), 11.5 (q, C-21), 10.5 (q, CH3C-10), 9.7 (q, CH3C-16), 9.7 (q, CH3C-18), 8.4 (q, 
CH3C-8), 6.5 (q, C-1), 2.2 (q ×3, CH3Si) 
LRMS  (EI), m/z (relative intensity): 592 ([M]+, 8), 523 (11), 467 (53), 349 (55), 180 (100), 179 
(43), 169 (22), 73 (54), 57 (56) 
HRMS  m/z calcd for C32H52O8Si: 592.3431; found: 592.3441 (EI). 
ent-(13R)-13-Dihydro-7-O-trimethylsilyl-caloundrin B (194).  
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    194  
Et2BOMe (1M in toluene; 0.27 mL, 0.27 mmol) was added to a stirred solution of aldol adduct 
191 (16 mg, 0.027 mmol) in THF (0.23 mL) and MeOH (0.077 mL) at 0 °C under argon. After 
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30 min, the solution was cooled to –78 °C and NaBH4 (44 mg, 1.1 mmol) was added. After 40 
min at –78 °C and 2.5 h at 0 °C, phosphate buffer (pH=7; 0.5 mL) and MeOH (0.5 mL) were 
added to the reaction mixture followed by dropwise addition of 30% aq H2O2 (0.5 mL) (caution: 
exothermic). After 5 min, the mixture was allowed to warm to ambient temperature. After 2 h, 
the mixture was extracted CH2Cl2 and the combined organic layers were dried over Na2SO4, 
concentrated, and fractionated by PTLC (30% ethyl acetate in hexanes) to yield diol 194 (9 mg, 
58%) and its borate diester (4.6 mg, 27%). The boronate ester, obtained as above from several 
experiments, was combined (20 mg) and taken up in THF (2 mL) and N-methyldiethanolamine 
(0.35 mL, 0.38 g, 0.87 mmol) was added. After 10 min, the mixture was cooled at 0 °C and 
phosphate buffer (pH=7; 2 mL) and 30% aq H2O2 (2 mL) were added sequentially. After 5 min, 
the mixture was warmed at room temperature and, after 2 h, was extracted with CH2Cl2. The 
combined organic layers were dried over Na2SO4, concentrated, and fractionated by PTLC (50% 
ethyl acetate in hexane) to yield diol 194 (17 mg, 91%). Thus, the overall yield of 194 was 84%. 
[α]D –3 (c 0.3, CHCl3) 
IR  νmax: 3413, 1652, 1592 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 4.42 (1H, br s, HOC-11), 3.98 (1H, br s, HOC-13), 3.80 (1H, d, 
J = 3.5 Hz, HC-5), 3.78 (1H, dd, J = 6, 6 Hz, HC-13), 3.61 (1H, dd, J = 5, 8 Hz, HC-11), 3.30 
(1H, dddd, J = 7 Hz, HC-14), 2.61 (2H, ap q, J = 8 Hz, H2C-20), 2.20-2.05 (3H, m, HC-4, HC-8, 
HC-10), 1.99 (1H, br q, J = 7 Hz, HC-6), 1.97 (3H, s, H3CC-16), 1.94 (3H, s, H3CC-18), 1.85 
(1H, ddq, J = 6, 8, 7 Hz, HC-12), 1.63 (1H, dq, J = 14.5, 7.5 Hz, HC-2), 1.53 (1H, dq, J = 14.5, 
7.5 Hz, HC-2), 1.27 (3H, d, J = 7 Hz, H3CC-14), 1.21 (3H, t, J = 7.5 Hz, H3C-21), 1.04 (3H, d, J 
= 7 Hz, H3CC-10), 1.03 (3H, d, J = 7 Hz, H3CC-6), 0.97-0.91 (6H, d, J = 7 Hz, H3CC-8, H3CC-
12), 0.93 (3H, t, J = 7.5 Hz, H3C-1), 0.90 (3H, d, J = 7 Hz, H3CC-4), 0.16 (9H, s, H3CSi ×3) 
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13C  NMR (125 MHz, CDCl3) δ: 180.1 (s, C-17), 165.9 (s, C-15), 164.5 (s, C-19), 118.3 (s, C-
16), 118.1 (s, C-18), 104.9 (s, C-9), 102.9 (s, C-3), 99.6 (s, C-7), 81.0 (d, C-11), 79.0 (d, C-5), 
78.4 (d, C-13), 41.8 (d, C-10), 40.2 (d, C-14), 39.6 (d, C-12), 37.7 (d, C-8), 37.4 (d, C-4), 36.7 
(d, C-6), 29.7 (t, C-2), 25.0 (t, C-20), 16.8 (q, CH3C-12), 13.8 (q, CH3C-10), 13.5 (q, CH3C-6), 
12.8 (q, CH3C-14), 12.6 (q, CH3C-4), 11.6 (q, C-21), 9.8 (q, CH3C-16), 9.7 (q, CH3C-18), 8.8 (q, 
CH3C-8), 6.5 (q, C-1), 2.2 (q ×3, CH3-Si) 
LRMS  (EI), m/z (relative intensity): 594 ([M]+, 3), 469 (12), 351 (15), 267 (19), 181 (17), 180 
(100), 153 (10), 73 (21), 57 (37) 
HRMS  m/z calcd for C32H54O8Si: 594.3588; found: 594.3597 (EI). 
ent-(13S)-13-Dihydro-11-O-triethylsilyl-7-O-trimethylsilyl-caloundrin B (195).  
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2,6-Lutidine (46 uL,42 mg, 0.392 mmol) and TESOTf (0.01 mL, 10 mg, 0.044 mmol) were 
sequentially added to a solution of diol 194 (23 mg, 0.039 mmol) in CH2Cl2 (3.9 mL) at –50 °C 
under argon. After 6 min, the reaction mixture was diluted with ethyl acetate and washed 
sequentially with 1% aq citric acid, saturated aq NaHCO3, and brine. The organic layer was dried 
over Na2SO4, concentrated, and fractionated by PTLC (30% ethyl acetate in hexanes) to yield 
recovered diol 194 (14 mg, 61%) and the titled compound as a colorless oil (9 mg, 31%; 79% 
BORSM). [α]D +10 (c 0.35, CHCl3) 
IR  νmax: 3437, 1653, 1611, 1596 cm-1 
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1H  NMR (500 MHz, CDCl3) δ: 4.00 (1H, dd, J = 3, 3 Hz, HC-11), 3.80 (1H, br s, HO), 3.78-
3.71 (2H, m, HC-5, HC-13), 3.11 (1H, dq, J = 4, 7 Hz, HC-14), 2.62 (2H, ap q, J = 7.5 Hz, H2C-
20), 2.37-2.25 (1H, m, HC-12), 2.05 (1H, dq, J = 4, 7 Hz, HC-4), 2.02-1.90 (2H, m, HC-6, HC-
10), 1.97 (3H, s, H3CC-16), 1.95 (3H, s, H3CC-18), 1.85 (1H, q, J = 6.5 Hz, HC-8), 1.70-1.46 
(2H, m, H2C-2), 1.24 (3H, d, J = 7 Hz, H3CC-14), 1.21 (3H, t, J = 7.5 Hz, H3C-21), 1.09 (3H, d, 
J = 7 Hz, H3CC-10), 1.03 (3H, d, J = 7 Hz, H3CC-6), 0.98 (3H, d, H3CC-8), 0.97 (3H, d, J = 7 
Hz, H3CC-12), 0.94 (9H, t, J = 8 Hz, H3CCSi ×3), 0.93 (3H, t, H3C-1), 0.89 (3H, d, H3CC-4), 
0.61 (6H, ap q, H2CSi ×3), 0.17 (9H, s, H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 180.3 (s, C-17), 166.5 (s, C-15), 164.6 (s, C-19), 117.9 (s, C-
16), 117.7 (s, C-18), 102.7 (s, C-3), 102.6 (s, C-9), 99.7 (s, C-7), 78.4 (d, C-5), 77.7 (d, C-11), 
75.6 (d, C-13), 46.6 (d, C-10), 39.0 (d, C-14), 37.5 (d, C-8), 37.3 (d, C-12), 37.0 (d, C-4), 36.8 
(d, C-6), 29.7 (t, C-2), 25.1 (t, C-20), 19.2 (q, CH3C-12), 13.4 (q, CH3C-6), 12.6 (q, CH3C-4), 
11.5 (q, C-21), 10.6 (q, CH3C-14), 9.8 (q, CH3C-16), 9.7 (q, CH3C-18), 8.6 (q, CH3C-8), 7.8 (q, 
CH3C-10), 7.0 (q ×3, CH3CSi), 6.5 (q, C-1), 5.2 (t ×3, CH2Si), 2.2 (q ×3, CH3Si) 
LRMS  (EI), m/z (relative intensity): 708 ([M]+, 3), 381 (12), 255 (17), 209 (37), 181 (15), 180 
(100), 115 (15), 73 (20), 57 (22) 
HRMS  m/z calcd for C38H68O8Si2: 708.4453; found: 708.4452 (EI). 
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ent-11-O-Triethylsilyl-7-O-trimethylsilyl-caloundrin B (196).  
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IBX (41 mg, 0.1467 mmol) was added to a stirred solution of alcohol 195 (13 mg, 0.0183 mmol) 
in DMSO (2.4 mL) at room temperature under Ar. After 13 h, the reaction was diluted with ethyl 
acetate and washed sequentially with saturated aq NaHCO3, distilled water and brine, dried over 
Na2SO4, concentrated, and fractionated by PTLC (30% ethyl acetate in hexane) to provide the 
titled compound (13 mg, 99%). [α]D +80 (c 0.3, CHCl3) 
IR  νmax: 1727, 1657, 1621 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 4.10 (1H, dd, J = 2.5, 7 Hz, HC-11), 4.08 (1H, q, J = 7 Hz, HC-
14), 3.74 (1H, d, J = 3.5 Hz, HC-5), 2.93 (1H, dq, J = 7, 7 Hz, HC-12), 2.49-2.57 (2H, m, H2C-
20), 2.08 (3H, s, H3CC-16 ), 2.02-1.91 (3H, m, HC-4, HC-6, HC-10), 1.95 (3H, s, H3CC-18), 
1.86 (1H, q, J = 6.5 Hz, HC-8), 1.64-1.43 (2H, m, H2C-2), 1.30 (3H, d, J = 7 Hz, H3CC-14), 1.14 
(3H, t, J = 7.5 Hz, HC-21), 1.01 (24H, d, J = 7 Hz, H3CC-6), 0.99 (3H, d, J = 6.5 Hz, H3CC-10), 
0.97 (3H, d, J = 6.5 Hz, H3CC-8), 0.96 (3H, d, J = 6.5 Hz, H3CC-12), 0.94 (9H, t, J = 8 Hz, 
H3CCSi ×3), 0.91 (3H, t, J = 7.5 Hz, H3CC-1), 0.87 (3H, d, J = 7 Hz, H3CC-4), 0.577,3.5 (6H, ap 
q, J = 8 Hz, H2CSi ×3), 0.16 (9H, s, H3CSi ×3) 
13C  NMR (125 MHz, CDCl3) δ: 209.2 (s, C-13), 180.1 (s, C-17), 165.0 (s, C-19), 161.6 (s, C-
15), 120.3 (s, C-16), 118.4 (s, C-18), 102.7 (s, C-3), 102.0 (s, C-9), 99.8 (s, C-7), 78.6 (d, C-5), 
75.0 (d, C-11), 50.9 (d, C-14), 47.5 (d, C-10), 46.2 (d, C-12), 38.0 (d, C-8), 37.1 (d, C-4 ), 36.7 
(d, C-6), 29.7 (t, C-2), 24.9 (t, C-20), 15.1 (q, CH3C-12), 13.5 (q, CH3C-6), 13.2 (q, CH3C-14), 
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12.7 (q, CH3C-4), 11.5 (q, C-21), 10.3 (q, CH3C-16), 9.7 (q, CH3C-18), 8.6 (q, CH3C-10), 7.5 (q, 
CH3C-8), 7.1 (q ×3, CH3Si), 6.4 (q, C-1), 5.4 (t ×3, CH2Si), 2.2 (q ×3, CH3Si) 
LRMS  (EI), m/z (relative intensity): 706 ([M]+, 8), 678 (18), 677 (37), 581 (56), 527 (30), 379 
(43), 349 (100), 255 (49), 180 (46) 
HRMS  m/z calcd for C38H66O8Si: 706.4296; found: 706.4270 (EI). 
ent-Caloundrin B (ent-3).  
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Pyridine (0.16 mL, 16 mg, 2.0 mmol), distilled water (0.007 mL, 7 mg, 0.4 mmol), and 
HF·pyridine (0.108 mL) were sequentially added to a stirred solution of ketone 196 in THF (2 
mL) at room temperature. After 2 h, the mixture was diluted with ethyl acetate and washed 
sequentially with 1% aq citric acid (×3), saturated aq NaHCO3 and brine. The organic layer was 
dried over Na2SO4, concentrated, and fractionated by PTLC (50% ethyl acetate in hexanes) to 
give ent-caloundrin B (ent-3) (7 mg, quantitative). [α]D +50 (c 0.2, CHCl3) 
IR  νmax: 3385, 1653, 1598 cm-1 
1H  NMR (500 MHz, CDCl3) δ: 4.14 (1H, q, J = 7 Hz, HC-14), 3.95 (1H, d, J = 7.5 Hz, HOC-
11), 3.83 (1H, br d, J = 3.5 Hz, HC-5), 3.68 (1H, ddd, J = 5, 5, 7.5 Hz, HC-11), 3.03 (1H, dq, J = 
5, 7 Hz, HC-12), 2.62 (1H, br s, HOC-7), 2.62-2.52 (2H, m, H2C-20), 2.24 (1H, q, J = 6.5 Hz, 
HC-8), 2.10 (1H, dq, J = 3.5, 7 Hz, HC-4), 2.09-2.03 (2H, m, HC-6, HC-10), 2.07 (3H, s, H3CC-
16), 1.95 (3H, s, H3CC-18), 1.65-1.54 (2H, m, H2C-2), 1.38 (3H, d, J = 7 Hz, H3CC-14), 1.16 
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(3H, t, J = 7.5 Hz, H3C-21), 1.09 (3H, d, J = 7 Hz, H3CC-6), 1.03 (3H, d, J = 7 Hz, H3CC-12), 
0.99 (3H, d, J = 6.5 Hz, H3CC-8), 0.97 (3H, d, J = 7 Hz, H3CC-10), 0.93 (3H, t, J = 7.5 Hz, H3C-
1), 0.93 (3H, d, J = 7 Hz, H3CC-4) 
13C  NMR (125 MHz, CDCl3) δ: 213.4 (s, C-13), 179.8 (s, C-17), 165.0 (s, C-19), 160.3 (s, C-
15), 120.4 (s, C-16), 118.7 (s, C-18), 103.1 (s, C-9), 103.0 (s, C-3), 97.4 (s, C-7), 78.6 (d, C-5), 
77.7 (d, C-11), 50.7 (d, C-14), 46.5 (d, C-12), 42.0 (d, C-10), 36.9 (d, C-8), 36.8 (d, C-4), 35.8 
(d, C-6), 29.7 (t, C-2), 24.9 (t, C-20), 16.3 (q, CH3C-12), 13.6 (q ×2, CH3C-6 anCH3C-14), 12.6 
(q, CH3C-4), 11.5 (q, C-21), 11.4 (q, CH3C-10), 10.4 (q, CH3C-16), 9.8 (q, CH3C-18), 7.7 (q, 
CH3C-8), 6.5 (q, C-1) 
LRMS  (EI), m/z (relative intensity): 520 ([M]+, 1), 236 (9), 207 (3), 181 (13), 180 (100), 179 
(16), 153 (12), 125 (8), 69 (7), 57 (42) 
HRMS  m/z calcd for C29H44O8: 520.3036; found: 520.3027 (EI). 
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